

Index

Note:

Abbreviations used in the index are listed on pages xxx–xli.

Alphabetization order: This index is in word-by-word order, whereby terms like ‘duct obstruction’ precede ‘ductal’.

Cross-reference targets in *italics* refer to general entries, or to subentries within the same main entry.

Page numbers in **bold** refer to pages on which tables or boxes appear; page numbers in *italics*, refer to figures.

vs denotes differential diagnosis, or comparisons.

a

- ABC-02 trial **1092**, 1094
ABCC8 gene mutations 31, 32
 abdominal compartment syndrome (ACS)
 205, 261–262, 313
 acute pancreatitis 205, *259*, 261–262, 313
 chronic pancreatitis pain 350, 422
 necrotizing pancreatitis
 necrosectomy 291
 abdominal hypertension 205, 261, 262, 313
 abdominal pain
 acute pancreatitis 219, 222
 autoimmune pancreatitis 506, 522,
 535, 556
 chronic pancreatitis *see* chronic
 pancreatitis
 pancreatic cancer *see* pancreatic cancer
 abdominal ultrasound
 autoimmune pancreatitis 550–551
 chronic pancreatitis 406
 pancreatic cancer 771
 pancreatic neuroendocrine tumors
 949, *950*
 abscesses, pancreatic 241, 302, 305, 316,
 318, **441**
 accessory pancreatic duct (duct of
 Santorini) 16
 anatomy 11, *11*
 development 4, 5
 incomplete fusion with duct of
 Wirsung 26
 small, pancreas divisum and 26
 ACE inhibitors, acute pancreatitis
 due to 233
 acetaldehyde 137, 138
 acetaldehyde dehydrogenase (ALDH)
 137, 140
 ALDH2 gene variants 140–141, 345
 groups (ALDH1, ALDH2) 140
 acetylation, epigenetic, acute pancreatitis 336
 acetylcholine (ACh)
 acinar cell stimulation 43, 44, *44*, 45,
 51–52, 88
 mechanism *48*, 48–50, *49*
 CCK-RP release 85, *85*
 nicotinic receptors 674, 675
 PIP₂ breakdown 48, *48*
 release by pancreatic neurons *85*, 88
 acetylic acid **423**
 acinar cell(s) 3, 43, 160
 absence/loss 30
 in acinar tubules 13
 acute pancreatitis initiation 64
 see also acute pancreatitis
 alcohol metabolism 137
 apoptosis *69*, 69–70, 109
 cathepsin B role *69*, 69–70, 180
 blood supply 22, 252
 Ca²⁺ entry/exit control 50–51, *51*, 67
 calcium dysregulation, acute pancreatitis
 158–159
 chronic pancreatitis etiology *334*
 culture, growth in 101
 cytoplasm 15, 16
 dedifferentiation 100, 101
 differentiation/development 5, 6
 malignancies with 683
 digestive enzyme release 43, 196, 426
 digestive enzyme synthesis control 95, 178
 ductal hypertension effect 149
 ductal metaplasia, carcinogens 675
 fluid secreted *see* acinar fluid
 focal dysplasia, smoking and 676
 functions 15, 43, 178
 histology 14–16, *16*, *17*
 inflammatory pathways, acute
 pancreatitis 67–68
 injury
 alcohol effects 136, *136*, 137–138, 336
 cigarette smoke effect 676
 cytokines/mediators released 71–72,
 252, 338
 in vitro 63
 inflammatory cell infiltration 71, 338
 ischemic 252
 trypsin role *68*, 68–70, 175,
 178–179, 242
 islet cells, structural relationship 123–124
 islet hormones, exposure to 124
 membrane capacitance 52
 mitochondria 15, *17*, 46–47
 necrosis *194*, 196, *196*
 pancreatic stone protein (PSP/Reg)
 expression 127
 protection from enzyme activation 64–65,
 178–179
 response to stress 336
 secretion, physiology 43–55, 426
 ACh and Ca²⁺ signal generation *48*,
 48–50, *49*
 ACh and CCK stimulating 43, 44, *44*,
 45, 51–52, 67
 Ca²⁺, abnormal levels, acute
 pancreatitis 67, 149
 Ca²⁺ control of enzyme
 secretion 51–52, 57
 Ca²⁺ control of fluid secretion 52, 57
 Ca²⁺ entry/exit 50–51, *51*, 67
 Ca²⁺ homeostasis, organelles *46*,
 46–48, *47*
 Ca²⁺ signal generation mechanisms *48*,
 48–50, *49*
 Ca²⁺ signaling 45, *45*, 46, *46*, *47*, 67, 149
 Ca²⁺ transport *46*, 46–48, *47*
 chloride-rich fluid 43, *44*, 44–45, 52,
 56–57
 Cl[−] exit from cells 52
 dangers of Ca²⁺ signaling 52–53
 of digestive enzymes 16, 18, 43, *44*,
 44–45, 56–57

The Pancreas: An Integrated Textbook of Basic Science, Medicine, and Surgery, Third Edition. Edited by Hans G. Beger, Andrew L. Warshaw, Ralph H. Hruban, Markus W. Büchler, Markus M. Lerch, John P. Neoptolemos, Tooru Shimosegawa, and David C. Whitcomb.
 © 2018 John Wiley & Sons Ltd. Published 2018 by John Wiley & Sons Ltd.
 Companion website: www.wiley.com/go/beger/thepancreas

- acinar cell(s) (*cont'd*)
- inhibition, by caerulein, in models 65, 65
 - inhibition reversal effect 66
 - pancreatic juice composition 43
 - prevention by elevated ductal pressure 149
 - repetitive Ca²⁺ spiking 50, 52, 53
 - sequential, with duct cells 56–57
 - store-operated Ca²⁺ channels 45, 50–51, 51
 - see also* digestive enzymes
 - staining 14, 17
 - stimulation, pancreatitis models 63
 - tight junctions between 15, 52
 - transition to ductular-like cells 14
 - turnover and division 98
 - ultrastructure 14, 15–16, 16, 17
 - volume of pancreas 43
 - zymogen granules 13, 16, 17, 20, 178
- acinar cell carcinoma (ACC)
- gene mutations 941
 - immunohistology 701
 - molecular mechanisms 683, 941
 - oncocytic neuroendocrine neoplasm *vs* 932
 - pancreatic neuroendocrine tumors *vs* 936
 - pathology 699–701, 700
 - tumor marker 763
- acinar cell cystadenoma 578, 699
- acinar cell neoplasms 573
- see also* acinar cell carcinoma (ACC); pancreatoblastoma
- acinar fluid 43–44
- components 43–44
 - secretion 43, 44, 44–45, 56–57
 - Ca²⁺ control 52
 - see also* acinar cell(s), secretion
- acinar tissue 13–16
- absence 28
 - see also* acinar cell(s); acinus (acini)
- acinar-to-ductal metaplasia (ADM) 14, 338
- acinar transport model 44
- acinar tubules 13, 17
- arrangements 13–14
- “acinar–duct–islet axis” 123, 124
- see also* insulo–acinar relationship
- acinus (acini) 43
- arrangements 13–14, 123
 - blood supply 252
 - early degeneration 30
 - low blood flow, damage 252
 - peri-insular (around islets) 123, 124
 - tele-insular 123
 - ultrastructure 13–16
- acquired immune deficiency syndrome (AIDS) 232
- ACTH, PanNETs secreting 955, 956
- medical treatment 973
- activated protein C (APC) 184
- acute biliary pancreatitis (ABP) 146–157
- cholecystectomy after, timing 153, 299, 328, 357
 - clinical features 152
 - diagnosis 296
 - endoscopic therapy 296–300
 - adverse events 297
 - cholecystectomy after 299
 - early treatment, benefits 298
 - indications for 296–297
 - outcomes and timing 297–299, 328
 - stone extraction 297, 298
 - techniques 297
 - epidemiology 146, 150–151, 296
 - etiology 146–150, 296
 - bile reflux 146, 147
 - common channel hypothesis 146–147, 149
 - ductal hypertension hypothesis 148–149
 - duodenal reflux hypothesis 147–148
 - gallstone mechanisms 146–149, 296
 - microlithiasis 151, 151
 - other causes (non-gallstone) 149, 149–150
 - two-phase hypothesis 149
 - gallstones 146–149, 160, 193, 196, 260, 296, 355
 - confirmation of presence 151–152, 152, 297
 - histopathology 196
 - management 260
 - obstruction and resolution 149
 - size and number 151
 - histopathology 196
 - historical aspects 146
 - imaging 148, 296, 297
 - ERCP 152–153, 296, 297, 298–299
 - mortality rate 152
 - natural course 196
 - pathogenesis 296
 - recurrent attacks 153, 299, 357
 - treatment 152–153, 260
- acute lung injury (ALI) 181–183
- acute necrotic collection (ANC) 195, 242–243, 243, 272, 277
- acute pancreatitis with *see* necrotizing pancreatitis
- definition 277, 306, 311
 - see also* pancreatic fluid collections (PFC)
- acute pancreatitis 63, 158
- abdominal compartment syndrome 205, 261–262
 - acute lung injury 181–183
 - acute-phase proteins 207–208
 - alcohol-induced *see* alcohol-induced acute pancreatitis
 - annular pancreas 215, 215
 - ARDS 181–183, 261
 - bacterial infections 183, 265–266, 266
 - biliary *see* acute biliary pancreatitis
 - biliary tract link, landmarks 146, 147
 - blood pressure 185, 258
 - systolic 259–260, 261
 - blood urea nitrogen (BUN) 207, 209, 262
 - C-reactive protein 207–208, 209
 - cardiovascular abnormalities 185, 185–186, 261
 - care after 327–328
 - chemokines 208, 209
 - in children *see* pediatric acute pancreatitis
 - cholecystectomy after, timing 328
 - choledochal cyst 214, 214–215
 - choledochocele 214, 214–215
 - chronic pancreatitis development *see* chronic pancreatitis
 - chronic pancreatitis overlap 323
 - classification systems 199–203, 204, 238–241
 - Atlanta (1992) system 199, 238–239, 265, 305
 - Atlanta (2012) system *see* Atlanta classification, revised (2012)
 - in children 224
 - determinant-based (DBC) 199, 200, 200, 201, 239, 241
 - future prospects 200–202
 - imaging for 238
 - matching to setting 200–201
 - modified DBC 202, 202
 - new 199–200
 - reasons for classifying 199
 - validation and comparison 200, 201, 241
 - see also* acute pancreatitis, severity assessment
 - clinical features 219, 222, 258
 - see also* pain, acute pancreatitis
 - clinical pathway for managing 258–260, 259
 - coagulopathies 184–185
 - congenital anomalies and *see* congenital anomalies
 - costs of 63, 251
 - creatinine (serum) 207, 209, 262
 - cytokines 71, 162, 208, 209
 - definition 193, 219
 - diabetic ketoacidosis 231, 262
 - diagnosis 238, 239
 - discharge planning 357
 - drug-related 232–234, 234
 - early intra-acinar events 64–72, 324
 - autophagy pathways 70
 - calcium signaling 67
 - cathepsin B role in apoptosis 69, 69–70, 180
 - colocalization, zymogens/lysosomes 66, 66
 - enzyme activation 53, 64–68, 178–180, 196–197, 336
 - ER stress 70–71
 - inflammatory pathway activation 64, 67–68, 71
 - inhibition of secretion 65, 65–66
 - innate immune system activation 67
 - mitochondrial dysfunction 70
 - systemic injury after 71–72, 252
 - trypsin role, acinar cell injury *see below*
 - early management 258–260, 259
 - ECG abnormalities 185–187
 - ectopic pancreatic tissue 215
 - edematous *see* acute pancreatitis, interstitial edematous

- etiology 230, 296, 355, 417
 alcohol *see* alcohol-induced acute pancreatitis
 bile reflux 146, 147
 biliary surgery causing 150
 congenital anomalies *see* congenital anomalies
 cystic lesions 327
 drugs causing 232–234, **234**
 gallstones *see* acute biliary pancreatitis
 hypertriglyceridemia mechanism 262
 infectious diseases 231–232, **232**
 examination for 258
 fatty acid ethyl esters (FAEE) 186
 fluid collections after 311–312
 conservative treatment 312–314
 endoscopic management 301–304
 minimally invasive therapy 313–314
 surgical management 305–310
 see also pancreatic fluid collections (PFC)
 follow-up 327–328
 free fatty acids, increased 186
 fungal infections 252, 266
 genetic factors 158–165, **159**
 multiple genetic defects 161
 see also genetic susceptibility factors
 gut permeability 183–184, **184**
 gut–lymph composition changes 168
 gut–lymph toxicity 169, **169**
 hematocrit 207, **209**, 259
 in hereditary pancreatitis 375–376
 histopathology 193–198, **335**
 etiology related to 196–197
 pathophysiologic mechanisms 196–197
 type 1 necrosis pattern 193, **194**, 196, 197
 type 2 necrosis pattern **194**, 196, **196**, 197
 type 3 necrosis pattern **194**, 196, **196**, 197
 unsolved questions 197
 see also necrosis, in acute pancreatitis
 historical aspects 178
 hypercalcemia and 230
 hypertriglyceridemia 230–231, 234, 262
 hypocalcemia 186–187
 hypomagnesemia 186–187
 hypoperfusion 258, 260
 hypotension 261
 hypovolemia 258, 260
 hypoxemia 181
 “idiopathic” 150, 151, 213
 children 222
 imaging 238–250
 classification/severity grading 238–241, **239**, **240**
 CT Severity Index 244–245
 diagnostic criteria **239**
 limitations/pitfalls 245–248
 of local complications **240**, 242–244
 long-term complications 327
 severe pancreatitis **241**, 241–242
 staging of severe pancreatitis 244–245, **248**
 incidence 63, 251, 311, 355, 417, **418**
 infectious complications 265–266, **267**
 prevention 266–267
 inflammatory response, and cytokines 71, 162, 208, **209**
 interleukins (IL-6, IL-8) 208, **209**
 interstitial edematous 193, **194**, 305, 311
 histopathology, initial phase 193, **194**, **195**, 241
 management 313
 outcome 194–195
 radiographic diagnosis **241**, 241–242
 laboratory variables 207–208, **209**, 258, **260**
 local complications 265, **266**, **306**, 316
 acute necrotic collection 195, 242–243, **243**, **266**
 APFC 242, **243**, **266**
 diagnosis/imaging **240**, 242–244
 fistula formation 316
 infections 265, **267**
 need for early diagnosis 248
 pseudocysts **244**, **248**, **266**, 316
 revised Atlanta classification 242, **306**
 “walled-off” necrosis 195, 239, 242, **243**, **244**, **244**, 265, **266**
 long-term complications 323, **325**, 327
 cancer and death 327
 chronic pancreatitis 324, **325**
 endocrine pancreas dysfunction 323, 324, **325**, 328
 exocrine pancreas dysfunction 323, 324–325, **325**, 328
 imaging findings 327
 incisional hernia 327
 pain 323, **326**, 326–327
 risk factors 324, **326**
 long-term outcome 323–330, **325**, **326**
 quality of life 326–327, 357, 359
 see also long term complications (above)
 magnesium deficiency 186
 metabolic/systemic disorders and 230–231, 252
 ICU management 262
 microRNAs 168
 mild **200**, **205**, 241, 242, 254
 see also acute pancreatitis, interstitial edematous
 models *see* experimental pancreatitis
 moderately severe 199–200, **200**, **205**, 241
 molecular/biochemical
 abnormalities 178–181
 cathepsin B **69**, 69–70, 180–181
 digestive protease activation 64–68, 178–180, 196–197
 monitoring 312
 mortality 178, 181, 271, 312, 327, 355
 natural course 178, 260, 261
 necrosis in *see* necrosis, in acute pancreatitis
 necrosis–fibrosis sequence 323
 necrotizing *see* necrotizing pancreatitis
 neurogenic inflammation *see* neurogenic inflammation
 neutrophil-inducing local injury 71–72
 organ failure 178, 181, 184, 205
 dynamics 205
 early, and persistent 205
 modified DBC classification 202, **202**
 multiorgan 178, 181
 see also multiple organ dysfunction syndrome (MODS)
 pancreas divisum 213, **214**
 in pancreatic cancer 327, 718
 pancreatic cystic neoplasms and 569
 pancreatic microcirculation 251–252
 pancreatic stellate cells **20**, 109
 paralytic ileus 183–184, **184**, 262
 parathyroid hormone, increased 186
 pathogenesis 178–179, 196–197
 in periampullary tumors 1038
 phases 64
 as polyfactorial disease 135, 138, 159
 primary hyperthyroidism and 230
 procalcitonin (PCT) 208, **209**
 prognostic factors
 calcium levels 186
 disseminated intravascular coagulation 184–185
 organ failure 205
 progression *see* chronic pancreatitis
 protein C deficiency 184
 pseudocysts after **244**, **248**, **266**, 316
 pseudocysts treatment strategies 301–304
 endoscopic 301–304
 surgical 305–310
 pulmonary dysfunction, management 261
 pulmonary failure 181–183
 radiologic diagnosis 241–244
 see also acute pancreatitis, imaging
 radiologic staging 244–245, **248**
 readmissions for 355–357, **356**
 risk factors **356**, 357
 recurrent (RAP) 325, **325**, 355, 417
 burden/incidence 357, 417, **418**
 in children 226–227
 chronic pancreatitis risk after 195, 359
 in cystic fibrosis 393, 398
 first recurrence 357
 hereditary pancreatitis 374, 376, 746
 histomorphologic pathways 323
 inborn errors of metabolism 33
 natural history 355–359
 prevention 302
 risk and risk factors 324, 357, **358**, 359
 risk/risk factors 357, 359
 second/further recurrences 359
 renal failure 183, 262
 response to, *MCP 1* 2518A/G
 mutation 162
 risk factors 159, **159**
 for recurrence 324, 357, **358**, 359
 serum amyloid A (SAA) 208
 severe **200**, **205**, 239, 241
 contrast CT avoidance 260
 definition 204
 edematous *see* acute pancreatitis, interstitial edematous

- acute pancreatitis (*cont'd*)
- enteral feeding 254–255
 - evolution 260, 261
 - ICU treatment 258–264
 - intestine role 167–168, **168**
 - necrotizing *see* necrotizing pancreatitis
 - radiologic diagnosis **241**, 241–242, 245–248
 - radiologic staging 244–245
 - severity 197, 265, 311, 355
 - classifying, reasons for 199, 201, 202
 - cytokine polymorphisms 162
 - genetic modifying factors 161–162
 - reduced, reversal of secretion inhibition 66
 - severity assessment 204–212, **209**
 - Balthazar's CT system 238
 - CT Severity Index 244–245
 - CT Severity Index, modified **248**
 - CT system/grades 238–239, 244–245
 - historical perspectives 204
 - imaging 204
 - Japanese CT Severity Index 245
 - laboratory variables 207–208, **209**
 - objective criteria 204
 - see also* acute pancreatitis, classification systems
 - severity scoring 205–207, **209**
 - APACHE II score 206, **209**
 - in children 224
 - Imrie/Ranson 205, **209**
 - Marshall 205, 206, **209**
 - organ failure-related 206–207
 - SOFA 205, 206–207, **209**
 - systemic abnormalities in 181–185, 252
 - systemic injury, inflammatory 71–72, 252
 - treatment (antibiotics) 265–270, 313
 - choice of drug 268–269, 313
 - clinical studies 267, **268**
 - on demand 268
 - indications 267–268, 313
 - limitations 269
 - necrosis with infection 267–269, 272
 - prophylactic 266–267, 313
 - rationale for 266–267
 - treatment (conservative) 251–257, 312–314
 - basic support 312
 - enteral/parenteral nutrition 254–255, 313
 - fluids *see* fluid resuscitation
 - treatment (ICU) 258–264
 - admission, indications 260–261
 - early management 261–262
 - initial and second phases 261
 - late management 262–263
 - of metabolic abnormalities 262
 - pre-ICU management 258–260
 - special considerations 260
 - transition planning 263
 - treatment (surgical) *see under* necrotizing pancreatitis
 - trypsin role 68–71
 - acinar cell injury mechanism **69**, 69–70, 178–179, 242
 - second phase of activation 71–72
 - tryptophan metabolites 168
 - walled-off necrosis after 195, 239, 242, **243**, 244, **244**, 265, **266**
 - walled-off necrosis treatment strategies 301–304
 - endoscopic 301–304
 - surgical 305–310
 - acute peripancreatic fluid collection (APFC) 195, 242, **243**, **266**, 311, 313
 - definition 242, 311
 - see also* pancreatic fluid collections (PFC)
 - acute-phase proteins
 - acute pancreatitis severity 207–208
 - SPINK1 protein 160
 - acute recurrent pancreatitis (ARP) *see* acute pancreatitis, recurrent
 - acute renal failure (ARF), in acute pancreatitis 183
 - acute respiratory distress syndrome (ARDS) 181–183, 261
 - adenoma
 - ampullary *see* ampullary adenoma
 - insulin-producing 31
 - solid serous 699
 - villous, periampullary 1040, **1040**
 - adenoma–carcinoma sequence 611, 614, 1047, 1058–1059, 1068, 1074
 - ADH1B** gene 140
 - adrenergic innervation, pancreas 88
 - adrenomedullin 123, 127
 - adverse drug reactions, classification 233
 - AE2 and AE4 56, 57, 59
 - afferent loop syndrome 910, **910**
 - age
 - IPMN 570, 612–613, 707
 - pancreatic cancer 776
 - pancreatic cysts 568, **568**
 - agenesis of pancreas 24
 - partial 24–25
 - AIP *see* autoimmune pancreatitis (AIP)
 - air embolism 281
 - alanine transaminase (ALT) 152, **152**
 - albumin 186, 262
 - alcohol
 - cyst ablation 637, **638**
 - direct effects on
 - acinar cells 136, **136**, 137–138, 336
 - duct cells 136, **136**, 138
 - pancreatic stellate cells 136, **136**, 138
 - effects on pancreas 343–344, **344**, 345
 - epigenetic proteins affected by 336
 - metabolism by pancreas 137, 343
 - metabolites, effects on pancreas 343–344, **344**
 - as modifier in chronic pancreatitis 336
 - withdrawal syndrome 263
 - alcohol consumption
 - abuse/heavy drinking/misuse 342, 343
 - acute pancreatitis 135, 138
 - chronic pancreatitis 336, 342, **343**
 - diabetes in chronic pancreatitis 496
 - pancreatic cancer risk 668–669, 720–721
 - recurrent acute pancreatitis 357
 - beverage type and periodicity of use 138
 - cessation/abstinence 357
 - chronic pancreatitis pain 423
 - after pancreatic resection 469
 - recurrent acute pancreatitis reduction 324
 - continuing, chronic pancreatitis 357, 397
 - counseling against use 357
 - dose–response relationship 342–343, **343**
 - alcohol dehydrogenase (ADH) 137, 140, 343
 - ADH I (ADH1C) 137, 140
 - ADH III 137
 - ADH1B** gene, variants 140, 345
 - alcohol-induced acute pancreatitis
 - alcohol volume causing 135
 - epidemiology 135–145, 355
 - etiology and pathogenesis 135–145, **335**
 - alcohol metabolites, toxicity 137, 138
 - direct cellular effects of alcohol **136**, 136–138
 - historical aspects 135–136
 - large duct theories 135–136
 - small duct (protein plug) theory 136
 - histopathology 196
 - hypertriglyceridemia in 231
 - individual susceptibility 138–142, **139**
 - environmental factors 138–140, **139**
 - hereditary factors 138, **139**, 140–142
 - model not available 64, 136–137
 - as polyfactorial disease 135, 138, 159
 - recurrence/progression 324
 - alcohol-metabolizing enzymes 137
 - polymorphisms 140–141, 345
 - alcoholic chronic pancreatitis 342–348, 359, 398
 - abdominal pain, patterns 361, 399
 - age at diagnosis 417
 - alcohol consumption levels 342–343, **343**, 345, 397
 - clinical features 361, 399
 - co-predisposing factors 345–346
 - diabetes in 402
 - endocrine insufficiency 399
 - epidemiology 342–343
 - experimental models 120, 344, 345
 - genetic susceptibility factors 345–346, 360
 - macrophage role 119, 120
 - pain management 423
 - pancreatic cancer risk 417, 418
 - pathophysiology 343–345, 398
 - cofactors involved 345
 - ethanol metabolism 343
 - ethanol/metabolite effects 343–344, **344**
 - genetic factors 345–346
 - in vitro* and *ex vivo* studies 344
 - in vivo* studies 344–345
 - pancreatic duct role 345
 - smoking and 345, 398, 435
 - survival rates 397
 - tropical chronic pancreatitis *vs* 385
 - undernutrition 429
 - alcoholic pancreatitis
 - acute *see* alcohol-induced acute pancreatitis
 - acute and chronic, as continuum 135
 - chronic *see* alcoholic chronic pancreatitis
 - as clinical paradox 135

- lack of experimental model 64, 136–137
 role of ER stress 71
- algenpantucel-L 859
- Alipogene tiparvovec (Glybara®) 34, 398
- alkaline phosphatase, elevated
 acute pancreatitis 148, 152
 chronic pancreatitis 400
 periampullary tumors 1038
- allergies, pancreatic cancer risk 669–670
- alpha-fetoprotein (AFP) 763
- α cells 123
 development 5, 6
 diabetes in chronic pancreatitis 495, 496–497
 immunostaining 21, 21, 22
see also glucagon
- ALT phenotype 938, 942/940
- alveolar edema 181
- American Joint Cancer Committee (AJCC),
 pancreatic cancer TNM staging
 772–773, 773
- amino acids, dietary 96
- 2-aminoanthracene 673
- ampulla of Vater
 anatomy 11, 75, 76, 1047, 1074
 lymphatic drainage 1075–1076
 biliary sludge 149
 gallstone obstruction 146, 149
 obstruction by parasites 150
 preinvasive neoplasms 1047–1048
 resection 1043, 1061
 somatostatinomas 1053
- ampulla of Vater tumors 1059, 1068, 1074
 benign 1059
 preprocedural evaluation 1068–1069
see also ampullary adenoma
 malignant 150, 1037, 1047–1051, 1058–1067, 1089
 adenocarcinoma 1058, 1069, 1074, 1093
 adjuvant therapy 1093–1094
 (peri)ampullary duodenal
 cancer 1048–1049
 biologic behavior 1058
 biopsy 1060, 1069
 classification 1058, 1059
 clinical features 1037–1038, 1059
 diagnosis 1059–1061, 1069
 endoscopic surgery 1061, 1068, 1075–1076
 epidemiology 1058, 1074
 genetics 1050–1051, 1059, 1074–1075, 1093
 histology 1049, 1050, 1074
 IAPN association 1048
 imaging 1039, 1059–1061, 1060, 1068–1069
 intestinal type 1050, 1050, 1059, 1093
 invasive 1048–1051, 1061
 long-term outcome 1063, 1077, 1077, 1078
 low-risk, surgery 1076, 1076
 lymph node metastases 1049, 1061, 1075, 1075–1076, 1101–1102
 management 1061–1062, 1062
- molecular pathology 1050–1051, 1074–1075
 nonsurgical management 1062
 not otherwise specified 1049, 1050
 palliative therapy 1094
 pathology and pathogenesis 1058–1059, 1068
 postoperative outcome 1077, 1077, 1101, 1101–1102
 prognosis 1049–1050, 1061, 1074
 prognostic factors 1061, 1101, 1101–1102
 recurrence 1102
 staging 1060, 1061, 1061
 subtypes 1048–1051, 1049, 1059, 1074
 surgery 1043, 1061–1062, 1062, 1068, 1075–1076
 surgery, ampullectomy 1061, 1075, 1076, 1076, 1077, 1077
 surgery,
 pancreatoduodenectomy 1076–1077, 1077, 1078
 surgery indications 1075
 surveillance after 1062, 1063
 survival 1049–1050, 1061, 1099, 1100, 1101
 “tubular” 1050
 types 1059
 uncommon 1051
- ampullary adenoma 1058, 1060, 1068, 1074, 1076
- ampullectomy 1075, 1076, 1076
 duodenal 1047
 endoscopic appearance/diagnosis 1069
 endoscopic papillectomy 1061, 1068, 1069–1071, 1070, 1075
 complications 1071–1072
 results 1071
 techniques 1069–1071, 1070
 large, treatment 1075–1076
 management 1061, 1062
 molecular pathology 1074
 preprocedural evaluation 1068–1069
 recurrence 1075
 remnant tissue, treatment 1071
 surgical resection 1061, 1068, 1075
 surveillance 1061, 1072, 1075
- ampullary carcinoma *see* ampulla of Vater tumors
- ampullary duct carcinoma 1049, 1049–1050
- ampullectomy 1061, 1062, 1063, 1075
 ampullary adenoma 1069–1071, 1070
 large adenomas 1075, 1076
 endoscopic 1061
 survival after 1077, 1077
 “underwater” 1069
- amylase, pancreatic
 α 2A, antibodies to 541
 carbohydrate in diet effect 96
 CCK-stimulated secretion
 glucagon inhibiting 125
 insulin increasing 96, 124
 pancreatic polypeptide inhibiting 126
- deficiency 29, 29, 400
 elevated 539
 autoimmune pancreatitis 539
 pediatric acute pancreatitis 222, 224
 intracellular, nicotine effect 674
 measurement, historical aspects 204
 pancreatic fistula diagnosis 317, 318
 pancreatic leak, marker 645
 pseudocysts and 593
 synthesis/levels 96
- amylase, total serum, chronic
 pancreatitis 400
- amylin 126
- amyloid A, serum (SAA) 208
- amyloid-like deposition 931–932, 933
- analgesics
 chronic pancreatitis pain 423, 423, 489
 pancreatic cancer 879–880
 guidelines 879–880
 intrathecal delivery 882–883
 WHO ladder 880, 880
 new adaptation 880, 881
- anastomotic ulcer 799
- anatomy 3–23
 aberrant, pancreatoduodenectomy
 and 644
 ampulla of Vater 11, 1047, 1075–1076
 common bile duct 11, 11, 75, 76, 1047
 duodenum 10, 75, 76
 pancreas 3, 10–23, 11, 12, 879
 arterial blood supply 13, 14, 124, 124, 251–252
 CT images 12, 13
 gross anatomy 10–13, 11, 12
 lymph nodes around 13, 15
 major blood vessels 10, 12
 nerve supply 13, 16, 88, 173, 174, 351, 421
 relationships to other organs 10, 12
 tail of 3, 10–11, 790–791
 ultrastructure 13–20
see also endocrine pancreas; exocrine pancreas
 sphincter of Oddi 75–76, 76
 terminology associated 10
- angiogenesis inhibitors, PanNETs 976
- angiotensin-converting enzyme (ACE)
 inhibitors 233
- annexinA2 860
- annular pancreas 25, 25–26
 acute pancreatitis 215, 215
 clinical features and imaging 25, 25, 215, 215
 incidence, and anomalies 25, 215
 surgical treatment 26, 215
- anomalous pancreaticobiliary ductal union (APBDU) 214, 214
- anterior intestinal portal 4
- anti-carbonic anhydrase type II 525, 540
- anti-CTLA-4 858, 858, 860, 861
- anti-endotoxin antibodies, depletion 168
- anti-inflammatory response syndrome 178
- anti-insulin infusion 125, 125
- anti-mesothelin vaccines 683

- antibiotics
 in acute pancreatitis *see* acute pancreatitis, treatment (antibiotics)
 overuse 269
 prophylactic
 acute pancreatitis 266–267, 313
 pancreatic fistulas and 318–319
 pancreatic pseudocysts 441–442
 resistance, multidrug, acute pancreatitis 266
 treatment “on demand” 268
- antidiabetic drugs, oral 400, 498–499
- antiepileptic drugs 234
- antinuclear antibodies, autoimmune pancreatitis 510, 540
- antioxidant(s)
 adverse effects 437
 deficiency
 chronic pancreatitis 435
 tropical chronic pancreatitis 386
 therapeutic 435, 436–437
- antiprotease treatment 170, 251
- antithrombin III, acute pancreatitis 185
- aorta, pancreas relationship 10, 12, 13
- AP-1 (activator protein-1) 138, 344
- APACHE II score, acute pancreatitis 206, 209
- APFC *see* acute peripancreatic fluid collection (APFC)
- apolipoprotein C-II deficiency 33, 34, 34–35
- apoptosis
 acinar cells, cathepsin B role 69, 69–70, 180
 extrinsic/intrinsic pathways 70
 pancreatic stellate cells 109
- Appleby procedure, modified 784, 792, 817, 817
- arginase-1 120
- arginine-induced pancreatitis model 63, 64
- arterial blood supply, pancreas 13, 14, 124, 124, 251–252
- arteriography, abdominal, pancreatic neuroendocrine tumors 951
- ARX 6
- Ascaris lumbricoides* 232
- ascending cholangitis 152, 260
- ascites 312
 pancreatic 168, 318, 366, 451
- aspartate transaminase (AST) 152, 152
- Aspergillus*, acute pancreatitis
 association 232
- Atlanta classification (1992) 199, 238–239, 265, 305
 “walled-off” necrosis 266, 273
- Atlanta classification, revised (2012)
 265, 271
 acute pancreatitis 181, 197, 199–200, 200, 205, 239, 241
 acute peripancreatic fluid collection 242, 266, 266
 determinant-based classification *vs* 200, 200, 201, 241
 histopathologic features 194
 interstitial edematous pancreatitis 194, 241–242
- local complications 242, 266, 306
- necrotizing pancreatitis 194, 242, 266
- organ failure 205, 241
- pancreatic necrosis 239, 266, 272
 “walled-off” necrosis 239, 266, 273, 305–306
- ATM* gene mutations 690, 746
- ATP, lacking, acute pancreatitis 70
- ATP12A (H⁺, K⁺-ATPase pump) 57, 58
- atropine 86
- ATRX* gene, mutation 938, 939, 940, 941, 942, 943
- ATRX* protein 938, 940, 943
- autoantibodies
 evidence for use in diagnosis 544–545
 non-organ/organ-specific 540
 type 1 autoimmune pancreatitis 510–511, 525, 540, 540, 541–542
- autodigestion of pancreas 64, 316, 344
see also digestive enzymes
- autoimmune diseases, chronic pancreatitis with 350
- autoimmune pancreatitis (AIP) 350, 503–564, 1037
 diabetes mellitus in 496
 diagnostic criteria (ICDC) 505, 521, 522, 523, 536, 550
 differential diagnosis 517
 pancreatic cancer *vs* 419, 546, 550, 552
 use of markers 545–546
 endocrine insufficiency after 557, 562, 562
- epidemiology 505–509, 546
 first international survey 505–506
 Japan, nationwide survey 505
 second international survey 506, 507
 third international survey 506–507, 508
- exocrine insufficiency after 557, 562, 562
- as fibroinflammatory disease 555
- histology 505, 516–519, 518, 520, 546, 550
- histopathology 368, 550
- historical aspects 520, 521, 534, 539
- imaging diagnosis 550–554
 abdominal CT 411, 523, 525, 551, 551
 abdominal MRI 411–412, 551
 abdominal ultrasound 550–551
 ERCP 523–524, 552, 552–553
 FDG-PET 524, 526, 528, 529, 551–552, 756
 MRCP 524, 553, 553
 nuclear medicine 551–552
 pancreatic duct imaging 552, 552–553, 553
 parenchyma imaging 550–552, 551
- inflammatory pancreatic head mass *vs* 366–367
- laboratory diagnosis 539–543
 autoimmunity markers 540, 541–542, 544
 β-γ globulin bridging 544, 545
 evidence for use of markers 544–549
 IgA and IgM 545
 IgG4 levels 524–525, 540, 541, 544, 545, 546
- markers, for diagnosis, evidence 544–545
- markers, for differential diagnosis 545–546
- markers, for relapse prediction 546, 546–547
- other markers 541
- serum markers 539–540
- long-term outcome after therapy 560–564
 exocrine/endocrine insufficiency 557, 562
 extrapancreatic cancer in 563
 “ordinary” chronic pancreatitis 562
 pancreatic cancer risk 517, 553, 557, 563
 relapse *see below*
- medical management 555–559, 560
 algorithm 558
 follow-up 557
 high-dose steroids 556, 557
 immunomodulators 556, 557, 558
 of initial presentation 556
 low-dose steroids 556
 of relapse 556–557, 560–561
 rituximab 556, 557, 559, 560
 side-effects and managing 557–558
 steroids 529, 555, 556–557
 steroids, in type 2 536, 546, 547, 558
- natural history 562, 562
- not otherwise specified (NOS) 521, 523
- pathogenesis 510–515
 autoantibodies 510–511, 525, 544
 B cells and plasmablasts 512
 cytokines/chemokines 511, 511–512
 genetic predisposition 510
 immunologic interactions 512
 plasma cells 512–513
 T cells 511, 511–512
- recrudescence 555–556
- relapse 556, 560–561, 562
 markers to predict 546, 546–547
 medical management 556–557, 560–561
 rates/frequency 560, 562
 symptoms 556
 type 2 507, 508, 536–537, 546, 547
- remission 555
 induction/maintenance 556
- symptoms 505, 506, 521–522
 type 1 505, 520, 521, 534, 539, 550, 555
 autoantibodies 510–511, 525, 540, 540
 blood tests 524–525
 “capsule-like rim” 522, 551, 551
 clinical features 520–533, 524
 definitive and probable 523
 diagnostic criteria (ICDC) 521, 522
 differential diagnosis 517
 diffuse enlarged pancreas 522–523
 epidemiology 506, 507, 507
 extrapancreatic lesions 526–529, 528, 529
 histology 516–517, 518, 520, 527, 546, 550
 IgG4 *see* immunoglobulin G (IgG), IgG4
 imaging 522–524, 525, 526
 pathogenesis 510–513, 512, 541, 541

- pathology 520, 525–526, 550
 patient profiles 521–522
 proteomic study 513, 541
 steroids, response/relapse 529
 storiform fibrosis 516, 517, 525
 symptoms 521–522
 treatment, and relapse 507, 508
 type 2 505, 520, 521, 534–538, 550, 555
 associated diseases 535
 clinical course/outcome 537
 clinical features 524, 535
 demographics 535
 diagnosis 535, 536
 diagnostic criteria (ICDC) 521, 523, 536
 differential diagnosis 518, 536
 epidemiology 506–507, 507, 535
 histology 518, 518, 518, 520, 527, 546, 550
 inflammatory bowel disease 513, 521, 526, 535
 pathogenesis 513, 513
 relapse 507, 508, 536–537, 546, 547
 steroid therapy 536, 546, 547, 558
 terminology 534–535, 535
 treatment 507, 508, 536, 558
 unclassified 518, 523
 autolysosomes 70
 autonomic nerves, pancreas 13, 16
 autophagosome 70
 autophagy 70, 138, 316, 344
 autosomal dominant polycystic kidney disease (ADPKD) 32, 569
 autosomal recessive polycystic kidney disease (ARPKD) 32
 azathioprine 234, 556
 azotorrhea 399
- b**
- B cells (B lymphocytes) 856, 857
 CD20 556, 561
 type 1 autoimmune pancreatitis 512, 517, 556
 B lymphocytes *see* B cells (B lymphocytes)
 bacteremia, gallstone association 152
 bacterial endotoxin *see* endotoxin, bacterial
 bacterial infections
 acute pancreatitis 265, 266
 complication of 265, 266, 267
 etiology of 231, 232
 prevention/treatment 266–267
 pancreatic abscess 241, 302, 305, 316, 318, 441
 spectrum 266
 superinfection of pancreatic necrosis 178, 266, 267
 bacterial overgrowth 183, 430
 bacterial translocation 166, 183, 184, 254
 bacterial translocation hypothesis 166
 bactibilia 913
 BALLARD trial 1092
 balloon enteroscopy-assisted ERCP 836
 Balthazar system 238
 basic helix loop helix (bHLH) transcription factor 6
 basilar cell membrane 15
 Bax (Bcl-2 apoptosis-promoting protein) 70
 Bcl-2 70
 BCL-10 701
 Beckwith–Wiedemann syndrome (BWS) 31, 33, 701
 Beger procedure 367, 368, 450, 453, 491
 laparoscopic 485
 outcome, Frey procedure *vs* 491–492
 benzo[a]pyrene 674
 benzodiazepines 263
 Bernard, Claude 146
 Berne/Farkas modification, of Beger procedure 367
 Berne procedure 450, 485, 491
 β-γ globulin bridging 544, 545
 β cells 21, 123, 124
 ATP-dependent potassium channel (K_{ATP}), defects 31
 deficit (number), in chronic pancreatitis, diabetes 495, 496
 development 5, 6, 7
 dysfunction
 in chronic pancreatitis, diabetes and 495, 496
 pancreatic stellate cell role 110, 112
 immunostaining 21, 21, 22
 insulinoma 1002
 see also insulin
 bevacizumab 976
 PanNETs 975, 976
 bias, referral 342
 bicarbonate (HCO₃⁻)
 as chaotropic ion 60
 ductal secretion 43, 44, 57, 58, 160
 CFTR role 160, 161
 cholinergic neurons and 88
 failure, acute pancreatitis 160–161
 functions 60
 insulin inhibiting 124–125
 pancreatic diseases 60
 regulation 59, 59
 secretin role 84
 entry into duct cell 160
 pancreatic juice composition 43–44
 bicarbonate (HCO₃⁻) transporters 59, 160
 Bid (Bcl-family) 70
 bile
 flow
 regulation 76, 77, 79
 see also sphincter of Oddi
 mucin in, acute pancreatitis 151
 reflux
 acute pancreatitis trigger 146, 147
 common channel syndrome 27, 146–147, 197
 bile duct(s)
 anatomy 11, 75
 cancer 688, 1051
 see also distal cholangiocarcinoma
 drainage, preoperative, in pancreatic cancer 835
 intraductal papillary neoplasms (IPNB) 1052
 narrowing/stenosis 553
 type 1 autoimmune pancreatitis 526, 527, 528, 534
 obstruction
 acute pancreatitis 147, 149, 152
 biliary drainage 835
 endoscopic stenting 829
 ERCP in pancreatic cancer 829, 835
 pancreatic cancer 770, 828, 829, 832, 835
 surgical treatment 451–452
 stones
 acute biliary pancreatitis 296
 removal 297
 strictures
 anastomotic, after
 pancreatoduodenectomy 911
 endoscopic therapy outcome 491
 inflammatory pancreatic head mass 366
 surgical treatment 451–452
 surgery, acute pancreatitis due to 150
 wall, and innervation 76
 biliary intraepithelial neoplasms (BilIN) 1051–1052
 biliary pancreatitis, acute *see* acute biliary pancreatitis
 biliary sludge 149–150
 acute pancreatitis due to 149, 150
 components 149–150, 150
 pancreatic duct obstruction 149
 biliary stent placement 837–838
 ampullary tumors 1071
 biliary surgery, acute pancreatitis due to 150
 biliary tract
 acute pancreatitis link 146, 147
 carcinoma 1051, 1052
 extrahepatic, tumors 1083
 neuroendocrine tumors 1024
 see also distal cholangiocarcinoma
 intraepithelial neoplasms 1051–1052
 bilirubin, elevated 1038
 binge drinking 135, 138
 biochemical markers
 acute pancreatitis 207–208
 autoimmune pancreatitis 541
 pancreatic cancer *see* pancreatic cancer, tumor markers
 PanNETs 956–957
 biopsy
 ampullary tumors, malignant 1060, 1069
 EUS-FNB, ampullary carcinoma 1060
 pancreatic cancer 776, 869
 pancreatic transplant rejection 1127
 bleeding
 post-DPPHR 460, 462
 post-endoscopic papillectomy 1071
 post-laparoscopic surgery 650
 post-necrosectomy, necrotizing pancreatitis 286
 post-pancreatoduodenectomy 645–646
 transmural drainage, infected pancreatic necrosis 280
 blood flow, low, in pancreatic acinus 252

- blood glucose
 perioperative management, insulinoma 1020–1021
 after total pancreatectomy 799
 type 1 diabetes 1121
 type 3c diabetes 497, **497**
see also glycemic control; HbA_{1c}; hyperglycemia; hypoglycemia
- blood group, non-O, pancreatic cancer risk 746
- blood pressure
 acute pancreatitis 185, 258
 systolic, severe acute pancreatitis 259–260, 261
- blood supply
 islets of Langerhans 22, 124, 124
 pancreas 13, 14, 124, 124, 251–252
- blood tests, type 1 autoimmune pancreatitis 524–525
- blood urea nitrogen (BUN), acute pancreatitis 207, **209**, 262, 312
- body mass index (BMI)
 chronic pancreatitis 429
 pancreatic cancer risk 667, 668, 720
see also obesity
- body of pancreas
 anatomy 3, 790–791
 cancer *see under* pancreatic cancer
 CT image 12
- BOLERO-1/BOLERO-3 trials 943
- bombesin, pancreatic secretion
 stimulation 87
- bone health, chronic pancreatitis 430
- bowel ischemia, post-necrosectomy 286
- bowel resection 320
- bowel rest 254
- bradykinins 233
- BRAF** gene, mutations, ductal adenocarcinoma 679, 680, 683, 867
- branched-chain ketoaciduria 34, 35
- BRCA1** gene, mutation 688
 pancreatic cancer 689, 746
- BRCA2** gene, mutation 679, 683, 746, 869
 familial pancreatic cancer 689, 746, 747
- breast cancer, familial pancreatic cancer 688, 689
- brittle diabetes 431, 497, 798
see also diabetes mellitus, type 3c
- brown bowel syndrome 430
- Brunner glands, nonampullary duodenal cancer 1052
- Büchloer–Bern procedure 492
- buprenorphine **423**
- “burn-out theory,” pain 350, 361
- C**
- C-peptide, insulinoma 954
- C-reactive protein (CRP), acute pancreatitis 207–208, **209**
- CA-125, pancreatic cancer 771
- CA12** gene, mutations 59, 60
- CA19-9 367, 451, 762
 elevated, conditions with 762
 cholangiocarcinoma 1038
 periampullary tumors 1038
- false-positives/-negatives 762, 770
 measurement 762, **763**
- pancreatic cancer 762, **763**, 770–771, 776, 906
 local recurrence marker 903
 normal after neoadjuvant therapy 844
 prognosis and 762, 770–771, 910
 screening 749
- cachexia 368
- cADPR (cyclic ADP-ribose) 47, 47–48
- caerulein 63
 acinar cell culture, growth 101
 chronic pancreatitis and 120, 344–345
 inhibition of secretion by, in models 65, **65**
- caerulein hyperstimulation model 63, 64, 67
- cathepsin B leakage 69, **69**
- calcifications, pancreatic **408**
 CT 407
 of cysts 570
 diabetes risk in chronic pancreatitis 496
 mucinous cystic neoplasm 596
 psammomatous 932
- calcineurin–NFAT pathway, pancreatic growth 99, 99–100
- calcitonin gene-related peptide (CGRP)
 chronic pancreatitis 350, 351
 pancreatic cancer 879
 sensory afferents releasing 173
- calcium
 dysregulation, acute pancreatitis 158–159
 elevated levels *see* hypercalcemia
 low levels in acute pancreatitis 186–187
- calcium channels
 acinar cell secretion 45
 Ca²⁺-selective CRAC (Ca²⁺ release activated) 51, 53
 store-operated 45, 50–51, **51**
- calcium injection test 949, 951, 1005, 1009–1010, **1010**
- calcium ions (Ca²⁺)
 acinar cell secretion 44, 44–45
 Ca²⁺ entry/exit 50–51, **51**
 Cl⁻ and K⁺ channel activation 52
 enzyme secretion control 51–52
 fluid secretion control 52, 56–57, **57**
 repetitive Ca²⁺ spiking 50, 52, 53
 signal generation mechanisms 48, 48–50, **49**
 signaling 45, **45**, 47, 149
 signaling, dangers 52–53
see also acinar cell(s)
- ductal cell secretion, activation 60
 elevated, exocytosis activation 44–45
 homeostasis (entry/exit) 50–51, **51**, 67
 organelles important for 46, 46–48, **47**
- intracellular stores, acinar cells 45
 increased, alcohol effect 138
 overload, acinar cells 52–53
 release from zymogen granules 179
- signaling 230
 acinar cell secretion *see above*
 acute pancreatitis 67, 230
 pancreatic stellate cells 109
 store-operated Ca²⁺ entry 45, 50–51, **51**
- transport, exocrine pancreas 46, 46–48, **47**
 transport in acinar cells 46, 46–47, **47**
 tunnel experiments 46
 uptake inhibited, zymogen activation prevented 230
- calcium-sensing receptor gene (CASR), gene mutations 161, **377**
- calculi, tropical chronic pancreatitis 385
- cancer vaccines 858–860
- cancerization
 ductal 694, **695**, 706
 periampullary 1047
- Candida**, acute pancreatitis association 232, 266
- capecitabine
 advanced pancreatic cancer 874, 876
 ampullary carcinoma 1093
 pancreatic cancer adjuvant therapy 849, **850**
- capillaries, exocrine pancreas 124, 252
- CAPOX therapy 1093, 1094
- CAPS3 study 747–748
- carbohydrate antigen 19–9 *see* CA19-9
- carbohydrates (dietary)
 digestion/metabolism 426
 regulation of pancreatic protein synthesis 96
- carbon dioxide, exhalation, exocrine function test and 402
- carbonic anhydrase 59, **59**
 CA12 59, 60
 type II, autoantibodies against 525, 540
- carboxyl ester lipase (CEL) 32, 137, 231, **427**
 hybrid allele (**CEL HYB**) 141
- carboxypeptidase A1 (CPA1) 179, **427**
- carcinoembryonic antigen (CEA) 595, 598
 mucin-producing cysts 440, 607
 neoplastic cysts 603, **604**, 607
 pancreatic cancer 771
 pancreatic cysts 440, 593, 595, 596, 598
 serous cystadenoma 603
- carcinogen(s) 673
 accumulation in pancreatic juice 676
 cigarette smoke 673–674, 675, **675**, 676
 metabolism, enzymes 673–674, 676
- carcinogenesis, pancreatic cancer 673–675, **675**
- carcinoid syndrome, classical 955, 956
 medical treatment 973, 974
- carcinoid tumors 1019
 gallbladder 1025
 liver 1024
- cardiac output, gut–lymph toxicity and 169, **169**
- cardiovascular abnormalities
 acute pancreatitis 185, 185–186, 261
 pancreas transplant and 1123
- Carney complex 707
- β-carotene 436, 437
- caspase-3 70
- caspase-9 70
- CASR** gene, mutations 161, **377**
- cassava 385–386

- β -catenin
 gene mutations 615, 866, **866**, 1050
 solid pseudopapillary neoplasm 584, 615, 699, 936
- cathepsin B 66, **66**, 68
 acinar cell injury role 69, 69–70, 180
 knockout mice 67, 180
 premature activation of digestive enzymes 180–181
 secretion, from exocrine pancreas 180
 “cathepsin B hypothesis” 180
 cathepsin B–pancreatitis hypothesis 180–181
 cationic trypsinogen *see PRSSI* gene; trypsinogen
- cavernous transformation 366
 CCK-JMV-180 65, **65**
 CCL1, type 1 autoimmune pancreatitis 511, 511–512
CCNE1 gene, mutations 866
 CCR8, type 1 autoimmune pancreatitis 511, 511–512
- CD4 cells *see* T cells, helper
 CD8 cells 856, 857, **857**
 CD10 111, 584
 CD20 556, 561
 CD28 857
 CD40 861
 CD56 577
 CD99 577, 584
 CDK4 867
 inhibitors 867
CDKN2A gene *see p16/CDKN2A* gene mutation
- CDX2 576, 613, 697, 709, 711, 1048
 CEA *see* carcinoembryonic antigen (CEA)
CEL HYB hybrid allele 32
 celiac artery (celiac axis, trunk) 13, 252
 pancreatic cancer 814, 824, 838
 staging 773
 resection
 distal pancreatectomy with 792
 pancreatic cancer 784, 816–817
 stenosis 467–468, 644
- celiac ganglion 16, 76, 173, **174**, 489
 celiac plexus
 blockade 489–490, 838
 pain in pancreatic cancer 838, 879
 ablation *see* celiac plexus neurolysis (CPN)
- celiac plexus neurolysis (CPN) 772, 838, 880–882
 complications 882
 contraindications 881–882
 EUS-CPN 838, 881
 percutaneous 838–839, 881
- cell(s), of pancreas 3
 death of *see* apoptosis
 differentiation/development 5–6
 early, plasticity 6
 growth in culture 101
see also acinar cell(s); duct cell(s); endocrine cell(s); pancreatic stellate cell (PSC)
- cell cycle, gene mutations
 ampullary carcinoma 1075
 pancreatic cancer 866, **866**
- cell lines 101
 central nervous system (CNS), chronic pancreatitis 349, 352
 centroacinar cells 13–14, 15
 function 16, 18
 histology 15, **17**
 cerulein *see* caerulein
 CFTR *see* cystic fibrosis transmembrane conductance regulator (CFTR)
 CFTRBD (CFTR, deficiency of bicarbonate conductance) 161
- chaotropic ions 60
 checkpoint inhibitors 857–858, **858**, 859, 860, 861
- chemical ablation
 celiac plexus *see* celiac plexus neurolysis (CPN)
 splanchnic nerves 880–882
- chemoembolization, hepatic metastases 1011
- chemokine(s)
 acute pancreatitis
 pathogenesis 64, 67–68, 71, 162
 severity assessment 208, **209**
 autoimmune pancreatitis, type 1 511, 511–512
 polymorphisms, acute pancreatitis 162
- chemoradiotherapy
 duodenal cancer 1081, 1092
 pancreatic cancer 848, **849**, 851–852, 886–887
 borderline resectable 887–888
 5-fluorouracil (5-FU) 843, 847, 886, 887
 isolated local recurrence 901–903, **902**
 locally advanced 876, 887–888
 recurrence, treatment **899**
- chemotherapy
 cyst ablation 637
 duodenal cancer 1081
 pancreatic cancer *see* pancreatic cancer
 PanNEC 975, 976, 1006
 PanNETs 964, 975–976, 1006
- children
 acute pancreatitis *see* pediatric acute pancreatitis
 enzyme replacement therapy 427, **427**
 genetic testing for hereditary pancreatitis 380
 pancreatoblastoma 701
- chloride, sweat 393
- chloride (Cl⁻) channels
 acinar fluid secretion, Ca²⁺-mediated control 44, 52, 56–57, **57**
 duct cell fluid secretion 57, **58**
- chloride ions (Cl⁻) 56–57, **57**
 Cl⁻/HCO₃⁻-exchangers 56, **57**
 Cl_{in} 59
 permeability of CFTR 160, 391
- cholangiocarcinoma
 CA19-9 1038
 distal *see* distal cholangiocarcinoma
- cholangiography, perampullary tumors 1040–1041
- cholangitis
 ascending 152, 260
 obstructive, endoscopic drainage 444
 sclerosing *see* sclerosing cholangitis
 treatment 152
- cholecystectomy
 acute biliary pancreatitis
 after endoscopic therapy 299
 timing after 153, 328, 357
 acute pancreatitis
 recurrence reduction 324
 same-admission vs interval 153
 timing after 328
 pancreatoduodenectomy procedure 470
- cholecystojejunostomy 829
 cholecystokinin (CCK) 127
 acinar cell culture, growth 101
 acinar cell stimulation 43, 44, **44**, 45, 48, 51–52
 ductal obstruction and 149
 enzyme secretion 44, 44–45, **85**, 85–86, 88
 fluid secretion 43, **44**, 44–45
 mechanism 48, 49–50, 85, **85**
 nicotine effect, pancreatic cancer 674, 675
- actions/functions 44, 45, 75, 85–86, 125
 adaptive growth of pancreas 99, 99–100
 intracellular pathways 99, 99–100
- amylase secretion, insulin stimulating 124, 125, 127
- analogue 63
 inhibition of secretion, models 65, 65–66
see also caerulein
- antagonists 85, 100
 effect on satiety 86
 elevated
 chronic pancreatitis 90
 pancreatic protein synthesis inhibition 98, **98**
- fasting levels 85
 insulin secretion, effect on 127
 molecular forms 85
 pancreatic function test involving 401, **401**
- pancreatic protein synthesis stimulation 96, **97**, 97–98
- pancreatic secretion stimulation 44–45, **85**, 85–86, 88, 125
 atropine effect 86
 insulin effect 124, 125
 peptide YY effect 126
- receptors 48, 64
 CCK-A and CCK-B 127
 CCK₁ 86, 87
- regeneration of pancreas 100
 release/secretion 85, **85**
 feedback regulation 29, 99
 insulin reducing 87
 stimulation 85
- sphincter of Oddi motility 78, **78**
- synthesis 85
 translational initiation, PI3K–PKB–mTORC1 96, **97**

- cholecystokinin-8 (CCK-8) 86, 344
 cholecystokinin-releasing factor (CCK-RF) 29
 cholecystokinin-releasing peptide (CCK-RP) 85, 85
 choledochal cyst 27, 214, 214
 acute pancreatitis with 214, 214–215
 frequency, clinical features 214
 “choledochal window” 75
 choledochocoele, acute pancreatitis with 214, 214–215
 cholesterol polyps 150
 cholesterosis 149, 150
 cholinergic pathways 86, 88
 chromatin remodeling 940
 chromogranin A 126, 701, 934–935
 acinar cell carcinoma 701
 elevated, conditions with 956–957
 from PanNETs 934–935, 953, 956, 1015
 chromogranin B 953
 chromosomal instability
 acinar cell carcinoma 683
 ductal adenocarcinoma 679, 681, 865
 chromosome 3p, loss of heterozygosity 581
 chromosome 6, isodisomy 31
 chromosome deletions, pancreatic cancer 679
 chronic pancreatitis 333–502, 406
 acute pancreatitis overlap 323
 acute pancreatitis progressing to 195, 324, 325, 325, 359, 417
 risk factors 324, 359, 360
 alcoholic *see* alcoholic chronic pancreatitis
 animal models *see* experimental pancreatitis
 autoimmune diseases and 350
 body mass index (BMI) 429
 bone health 430
 calcifying 398, 407, 408, 443, 569
 calcifying nonalcoholic *see* tropical chronic pancreatitis (TCP)
 CCK level elevation 90
 Clinical Diagnostic Criteria (Japan) 371
 clinical presentation 397–398, 400
 early disease 371, 398
 pain *see below*
 symptoms 361–362, 397–398, 439
 CNS involvement 349
 common features (pathology) 374, 495
 complications 406, 412–413, 439, 458
 frequency 459
 imaging 413, 414
 congenital cysts associated 28
 in cystic fibrosis 393
 definition/concept 333, 334, 349, 371, 374
 diabetes in *see* diabetes mellitus, in chronic pancreatitis
 diagnosis, time interval for 397–398
 diagnostic imaging 406, 407–410
 abdominal ultrasound 406
 CT 406, 407, 407, 408, 454
 endoscopic ultrasound 406
 MRI and MRCP 406, 407, 407–409, 408, 409, 410
 diagnostic path 372
 differential diagnosis
 autoimmune pancreatitis 411–412, 412
 pancreatic cancer 367, 411, 451, 756
 pancreatic mass 411, 412
 ductal stones in 442
 endoscopic therapy 442–444, 443
 early 371–373, 406
 diagnosis 371, 372, 397–398, 406
 imaging 371, 372, 406
 endocrine insufficiency 361, 399–400, 495, 496–497
 nutritional support 431, 497
 see also diabetes mellitus, in chronic pancreatitis
 environmental exposures and 336
 epidemiology 342–343, 355, 359, 361, 397, 417, 418
 epigenetics 336, 337
 etiology 334, 359, 361, 398, 421, 458
 alcohol *see* alcoholic chronic pancreatitis
 metabolic disorders 398
 modifying factors 336
 serum tests to identify 400
 exocrine insufficiency 350, 361, 426, 429, 431
 function testing 401, 401–402
 fibrogenesis/fibrogenic response 334, 337, 337–338
 fibrosis/fibrotic response 333, 334, 335, 337, 371
 macrophage role 119–120, 338
 pancreatic stellate cells role 109–110, 117, 338
 focal *see* groove (duodenal) pancreatitis
 follicular, differential diagnosis 517
 genetic influences 337, 359
 genetic testing in 402, 402
 in hereditary pancreatitis 374, 375, 376, 746
 see also hereditary pancreatitis
 histology 109
 historical aspects 397
 idiopathic 349, 398
 epidemiology 398
 genetic testing 402, 402
 in India 384–385
 tropical chronic pancreatitis *vs* 385
 IgG4 levels 545
 IL-8 increase 352
 imaging
 diagnosis *see diagnostic imaging (above)*
 differential diagnosis 411–413, 412
 immune cell infiltrates 117, 337, 338
 immune response 333, 334, 337–338
 inborn errors of metabolism 33, 34, 35
 inflammatory mass *see* inflammatory pancreatic head mass (IPHM)
 inflammatory response 337, 337–338, 421
 injury–wound cycle 334–336, 335
 islet autotransplantation 1115
 jaundice 400
 laboratory diagnosis 400–402
 direct function tests 400, 401, 401
 exocrine function tests 400–401
 indirect function tests 401, 401–402
 noninvasive function tests 401–402, 402
 provocative tests 400, 401
 serum tests 400, 401
 long-term outcomes after treatment 488–494
 for biliary/pancreatic duct stenoses 491–492
 for pain 489–490
 for pseudocysts 488–489
 malabsorption 399, 431
 malnutrition 429
 management
 lifestyle factors 419
 nerve injections 175
 of pain *see below*
 mass-forming
 differential diagnosis 411, 412
 surgical resection 439, 450, 451
 models *see* experimental pancreatitis
 molecular mechanisms 333–341
 mortality 475
 natural history 359–362
 nonalcoholic duct-destructive (NADCP) 520
 nutrient deficiency 429–430
 nutritional assessment, structured 431, 432
 nutritional support 429–434, 432
 dietary 430–431
 enteral/parenteral 431
 micronutrients 430
 osteoporosis 430
 pain 361, 398–399, 421
 abdominal 361, 398–399, 439, 453, 458
 acute intense 349, 398
 extrapancreatic 349–350
 measurement 422, 422
 neuropathic 421, 435
 pancreatic 350
 pancreatic head as “pacemaker” 450
 patterns 361, 421
 persistent severe 349, 361, 398, 489
 pseudocysts causing 350, 440
 pain management 361, 421–425, 423–424
 analgesics 423, 423, 439, 489
 antioxidants use 435–437
 endoscopic 423–424
 outcome 489–490
 postoperative 469
 pseudocyst treatment 440–442
 surgical 423–424, 453, 455, 467, 469, 490
 timing 424
 pain mechanisms 349–354, 421–422, 435, 453, 489
 “burn-out theory” 350, 361
 central involvement 352
 compartment syndrome theory 350, 422
 ductal hypertension hypothesis 350, 422, 442, 453
 GAP-43 and 351
 neural/perineural changes 350–351, 421

- neurogenic remodeling 350–352, 421, 453
 “neuroimmune interaction” hypothesis 351
 NGF and TrkA role 351
 oxidative stress 435–436
 plumbing theory 421–422
 substance P and IL-8 release 352
 substance P and NK-1R role 351
 in pancreas divisum, gene mutations 26
 pancreatic cancer 720–721
 differential diagnosis 367, 411, 451, 756
 etiologic similarities 417
 incidence 417, **418**, 721
 reverse causality 418
 risk 361–362, 417, 418, 451
 risk factors 417–420, 669, 720–721, 746
 strength of association 417–418, **418**
 surgical resection 439
 pancreatic head mass, resection 450, 451
 pancreatic nerve fiber increase 350–351
 pancreatic secretion, feedback regulation 90
 pathogenesis 333–341, 371
 repeated injury and fibrosis 333, 334, **335**, 339
 sentinel acute pancreatic event model 334–336, **335**, 338–339
 pathology 109, 333, 334, 374
 pseudocysts in 440
 outcome of treatment 488–489
 treatment 440–442, 488
see also pseudocysts, pancreatic
 quality of life and survival 362
 risk factors 333–334, 349, 359
CFTR gene mutations 337, 391–392, **392**
 recurrent acute pancreatitis 359
 severity, imaging **407**
 “small duct disease” 455
 socioeconomic significance 397
 subclinical 323, 336
 treatment (conservative) 421–438
 antioxidants 435–438
 enzyme *see* enzyme replacement therapy, pancreatic
 medical 426–428, 435–438, 489
 nutritional *see* chronic pancreatitis, nutritional support
 outcome 489–490
 pain management *see above*
 treatment (endoscopic) 449, 453
 common bile duct obstruction 444
 drainage 423, 483–484
 ductal stones/stenoses 442–444, **443**, 453, 491
 indications 439–440
 lost stents, failure **453**, **454**
 outcomes 488, 490, 491
 pseudocysts 440–442, **441**, 488
 surgery (open) *vs* 458, 490
 treatment (surgical) 439–502
 benefits 459
 for biliary obstruction 451–452
 choice of procedures 449, **450**, 453
 comparison of procedures 491–492
 DPPHR *see* duodenum-preserving pancreatic head resection
 drainage *vs* resection, outcome 491–492
 drainage with resection 484–485
 endoscopic therapy *vs* 458, 490
 Frey procedure *see* Frey procedure
 goals 449, 459
 hemipancreatectomy 459
 indications 439–440, 449, 453–454, 458, 469
 laparoscopic *see* laparoscopic surgery
 major resection *see* pancreatic resections
 outcomes 488–489, 490, 491–492
 pancreatectomy *see* pancreatectomy
 pancreatic duct drainage *see* pancreatic duct(s)
 pancreatoduodenectomy *see* pancreatoduodenectomy
 resections *see* pancreatic resections
 strategies 439–448
 timing 490
 tropical *see* tropical chronic pancreatitis (TCP)
 undernutrition 429
 vitamin deficiencies 429–430
 weight loss 399
 chylomicronemia 35
 chymotrypsin 179, **427**
 CCK release inhibition 90
 gene mutations 141–142
 secretion, fecal test and 401
 chymotrypsin C (CTRC) 162, 179, **427**
CTRC gene mutations 141–142, 162, **377**
 hereditary pancreatitis **377**, 379
 tropical chronic pancreatitis **387**
 chymotrypsinogen 162, **427**
 cigarette smoke
 carcinogens 673–674
see also smoking
 ciliopathies 33
 cineradiography, sphincter of Oddi motility 78
 circulating tumor cells (CTC), pancreatic cancer 763, 869
 cisplatin 976, 977, 1006, 1011, 1053
 distal cholangiocarcinoma 1090
 CIT-07 trial 1112, 1115
 CK7 and CK20 1048, 1050, 1059, 1075
 Cl⁻/HCO₃⁻ exchangers 56, 57
 CLARINET trial 964, 974
 claudin 2 141, 162
 gene mutations 141, 162, 346
CLDN2 gene mutations 141
 Clinical Islet Transplantation (CIT) Consortium 1109, 1112
Clonorchis sinensis 232
 closed lavage, lesser sac 290, **291**, **291**, 317
 closed packing 292–293, **293**, **293**, 317
 coagulopathies 637
 acute pancreatitis 184–185
 “coffee bean appearance” 607
 coffee consumption 186
 colipase, deficiency 28–29, **29**
 Collaborative Islet Transplant Registry (CITR) 1109, 1113
 collagen 109
 collateral circulation 13
 colloid (mucinous) carcinoma 576, 695
 invasive IPMN 662, 709
 colloid solutions, acute pancreatitis models 253
 colocalization, zymogens and lysosomes 66, **66**, 69
 colonic fistula 317, 320
 colonic necrosis 286
 colony-stimulating factor 1 (CSF-1), antibodies to 861
 common bile duct (CBD)
 anatomy 11, **11**, **75**, **76**, 1047
 common channel 27, 75, **76**
 anomalous pancreaticobiliary ductal union 214, **214**
 common channel syndrome 27, 146–147, 197
 conservation, in DPPHR 623, 624, **624**
 development 4, 5, 724, **725**
 diameter 76
 dilated 76
 distal 1047
 cancer *see* distal common bile duct carcinoma (DBDC)
 functions 76
 narrowing/strictures/stenosis
 endoscopic therapy 439, 491
 inflammatory pancreatic head mass 366, 367
 pancreatic cancer 718
 obstruction, therapy 367, 444
 stenting 367, 439, 443, **443**
 stone **148**
 common channel 147
 anatomy 11, 13, 27, 75, **76**
 gallstone obstruction 146–147, 149, 197
 long (common channel syndrome) 11, 27
 sphincter ampullae 75
 common channel hypothesis, gallstone pancreatitis 146–147, 149, 197
 common channel syndrome 11, 27
 acute biliary pancreatitis 146–147, 149, 197
 common hepatic artery 252
 pancreatoduodenectomy 470, **471**, **473**
 staging laparoscopy 767, **767**
 compartment syndrome theory
 chronic pancreatitis pain 350, 422
see also abdominal compartment syndrome (ACS)
 computed tomography (CT)
 acute biliary pancreatitis 296, 297
 acute fluid collections 312
 acute necrotic collection 242, 243, **243**
 acute pancreatitis
 CT Severity Index (CTSI) 244–245
 grading 238, 244–245
 Japanese CT Severity Index 245
 outcome 327
 pediatric 225
 ampullary carcinoma 1059, **1060**

- computed tomography (CT) (*cont'd*)
 anatomy of pancreas 12, 13
 autoimmune pancreatitis 411–412, 551, 551
 chronic pancreatitis
 diagnosis 406, 407, 407
 differential diagnosis 411
 preoperative 469
 cone beam (CBCT), pancreatic cancer 891
 contrast-enhanced (CE-CT)
 accuracy limitations 245–246
 acute edematous pancreatitis 241, 241–242
 acute fluid collections 312
 acute necrotizing pancreatitis 242, 289
 avoidance in severe acute pancreatitis 260
 inflammatory pancreatic head mass 366, 367
 nephrotoxicity of contrast 247
 pancreatic cancer 734, 734–735, 735, 815, 824
 parenchymal necrosis 242, 243, 244, 245–246, 246
 radiation dose 248
 dynamic, PanNETs 957
 groove pancreatitis 412–413
 insulinoma 1004, 1004
 IPMN 598
 jaundice work-up 1043, 1044
 lymphoepithelial cyst 595–596, 596
 mucinous cystic neoplasm 596, 597
 multidetector (MDCT) 407, 412
 metastatic disease 737–738
 pancreatic cancer 724, 733–738, 740, 741–742
 pancreatic cancer diagnosis 734, 734–735, 735, 755, 766, 771, 771
 pancreatic cancer staging 736, 736, 737, 771, 771, 777
 technique 733–734
 pancreatic cancer 771, 771
 3D reconstructions 734
 screening test 747
 pancreatic fistulas 318
 pancreatic pseudocysts 593
 pancreatic swelling, delayed enhancement 523, 525, 551, 551
 pancreaticobiliary, protocols 733–734
 PanNETs 949, 950, 957, 968, 969
 perfusion
 acute necrotic collection 242, 243, 243, 244, 246
 radiation dose 248
 periampullary tumors 1039, 1039, 1042, 1042, 1043
 preoperative, in chronic pancreatitis 469
 spiral, periampullary tumors 1042, 1042
 computed tomography (CT) scanners 734
 congenital anomalies 24–39, 213
 acute pancreatitis with 213–218, 221
 annular pancreas 25, 25–26, 215, 215
 anomalous pancreaticobiliary ductal union 214, 214
 choledochal cysts *see* choledochal cyst
 ductal anomalies 27
 duplication cysts within pancreas 28, 215–216, 216
 ectopic pancreas 26–27, 27, 215
 isolated enzyme deficiencies 28–29
 Johanson–Blizzard syndrome 30, 30–31
 pancreas divisum 26, 26, 213, 214
 pancreatic agenesis 24–25
 pancreatic cysts 27–28, 28
 pancreatic hypoplasia 24–25
 Pearson marrow pancreas syndrome 30
 secretory insufficiency 28
 Shwachman–Diamond syndrome 29, 29–30
 congenital disorders, pancreatic endocrine function 31–32
 secretory insufficiency 28
see also hereditary disorders
 congenital hyperinsulinism (CHI) 31
 congenitally short pancreas 25
 CONKO-001 trial 848, 848, 851, 851, 886, 896, 906, 908
 CONKO-005 trial 852
 continuous closed lavage, lesser sac 290, 291, 291
 corticosteroids, in autoimmune pancreatitis 529, 555, 556, 557
 relapse treatment 556–557, 560–561
 side-effects and managing 557–558
 type 2, response 536, 546, 547, 558
 corticotropin-releasing hormone (CRH) 956
 cost-effectiveness
 laparoscopic surgery 652
 treatment *vs* surveillance, cystic neoplasms 620–621
 COX-2 111
 COX-2 inhibitors 233, 880
 coxsackievirus B infection 232
 CPA1 gene, mutation, pancreatic cancer 746
 CRAC Ca²⁺-selective channels 51, 53
 creatinine, serum, acute pancreatitis 207, 209, 262
 CRISPR/Cas system 1116
 critical illness, intestine driving 166
 CRS-207 859
Cryptosporidium infections 80
 crystalloid fluid resuscitation, animal studies of acute pancreatitis 252–253
 CTFR gene *see* cystic fibrosis transmembrane conductance regulator (CFTR)
 CTLA-4 857–858, 858, 860
 antibodies 860
 antibodies (ipilimumab) 858, 858, 860, 861
 CTRC *see* chymotrypsin C (CTRC)
 CTRC gene, mutations *see* chymotrypsin C (CTRC)
ctsb gene 180
 CTTN1 gene mutation 584
 Cushing syndrome 956, 1015
 CXCL4 71
 cyclic ADP-ribose (cADPR) 47, 47–48
 cyclic AMP (cAMP), in duct cell secretion 57, 58, 60
 cyclo-oxygenase 2 (COX-2) inhibitors 233, 880
 cyclophosphamide (Cy)
 GVAX (whole-cell vaccine) 858–859, 861
 whole-cell vaccine with 858–859
 cyclosporine A 345
 cyst(s), pancreatic 567
 age and 568, 568
 asymptomatic 589, 618
see also cystic neoplasms/tumors
 benign *see* cystic lesions, pancreatic (PCL), nonneoplastic
 calcification 570
 classification 590
 clinical presentation 589
 congenital 27–28, 28
 diabetes and insulin use 569
 epidemiology 567–569, 568, 748
 ethnic and geographic factors 568–569
 gender and 568
 identified by screening 747–748
 low-risk, types 593
 lymphoepithelial, imaging 595–596, 596
 misclassification 580
 mucin producing 603–604
see also intraductal papillary mucinous neoplasia (IPMN); mucinous cystic neoplasm (MCN)
 multifocality, enucleation
 contraindication 634
 pancreatic cancer risk 419
 polycystic kidney disease with 32
 potential malignancy *see* cystic neoplasms/tumors
 risk factors 568–569
 size/morphology 569
 detected by screening 748
 enucleation contraindication 634
 surveillance 748
 treatment 440–442
 ablation 637–638, 638
 aspiration 637
 enucleation *see under* cystic neoplasms/tumors
 surgical resection 580
 unilocular/oligolocular 637
 von Hippel–Lindau syndrome 33
see also pseudocysts, pancreatic
 cyst gastrotomy *see* cystogastrotomy
 “cyst-in-cyst” appearance 574, 575, 596, 597, 710
 cystadenoma
 acinar cell 578, 699
 serous *see* serous cystadenoma
 cysteine protease cathepsin B *see* cathepsin B
 cystic change, neuroendocrine tumors (CPNT) 567, 569, 570
 cystic duct, gallstone acute pancreatitis 151
 cystic fibrosis (CF) 28
 “atypical” 161
 CFTR gene mutations 161, 391, 392, 393
 therapy targeting 60, 394
 chronic pancreatitis 393
 clinical features 392
 diabetes in 393
 diagnosis 393

- ductal secretion damage 60
 gene therapy 394
 genotyping 393
 inheritance 398
 lack of CFTR, effects 391
 malignancy risks 392–393
 organs affected by 391
 recurrent acute pancreatitis 393, 398
 Shwachman–Diamond syndrome *vs* 29
 treatment 393–394
 enzyme replacement 393
 gene therapy 394
- cystic fibrosis-related diabetes mellitus (CFRD) 393
- cystic fibrosis transmembrane conductance regulator (CFTR) 57, 58, 59, 60, 160–161, 378
 alcohol effect on 138, 345
 bicarbonate excretion 160, 161
 cells expressing 391
 CFTR gene mutations 26, 28, 35, 60, 142, 158, 160, 391
 acute recurrent pancreatitis in children 227
 CFTR p.R75Q 161
 chronic pancreatitis risk 337, 391–392, 392, 398
 classification (defect types) 391, 392
 cystic fibrosis 161, 391, 392, 393
 epidemiology 393
 F508del 391
 genotyping 393
 hereditary pancreatitis 374, 375, 377, 378–379, 746
 heterozygotes 161
 number 161, 391
 SPINK1 mutations with 161
 T5 and TG12 alleles 392, 392
 therapeutic agents targeting 60, 394
 chloride permeability 160, 391
 function 160
 lack of 391
 pancreatic disease associated 391–396
 clinical features 392–393
 diagnosis 393
 genotype–phenotype correlations 391–392
 pathophysiology 391–392
 therapy 393–394
 see also cystic fibrosis (CF)
 as therapeutic target 60, 394
 cystic lesions, pancreatic (PCL) 567
 classification 574, 590
 distribution by type 570
 epidemiology 567–569, 568
 family history of pancreatic cancer 569
 low-risk 593–596
 misclassification, and surgery for 580
 neoplastic *see* cystic neoplasms/tumors
 nonneoplastic 567, 580, 589, 590
 classification 574
 imaging 593–596
 see also cyst(s), pancreatic; cystic fibrosis; pseudocysts, pancreatic
 size, and neoplastic nature 567
- cystic neoplasms/tumors 565–664, 589
 ablation 637–638, 638
 acute pancreatitis in 569
 asymptomatic 618
 cost-effectiveness of management 620–621
 quality of life 619
 surveillance frequency 619
 surveillance strategy 618
 surveillance *vs* surgery 618, 619, 641
 treatment algorithm 620
 treatment guidelines 619, 620, 621
 characteristics 590
 classification/types 567, 574, 589, 590, 641
 clinical presentation 589–592
 cytological evaluation 603–610, 604
 diagnosis 589, 632, 646, 721–722
 enucleation 632–640, 645
 contraindications 633–634, 634, 637
 indications 632–633, 633
 laparoscopic 650–651
 outcomes 635–637, 636, 645
 pancreatic fistula 634, 635, 637, 645
 patient selection 632–633, 637, 638
 postoperative management 635
 technique 634, 635
 epidemiology 567–572, 569–570, 570, 573, 590, 641
 epithelial 574
 histologic classification 573–579
 histology 697, 697–698, 698, 698–699
 imaging 593–602, 596–600, 628, 632, 724
 invasive cancer after 567, 573, 580
 clinical features 589
 enucleation contraindication 633
 resection 632
 risk 618
 long-term outcome 660–664
 molecular mechanisms 580–588
 clinical applications 584–585
 gene mutations 582
 implications for families 585
 natural history 611–617, 661–663
 nonepithelial 574
 pancreatic pseudocysts *vs* 440
 pathology 696–699
 recurrence, management 655–659
 secondarily cystic 607
 surgery 622–626, 641–648, 649, 749
 alternative procedures 645
 central pancreatectomy 642, 645
 complications 641, 992
 distal pancreatectomy 614, 642, 644
 DPPHR 622, 623–624, 624, 624, 625, 992
 DPPHR, subtotal head resection 623–624, 624, 624, 625, 625
 enucleation *see above*
 laparoscopic *see* laparoscopic surgery
 local pancreatic head resection 622–623
 middle segment resection *see* pancreatic middle segment resection (PMSR)
 middle segment resection (PMSR)
 minimally invasive 645
- pancreatectomy 643–645
 pancreatoduodenectomy 622–623, 643–644
 parenchymal preservation methods 650, 651
 postoperative management 645–646
 preoperative evaluation 643
 resection rationale and goals 622, 623, 632
 surveillance *vs* 618, 619, 641
 total pancreatectomy 642, 644
 surveillance 660, 663, 748
 asymptomatic neoplasms 618, 619, 641
 IPMN *see* intraductal papillary mucinous neoplasia (IPMN)
 mucinous cystic neoplasm 642–643, 661
 serous cystic neoplasms 660
see also specific types (as listed page 574)
- cystic PanNETs (cPanNET) *see* pancreatic neuroendocrine tumors (PanNET)
- cystic teratoma, mature 578
- cystinuria 34
- cystogastrostomy
 laparoscopic 283, 308, 483, 484
 laparoscopic *vs* endoscopic 483
 open 293
- cytochrome *c* oxidase deficiency 34
- cytochrome P450
 carcinogen metabolism 673–674
 CYP2A6 676
 CYP2E1 137, 140
 CYP2E1 gene variants 141
 tropical chronic pancreatitis 386
- cytohistology 603
- cytokeratins, PanNETs 935
- cytokine(s)
 acute pancreatitis
 pathogenesis 64, 67–68, 71
 polymorphisms 162
 severity assessment 208, 209
 autoimmune pancreatitis, type 1 511, 511–512
 autoimmune pancreatitis, type 2 513, 513
 in inflammatory response 338
 islet dysfunction, chronic pancreatitis 496
 pancreatic stellate cell activation 107, 138
 pancreatic stellate cells producing 107–108, 138
 proinflammatory 162, 338
 acinar cell injury 71–72, 252
 substance P interactions 352
- cytology
 cystic neoplasms 603–610, 604
 pancreatic cancer 767, 767–768
 PanNETs 933–934, 934, 935
- d**
 D-dimer, activated protein C decreasing 184
 Dagradi-Serio-Iacono operation *see* pancreatic middle segment resection (PMSR)
 damage-associated molecular pattern molecules (DAMP) 242, 316

- DAXX* gene mutation 938, **939**, 940, 941, 943
DAXX protein 938, 940, 943
 death domain-associated protein (*DAXX*) 938, 940, 943
DAXX gene mutations 938, **939**, 940, 941, 943
 debridement
 endoscopic *see* endoscopic debridement
 necrosis in acute pancreatitis *see* necrosectomy; necrotizing pancreatitis
 delayed gastric emptying (DGE) 645, 718, 785, **785**, 793
 δ cells 123
 development 6
 immunostaining 21, **21**, **22**
 see also somatostatin
 dermoid cysts 578
 desmin, PSCs expressing 106, **107**
 determinant-based classification (DBC), acute pancreatitis 199, 200, **200**, **201**, 239, 241
 modified 202, **202**
 development, of pancreas *see* organogenesis
 developmental disorders *see* congenital anomalies
 dexamethasone test 956
 diabetes mellitus
 acute pancreatitis complication 324, **325**
 in autoimmune pancreatitis 496
 type 1 522
 brittle 431, 497, 798
 see also diabetes mellitus, type 3c
 in chronic pancreatitis 361, 399, 402, 431, 495
 β -cell dysfunction 495, 496
 histology 496
 hormone changes 495, 496–497
 incidence 495–496
 pathogenesis 496–497
 PSC role 110
 risk factors 496
 see also diabetes mellitus, type 3c
 in cystic fibrosis 393
 experimental models, pancreatic exocrine dysfunction 127–128
 in hereditary pancreatitis 376, 377
 hypertriglyceridemia 231
 insulin-dependent (IDDM) 1121
 long-standing, pancreatic cancer risk 668
 maturity-onset of the young (MODY) 7, 32
 pancreatic cancer relationship 667, 668, 720, 911
 diabetes prior to cancer 717–718, 720
 pancreatic cancer risk factor 667, 668, 720
 reverse causality 911
 pancreatic cystic lesions 569
 pancreatic exocrine dysfunction 127, 495, 496–497
 pancreatoduodenectomy
 complication 622, **623**, 911
 PDX1 mutation 7
 permanent neonatal (PNDM) 32
 postoperative, after distal pancreatectomy 793, 911, **912**
 resolution after pancreatic cancer resection 911
 total pancreatectomy, after 798–799
 transient neonatal 31
 in tropical chronic pancreatitis 385, 387
 type 1 1121
 islet transplantation *see* islet transplantation
 pancreas transplant *see* transplantation, pancreatic
 pancreatic cancer risk factor 720
 type 2
 pancreas transplantation 1123
 pancreatic cancer and 718, 720
 type 3c (pancreatic/pancreatogenic) 361, 377, 431, 495, 911
 clinical features 497
 complications 498, 799
 definition and prevalence 495
 diagnosis 497, **497**
 enzyme replacement therapy 499
 glycemic control, brittle diabetes 431, 497, 798–799
 hypoglycemic agent therapy 498–499
 insulin therapy 498, **499**, 799
 islet cell hormone response to meal 497, **498**
 after left pancreatectomy 793, 911, **912**
 after pancreatoduodenectomy 911, **912**
 pathogenesis 495, 496–497
 prognosis 500
 therapy 498–500
 after total pancreatectomy 798–799
 TPIAT 500
 see also diabetes mellitus, in chronic pancreatitis
 diabetic ketoacidosis 231, 262
 diabetic neuropathy 498
 diarrhea
 chronic pancreatitis 399
 isolated enzyme deficiencies 28
 pancreatic cancer 717
 total pancreatectomy, after 799
 diazoxide 972, 1005
 diet 426
 acute pancreatitis management 254, 255
 chronic pancreatitis
 management 430–431
 fruit/vegetables, pancreatic cancer risk reduction 669
 hereditary pancreatitis 377
 pancreatic adaptive growth **99**, 99–100
 pancreatic cancer risk 669
 pancreatic protein synthesis regulation 95–96
 see also nutritional supplementation
 dietary factors, alcohol-induced acute pancreatitis 138
 digestion, of nutrients 426
 digestive enzymes 10, 43, 426
 acinar cell secretion of 43, 196, 426
 Ca²⁺-mediated control 51–52
 CCK role 43, 44, 85–86
 see also acinar cell(s), secretion; cholecystokinin (CCK)
 activation 43, 378, 426
 acute pancreatitis 53, 64–65, 178–179, 196–197, 336
 cathepsin B role 180–181
 premature 158, 178–179, 180–181, 378
 see also protease(s), pancreatic; trypsinogen
 amylase *see* amylase, pancreatic
 functions 426, 799
 increased, chronic alcohol use effect 137, 344
 insufficiency/failure to secrete *see* exocrine insufficiency
 lipase *see* lipase, pancreatic
 pancreatic growth and 95
 proteases *see* protease(s), pancreatic
 recombinant 428
 secretion *see* pancreatic secretion (process)
 storage 64
 synthesis 64, 95–98, **97**
 alcohol effect 344
 see also protein synthesis, pancreatic
 see also enzyme(s); exocrine pancreas; protease(s), pancreatic
 digestive tube, primitive 3
 dipeptidyl-peptidase-4 (DPP-4) inhibitors 234, 499
 direct endoscopic necrosectomy (DEN), infected pancreatic necrosis 275, 278–279, **279**, 280
 disconnected duct syndrome 302, 317–318
 distal pancreatectomy in 475
 stenting 319
 disease-specific ligands 600
 disseminated intravascular coagulation (DIC) 184
 distal cholangiocarcinoma (bile duct carcinoma) 1049, 1051–1052, 1083
 adjuvant therapy 1089–1090, **1091**
 ERCP 1041, **1041**
 frequency 1037, **1038**
 gene mutations 1051
 long-term survival 1051, **1085**, **1085**, 1089–1090, 1097–1099, **1098**
 lymph node involvement 1083, 1084, 1099
 neural plexus invasion 1086
 palliative therapy 1089, 1090, 1092, **1092**
 preinvasive neoplasms 1051–1052
 prognostic factors 1051, 1084, **1084**, 1086, 1099, **1099**
 recurrence 1099
 superficial spreading 1086–1087
 surgery 1083–1088
 bile duct cut margin 1086–1087
 complications 1087
 hepatoduodenal ligament skeletonization 1086
 lymph node dissection 1084–1085, **1086**
 pancreatoduodenectomy 1083, 1087

- pyloric ring preservation 1083–1084
survival after 1097–1099, **1098**
- distal common bile duct carcinoma (DBDC)
1037, **1038**, 1049, 1051–1052, 1089
definition 1051
see also distal cholangiocarcinoma
- DNA
adducts, carcinogens in cigarette smoke
673, 676
circulating tumor (ctDNA) 683–684, 869
damage, carcinogens in cigarette
smoke 673
increased, pancreatic hyperplasia/
hypertrophy 98, 99
measurements, PanNETs 953, 957
methylation
carcinogens inducing 674
pancreatic cancer 682
PanNETs 943
modifications, chronic pancreatitis 336
repair, defective, pancreatic cancer 681,
683, 746, 865, **866**
telomeres 852
- dorsal motor nucleus (DMV) 88
dorsal pancreatic bud 4, 5, 24, 724
dorsal pancreatic duct 724, 725
dorsal root reflex 175
DOTA compounds 958, 959, 962, 977,
1016, 1021
“double bubble” sign 25, 215, **215**
“double-duct” sign 739, 1041, **1041**, 1059
Down syndrome, annular pancreas 25
doxorubicin
ampullary carcinoma 1093
PanNETs 975, 1006
- DPPHR *see under* head of pancreas
- drainage
bile duct obstruction 835
chronic pancreatitis *see* chronic
pancreatitis
endoscopic *see* endoscopic drainage
inflammatory pancreatic head mass
367, 368
laparoscopic, in chronic
pancreatitis 483–484
obstructive cholangitis 444
pancreatic ducts *see* pancreatic duct(s)
pancreatic fluid collections 306, 313–314
pancreatic pseudocysts 440–441, 488
percutaneous *see* percutaneous catheter
drainage
preoperative, pancreatic cancer 835
- drug(s)
acute pancreatitis due to *see* acute
pancreatitis
pediatric acute pancreatitis and **221**
“drunkard’s pancreas” 342
DU-PAN-2, pancreatic cancer marker 763,
776
dual X-ray absorptiometry (DXA) 430
duct(s) *see* pancreatic duct(s)
duct cell(s) 13, **20**
at acinar tubule interface *see* centroacinar
cells
- alcohol, direct effects on 136, **136**, 138
chronic pancreatitis etiology **334**
culture, growth in 101
differentiation/development 5, 6
fluid/electrolyte secretion 56–62
activation, Ca²⁺ and cAMP
pathways 60
functions 60
mechanisms 57, **58**
pancreatic diseases 60
regulation 44, 58–59, **59**
as therapeutic target 60
ion channel and transporter
expression 160
islet hormones, exposure to 124
islet hormones expressed 123
ultrastructure 19–20
duct obstruction–bile reflux theory 197
duct of Santorini *see* accessory pancreatic
duct
duct of Wirsung *see* pancreatic duct(s), main
“duct penetration sign” 551
ductal cancerization 694, **695**, 706
ductal cells *see* duct cell(s)
ductal epithelium 19
ductal hyperplasia, atypical 676
ductal hypertension hypothesis 148–149,
197, 350, 422, 442, 453
ductal pressure, acute pancreatitis 148–149,
197, 350, 422, 442, 453
ductal system 160
anatomy 13, 16, 18–20
congenital anomalies 27
early development 4–5, 5, 24, 724, 725
histology/ultrastructure 17, 18, 18–20,
19, **20**
see also duct cell(s)
islets, anatomical/functional relations 123
lumen, lining 17, 18
necrosis *see* necrosis, in acute pancreatitis
see also pancreatic duct(s)
ductules 13, **20**
duodenal gangliocytic paraganglioma 1053
duodenal pancreatitis *see* groove (duodenal)
pancreatitis
duodenal papilla
anatomy 11, 75, 76, 1047, 1074
bleeding 1071
see also ampulla of Vater
duodenal reflux hypothesis 147–148
duodenojejunostomy 473, **474**
duodenum
ampullary 1048
adenomas 1047
carcinoma 1047, 1048–1049, **1049**
anatomy 10, 75, 76
cancer 1037, **1038**, 1081–1082, 1089
adenocarcinoma 1037, **1038**, 1081,
1092–1093
adjuvant therapy 1092
(peri)ampullary 1048–1049
chemoradiotherapy 1081, 1092
chemotherapy 1081
nonampullary (NADC) 1052–1053
- palliative therapy 1092–1093
pancreatoduodenectomy 1081
prognostic factors 1081, 1102, **1104**
recurrence 1104
survival 1081, **1081**, 1102, **1103**
development 4
duplication 216
metal stent placement, palliative
therapy 837
neuroendocrine tumors 1022–1024
gastrinoma 1009, 1010, 1021,
1023, 1032
nonfunctioning 1024
somatostatinoma 1023–1024
surgical excision 1024
types 1022–1023
obstruction
pancreatic cancer 828, 829, **832**
pancreatitis due to 147, 148
periampullary tumors 1038
pancreatoduodenectomy procedure
472, **473**
pH, secretin release control 84
stenosis 366
volume receptors, stimulation 88
duodenum-preserving pancreatic head
resection (DPPHR) 459–466
early postoperative course 460–461
effectiveness in chronic pancreatitis 460
Frey procedure as alternative 463–464
indications 459, 459–460, 623–624, **624**,
990–991, **991**
chronic pancreatitis pain 424
cystic neoplasms 622–623, 623–624,
624, **624**, **625**, **625**
inflammatory pancreatic head mass
367, 368
PanNETs 990–991, **991**, **991**, **992**
long-term outcomes 462, **463**, **464**, 491,
991, **992**
pancreatoduodenectomy vs **463**,
491–492, 622–623
partial head resection 624, **624**, **624**, **625**,
625, 991, **991**
rationale 459–460
results **462**
segment resection (DPPHR-S) 623, **624**
technique 460, **460**, **461**
modifications 460, **462**
total head resection (DPPHR-T) 623, 624,
624, **624**, **625**, 991, **992**
- duplication cysts 28
enteric 215–216, **216**
dysontogenetic cysts 440
- e**
e-cadherin 584
E-selectin 71
ectopic pancreas 26–27, **27**, 215
edema, fluid collection management 313
EIF2AK3 gene mutations 32
eIF2B complex 98
eIF4F complex 96, 97, **97**
elastase **427**

- elastase-1
 fecal *see* fecal elastase-1
 serum 539
- elastography, EUS, pancreatic cancer 728–729
- electrocardiogram (ECG), acute pancreatitis 185, 185–187
- electrolyte(s), duct cell secretion 57, 58
- electrolyte management, acute pancreatitis 312–313
- electroporation, irreversible 845, 876
- embryology, pancreas *see* organogenesis
- emergency department *see* acute pancreatitis, treatment (ICU)
- endocrine cell(s)
 differentiation/development 5, 6
 immunostaining 21, 21–22, 22
 types and numbers 21–22
see also islets of Langerhans, cells; *specific cell types*
- endocrine function tests 402
- endocrine insufficiency
 acute pancreatitis complications risk 324
 autoimmune pancreatitis treatment, after 557, 562, 562
 chronic pancreatitis *see* chronic pancreatitis
 exocrine insufficiency with *see* exocrine insufficiency
 isolated congenital 31–32
 pancreatic calcification and 496
 pancreatoduodenectomy, after 622, 623
- endocrine pancreas 10, 123
 anatomy 20–21
 congenital disorders 31–32
 dysfunction, acute pancreatitis
 complication 324–325, 325, 328
 fibrosis, pancreatic stellate cell role 110
 functional reserve 24
 histology 20–22, 21, 22
 tumors *see* pancreatic neuroendocrine tumors (PanNET)
see also islets of Langerhans
- endocrine tumors, pancreatic *see* neuroendocrine tumors
- endoderm 3, 4, 4
 mesoderm interaction 5
- endoluminal ultrasound, gallstones
 investigation 151
- endophlebitis 385
- endoplasmic reticulum (ER)
 Ca²⁺ release 46, 46, 50–51, 51
 stress during acute pancreatitis 70–71, 98
 alcohol effects 138
 protein synthesis inhibition 98, 98
 stress during chronic pancreatitis 336
 unfolded proteins 70–71
- endoscopic debridement
 necrotizing pancreatitis 274, 274
 pseudocysts/WON, after acute
 pancreatitis 301–302
- endoscopic drainage
 chronic pancreatitis pain 423
 infected pancreatic necrosis 278–280, 279, 280–281
 pancreatic fluid collections 313–314
- pancreatic pseudocysts 440–441, 488
 transmural 278–280, 279, 280–281
 transpapillary 278, 829
- endoscopic necrosectomy *see* necrosectomy
- endoscopic retrograde
 cholangiopancreatography (ERCP)
 acute biliary pancreatitis 152–153, 296, 297, 298–299
 acute pancreatitis due to 150
 NSAIDs role in preventing 251
 ampullary tumors 1059–1060
 benign 1069
 annular pancreas 25, 25
 autoimmune pancreatitis 526, 552, 552–553
 balloon enteroscopy-assisted 836
 common bile duct diameter 76
 complications, pancreatitis 179–180
 disconnected duct syndrome 302
 gallstones investigation 151
 pancreas divisum 26, 26
 pancreatic cancer 771, 829, 835, 839
 biliary decompression 829, 835
 pancreatic fistula 318, 319
 pancreatic neuroendocrine tumors 949
 pancreatic pseudocysts drainage 442
 pediatric acute pancreatitis 225
 periampullary tumors 1041, 1041, 1041–1042
 preoperative, in chronic pancreatitis 469
- endoscopic retrograde pancreatography (ERP)
 early chronic pancreatitis 371
 secretin stimulation of exocrine
 function 401
- endoscopic secretin test 401, 401, 406
- endoscopic sphincterotomy (ES)
 acute biliary pancreatitis treatment 152–153, 297
 ampullary tumors 1060, 1071
 pancreatic fistula 319
- endoscopic stenting
 indications 1042
 main pancreatic duct 367
 pancreatic cancer 772, 829, 830, 831, 836
 palliative 839
 periampullary tumors 1042
- endoscopic therapy
 ampullectomy, in ampullary
 carcinoma 1061
 biliary pancreatitis *see* acute biliary
 pancreatitis (ABP)
 chronic pancreatitis *see* chronic
 pancreatitis, treatment
 common bile duct obstruction 444
 common bile duct stenosis 439, 491
 cyst gastrostomy 483
 drainage *see* endoscopic drainage
 ductal stones 442–444, 443, 491
 gastric outlet obstruction 439
 infected pancreatic necrosis 277–282
 adverse events 280–281
 development and reasons for 278
 dual-modality drainage 279
 EUS-guided multi-gateway 279
 goals 278
- necrosectomy 275, 278–279, 279, 280
 results 280
 stent placement 278, 279, 280
 timing 272, 278, 283
 transgastric access 278
 transmural drainage 278–280, 279, 280–281
 transmural entry devices 279
 transpapillary drainage 278
 pancreatic cancer (PDAC) 772, 829
 biliary decompression 829, 830, 831
 pancreatic fistulas 318
 papillectomy 1068, 1069–1072, 1070, 1075
 pseudocysts/WON after acute pancreatitis
 drainage *vs* necrosectomy 301–302
 indications 301
- endoscopic ultrasound (EUS)
 acute biliary pancreatitis 296, 297
 acute fluid collections 312
 ampullary adenoma 1069
 ampullary carcinoma 1060, 1060–1061
 celiac plexus blockade guided by 490
 chronic pancreatitis diagnosis 371, 406
 contrast-enhanced (CH-EUS)
 IPMN 598
 pancreatic cancer 728–729
 cystic neoplasms, asymptomatic 619, 620
 early chronic pancreatitis diagnosis 371
 elastography, pancreatic cancer 729
 equipment 728, 729, 731
 fine-needle aspiration (FNA)
 ampullary carcinoma 1060–1061, 1069
 complications 730
 contraindications 729
 cystic neoplasms 603, 607, 619, 620
 diagnostic yield/safety 729–730
 equipment 731
 factors affecting 731
 nonfunctioning PanNET 968
 pancreatic cancer 693, 729–730, 739, 771–772
 PanNETs 949, 950, 951, 957, 971
 fine-needle biopsy (EUS-FNB), ampullary
 carcinoma 1060
 gastrojejunostomy guided by 837, 838
 infected pancreatic necrosis
 treatment 279
 insulinoma 957, 1004, 1005, 1020
 IPMN 598, 598, 642
 jaundice work-up 1043, 1044
 lymphoepithelial cyst 595–596, 596
 pancreatic cancer (PDAC) 693, 728–732, 771–772
 advantages/disadvantages 729
 celiac plexus neurolysis 838, 881
 obstructive jaundice palliation 836
 screening test 747
 pancreatic intraepithelial neoplasms 748
 pancreatic pseudocysts 593, 594
 PanNETs 962, 1015–1016
 pediatric acute pancreatitis 225
 periampullary tumors 1040, 1040, 1042, 1043
 preoperative, in chronic pancreatitis 469

- pseudocyst drainage 488
radiofrequency ablation guided by 772, 839
serous cystic neoplasm 595
- endoscopy
ampullary tumors 1059–1060
periampullary tumors 1040–1041
- endothelial cells, death, nafamostat action 170
- endotoxin, bacterial 118, 119, 140, 166
alcohol-induced acute pancreatitis 140
alcoholic chronic pancreatitis 345
antibodies to, depletion 168
TNF- α in immune response to 162
- ENETS 2006 grading 930, 989, 1029
PanNETs 925, **925**, 926, 927, 970, 979, 1002
- enteral feeding/nutrition 168
acute pancreatitis management 254–255, 313
chronic pancreatitis 431
early, in pediatric acute pancreatitis 225
pancreatic fistula 319
polymeric *vs* elemental formulation 255
- enteric duplication cysts 215–216, **216**
- enteric fistulas 286
- enterochromaffin cells 87
- enteroglucagon 89
- enterokinase 64, 159
deficiency 29, **29**
- enteropancreatic neural reflex 88
- enucleation
cystic neoplasms *see* cystic neoplasms/
tumors
PanNETs *see* pancreatic neuroendocrine
tumors (PanNET)
- environmental factors
acute pancreatitis risk 159
alcohol-induced acute pancreatitis 138–140
chronic pancreatitis risk 336
pancreatic cancer 721, **721**
pancreatic cysts 568–569
- enzyme(s) (pancreatic)
activation *see under* digestive enzymes
autoimmune pancreatitis
diagnosis 539–540
carcinogen metabolism 673–674, 676
chronic pancreatitis diagnosis 400
isolated deficiencies 28–29, **29**
in pancreatic acinar juice 43, 50–51, 426
protease precursors 43
secretion by acinar cells *see* acinar cell(s)
see also digestive enzymes; pancreatic
secretion (process)
- enzyme replacement therapy, pancreatic 426–428, **427**
chronic pancreatitis 426–428, **427**
diabetes (type3c) 499
dietary interventions with 430–431
pain reduction 350
cystic fibrosis 393
dosage 427, **427**
exocrine failure after acute
pancreatitis 325
- hereditary pancreatitis 377
indications 426
limitations 428
total pancreatectomy, after 799
- enzyme Y 179
- EORTC 40013 study **848**, 851, **897**
EORTC 40891 trial 847, **848**, 851, 886, **896**
- epiblast 3, **4**
- epidermal growth factor receptor (EGFR),
inhibition 867–868, 887
- epigenetics 336
carcinogen action, pancreatic cancer 673–674, 675, **675**
chronic pancreatitis 336
- epinephrine 261
- epithelial cells
cuboidal, duct lumen 18
differentiation/development 5
- epithelial–mesenchymal transition
(EMT) 111
- ϵ cells 123, 126
development 6
- ERK pathway
pancreatic cancer therapeutic target 867
pancreatic growth **99**, 99–100
- erlotinib 852, 868, 874, 887
adverse effects and costs 874
- erythema ab igne 399, **399**
- ESPAC-1 trial 847–848, **848**, **849**, 851, **853**,
886, **896**, 906
- ESPAC-3 trial 848, **848**, **850**, 851, 853, **853**,
886, **896**, 906
periampullary cancer 1090, 1092, 1093
- ESPAC-4 trial **848**, 849, **850**, 851, **851**, 853,
853, 886, 1093, 1094
- estrogens, acute pancreatitis due to 233
- ethanol *see entries beginning alcohol*
- ethnic factors, pancreatic cysts 568
- EUROPAC study 375, 376
- everolimus 943
PanNET treatment 941, 943, 964, 976,
976, 1006
gastrinoma 1011
insulinoma 973, 1006
- Ewing sarcoma 936
- exenatide 234
- exocrine function tests, chronic pancreatitis 400–401, **401**
- exocrine insufficiency 426
acute pancreatitis complications
Pan(306(e Ona)95)9(anc)5(end(f)(ic)F200(oc)5.9(y)]TJ/SpanActualTextEFF2003 panA6 19.]BD

- extracellular matrix (ECM)
 cell membrane interactions 109
 hyaluronic acid, targeted therapy 868
 turnover, stellate cell role 106, 112, 338
- extracellular matrix (ECM) proteins
 excess, fibrogenesis 106, 107
 acute pancreatitis 109
 removal, stellate cell role 109
 pancreatic cancer progression and
 synthesis, stellate cell role 106, 112
- extracorporeal shock wave lithotripsy (ESWL)
 423, 439–440, 442, 490
- extrahepatic biliary tract *see* biliary tract,
 extrahepatic
- extrapancreatic cancer, in autoimmune
 pancreatitis 563
- f**
- Fajan's index for insulinoma 949
- familial adenomatous polyposis (FAP)
 1038, 1058
- ampullary adenoma 1047, 1058, 1068
 ampullary carcinoma 1050, 1058,
 1068, 1075
- duodenal cancer 1081
- IPMN 707
- periampullary cancer 1038
- familial cancer syndromes 585, 688
- cystic neoplasm risk 585
 IPMN risk 585, 707
 pancreatic cancer risk 688, 690
 pancreatic cystic lesion risk 569
- familial hypertriglyceridemia 34, 35
- familial pancreatic cancer *see* pancreatic
 cancer, familial
- familial pancreatitis 374, 379
- family history, pancreatic cancer risk 670,
 688, 721, 745–746
- Fasciola hepatica* 232
- fasting
 acute pancreatitis and 313
 reduced pancreatic protein synthesis 96
 sphincter of Oddi motility 78–79, 79
- fasting test, insulinoma 949, 954, 1003,
 1003, 1020
- fat
 fecal, quantitation 402
 replacement of pancreas with 29, 29
- fat (dietary)
 digestion/metabolism 426
 malabsorption 499
 maldigestion, CFTR-associated
 disease 392
 metabolism, inherited disorders 33–35, 34
 regulation of pancreatic protein
 synthesis 96
- fat necrosis, acute pancreatitis 186,
 193–194, 194
- outcome 195, 195
- pathophysiology 196–197
- fatty acid(s)
 CCK release in response 85
 metabolism 231
 regulation of pancreatic protein
 synthesis 96
- fatty acid-binding protein 168
- fatty acid ethyl esters (FAEE) 137, 140,
 231, 343
- acute pancreatitis 186
 gene mutations 141
 toxicity mechanisms 137, 138
- fatty acid ethyl esters (FAEE) synthases 343
- fatty stools *see* steatorrhea
- FDG-PET 755, 756
- autoimmune pancreatitis
 diagnosis 551–552, 756
 type 1 524, 526, 528, 529
- pancreatic cancer
 diagnosis 756, 756, 759, 771
 response to therapy 757–758
 staging 757, 757
- PanNETs 957, 1016
see also positron emission
 tomography (PET)
- FDG-PET-CT, pancreatic cancer staging
 757, 757
- FDG-PET-MRI, pancreatic cancer 758,
 758–759, 759, 760
- fecal elastase-1 127, 401, 401, 426
- autoimmune pancreatitis 541
 chronic pancreatitis 401, 401, 426
- fecal fat quantitation 402
- feces
 discoloration 718
 stones in 146
- feedback regulation, pancreatic
 secretion 89–90, 99
- FGF10–FGF2R ligand–receptor pair 5
- fibroblast growth factor (FGF) pathway 5
- fibrogenesis 106, 107, 109
- chronic pancreatitis 334, 337, 337–338
- macrophage role *see* macrophage(s)
- preventing/reversal 110
- PSC role *see* pancreatic stellate cell (PSC)
- fibroinflammatory biliary stricture
 (FIBS) 1053–1054
- fibrolysis, PSC role 109
- fibrosis, pancreatic
 chronic pancreatitis *see* chronic
 pancreatitis
- feed-forward loop, sensory fiber
 sensitization 174, 175
- in hereditary disorders 32, 33
- intralobular, tropical pancreatitis 385
- PRSS1* gene mutation and 378
- recurrent acute pancreatitis 323
- reversal 110
- storiform, type 1 autoimmune
 pancreatitis 516, 517, 525, 527
- fine needle aspiration (FNA)
 CT-guided, pancreatic necrosis with
 infection 271, 272, 311
- cystic neoplasms 603, 607, 619, 620
- EUS-guided *see* endoscopic
 ultrasound (EUS)
- pancreatic cancer 693, 729–731, 730
- pancreatic cysts 440
- pancreatic necrosis with infection 271,
 272, 273, 278, 311
- fistula, pancreatic *see* pancreatic fistula
- fistulography 318
- flatulence, pancreatic cancer 717
- fluid
 acinar, secretion *see* acinar fluid
 ductal, secretion *see* duct cell(s)
- fluid collections *see* pancreatic fluid
 collections (PFC)
- fluid resuscitation
 aggressive, acute pancreatitis 251–254,
 258, 312–313
- animal studies 252–253
- guidelines 253
- human studies 253–254, 254, 312–313
- monitoring 312–313
- over-aggressive 253–254
- pediatric 225
- pre-transfer to ICU 260
- rationale for, and role of 252, 312
- colloid 253, 313
- crystalloid, acute pancreatitis
 animal studies 252–253
 human studies 253, 254, 313
- ¹⁸F-fluoro-deoxyglucose PET *see* FDG-PET
- 5-fluorouracil (5-FU)
 adjuvant, pancreatic cancer 848,
 850, 853
- radiation with 843, 847, 886, 887
- advanced pancreatic cancer
 first-line therapy 873, 874
 second-line therapy 876
- adverse reactions 874
- ampullary carcinoma 1093
- distal cholangiocarcinoma 1090
- pancreatic cancer recurrence after 898
- PanNETs 975, 1006
- FOLFIRINOX regimen 773, 844, 852, 877
- adjuvant therapy 852
- advanced pancreatic cancer 874–875
 first-line vs gemcitabine 875
- adverse effects 875
- downstaging borderline resectable
 disease 844, 844
- drugs in 874
- locally advanced pancreatic cancer 784,
 785–786, 817, 824, 875, 876
- FOLFOX regimen 1093
- follicular pancreatitis 517
- foregut 4
- FOXF1* gene mutations 25
- FOXP3* gene mutations 32
- Frantz tumor *see* solid pseudopapillary
 neoplasm (SPN)
- free fatty acids (FFA) 137, 186, 262
- Frey procedure 367, 450, 451, 453, 454,
 463–464, 491
- as alternative to DPPHR 463–464, 492
- laparoscopic 484–485, 485
- long-term outcomes 450, 462, 492
- outcome, Beger procedure vs 368,
 491–492
- fucosyltransferase 2 nonsecretor status
 (*FUT2*) 346
- fungus infections
 acute pancreatitis due to 232, 232
- necrotizing pancreatitis complication 266

g

- GABA 674
- gabexate mesilate 179
- α -galactosylated (α -gal) epitopes 859
- galanin 77, 80, 126–127
- gallbladder
- neuroendocrine tumors (NET) 1025
 - removal *see* cholecystectomy
- gallium citrate (Ga-67) scintigraphy 551–552
- gallstone(s)
- acute pancreatitis *see* acute biliary pancreatitis (ABP)
 - ampulla of Vater obstruction 146
 - in common channel 146–147, 149
 - incidence 151
 - passage, reflux of duodenal contents 147, 148
 - pediatric acute pancreatitis 221
 - presence, confirmation 151–152, 152, 297
 - sphincter of Oddi dysfunction 150, 260
- gallstone pancreatitis, acute *see* acute biliary pancreatitis
- gangliocytic paraganglioma 1024
- Gardner's syndrome 1038, 1058
- gastroctomy, distal, complications 910, 910–911
- gastric acid hypersecretion 948, 961, 963, 1009
- gastric decompression, pancreatic cancer 831
- gastric emptying, delayed 645, 718, 785, 785, 793
- gastric inhibitory peptide (GIP) 96
- gastric outlet obstruction (GOO)
- chronic pancreatitis 439
 - ductal adenocarcinoma (PDAC) 772, 828–829, 831
 - palliative therapy 837–838
- gastric remnant cancer 910–911
- gastrin, elevated 718, 948, 954, 963
- gastrinoma 1009–1012, 1021–1022, 1032
- clinical features 718, 719, 948, 948
 - diagnosis 949, 954
 - duodenal 1009, 1010, 1021, 1023, 1032
 - investigations 951, 954, 1009–1010, 1021
 - imaging 954, 1009, 1010
 - serum-based laboratory 949, 954, 955, 1009–1010
 - liver metastases 963, 1011, 1022, 1032
 - localization 1009–1010, 1021
 - long-term outcome 1032
 - lymph node metastases 1010
 - malignant 1009
 - in MEN1 961, 962, 963, 973–974, 1022
 - treatment 1009–1012, 1032
 - chemotherapy 1011
 - medical 964, 973, 973–974
 - strategy 1009
 - surgical 963, 990, 1010, 1022, 1032
- see also* Zollinger–Ellison syndrome
- “gastrinoma triangle” 1021
- gastritis, reflux 910, 910
- gastroduodenal artery (GDA)
- in pancreatoduodenectomy 470, 471, 644, 784
 - robotic pancreatoduodenectomy 806
- gastrointestinal duplication cysts 28, 215–216, 216
- gastrointestinal fistulas 320
- gastrointestinal hormones 99
- gastrointestinal microbiome 669
- gastrointestinal tract, embryogenesis 3, 4, 724
- Gastrointestinal Tumour Study Group (GITSG) 847, 848, 851
- gastrojejunostomy 644
- advanced pancreatic cancer 772, 831–832, 837
 - anastomotic ulcer 799
 - EUS-guided 837, 838
 - laparoscopic
 - pancreatoduodenectomy 772
 - prophylactic 831–832
 - robotic pancreatoduodenectomy 806
- gastrostomy
- palliative, pancreatic cancer 831
 - see also* cystogastrostomy
- gastrulation 3, 4
- GATA6 gene 24, 675
- GATA6 transcription factor 853
- GCK gene mutations 32
- gefitinib 887
- Gem-Cap trial 874
- Gem-Erlotinib trial 874
- gemcitabine
- adverse effects 873
 - ampullary carcinoma 1093
 - distal cholangiocarcinoma 1090–1091
 - pancreatic cancer
 - adjuvant therapy 848, 849, 850, 851, 852
 - advanced, first-line therapy 873–874, 876
 - combination therapy 874, 876
 - induction chemotherapy and SBRT 888
 - locally advanced, chemoradiation 876
 - metastatic disease 874
 - neoadjuvant therapy 786, 888
 - radiotherapy with 886, 887
 - recurrence after 898
 - targeted therapy with 868
- gender
- pancreatic cystic neoplasms 570
 - pancreatic cysts 568
- gene(s), overexpressed, ductal adenocarcinoma 682
- gene mutations *see specific genes and specific diseases*
- gene testing *see* genetic testing
- gene therapy
- cystic fibrosis 394
 - hereditary lipoprotein lipase deficiency 34, 398
- genetic modifying factors, acute pancreatitis 159, 161–162
- genetic predisposition *see* genetic susceptibility factors
- genetic susceptibility factors
- acute pancreatitis 158–162, 158–165, 159
 - acinar cell-associated 158–160, 159
 - alcohol-induced 138, 139, 140–142
 - alcohol-metabolizing enzymes 140–141
 - CASR gene 161, 377
 - CFTR gene 142, 160–161, 227
 - children 221, 227
 - chymotrypsin gene mutations 141–142, 162
 - claudin 2 mutations 141, 162
 - duct-associated 159, 160–161
 - multiple defects 161
 - pediatric 221, 222, 224, 227
 - progression to chronic pancreatitis 162
 - PRSS1 gene 141, 159–160, 227
 - PRSS2 gene 141
 - SPINK1 gene 141, 160, 161, 227
 - alcoholic chronic pancreatitis 345–346
 - autoimmune pancreatitis, type 1 510
 - chronic pancreatitis 337
 - hereditary pancreatitis *see* hereditary pancreatitis
 - pancreatic cancer 689–690, 746
 - see also individual genes*
- genetic testing
- hereditary pancreatitis 379–380, 402, 402
 - idiopathic chronic pancreatitis 402, 402
 - pancreatic cancer susceptibility genes 745
 - predictive 379, 380
- genome, human 679
- genome-wide association studies (GWAS) 746
- germ disk 3, 4
- ghrelin 87, 126, 956
- cells producing (ϵ cells) 123, 126
- GHRHoma 956, 1013, 1014
- giant cells, undifferentiated ductal carcinoma with 696
- glitazones 499
- glomerular filtration rate (GFR) 1113, 1114
- glucagon
- from α cells 21
 - excess secretion 948, 954
 - pancreatic secretion inhibition 89, 125
 - type 3c diabetes 496–497, 911 495
- glucagon-like peptide 1 (GLP-1) 89
- agonists 234
 - diabetes in chronic pancreatitis 497, 499
 - pancreatic secretion inhibition 89
 - PanNET investigation 959, 963, 1020
- glucagonemia 954
- glucagonoma
- clinical features 718, 719, 948, 948, 1013, 1014
 - diagnosis 954
 - investigations 954, 955
 - long-term outcome 1032
 - medical treatment 973
 - in MEN1 954, 963
 - surgical treatment 963, 990
- glucokinase (GCK), gene mutations 32

- glucose
 abnormal metabolism, pancreatic cancer and 720, 756
 blood *see* blood glucose; glycemic control
 α -glucosidase inhibitors (α -GI) 499
 GLUT-1 581
 glutathione S-transferase (GST) 159, 676
 glycemic control
 after islet transplantation 1112–1113
 type 3c diabetes 497, 499
see also blood glucose
 glycogen storage disorders 34
 glycoprotein(s), expression, changes in
 IPMN 583
GNAS gene, mutations 577, 583, 585, 683
 intraductal tubulopapillary neoplasms 710
 IPMN 577, 583, 584–585, 683, 697, 706, 709, 748
 pancreatic cancer screening 749
 pancreatic intraepithelial neoplasms 706
 Golgi, in acinar cells 15–16, 17
 granulation tissue, necrotizing hemorrhagic pancreatitis 195
 granulocyte colony-stimulating factor (G-CSF) 763
 granulocyte-macrophage colony-stimulating factor (GM-CSF) 857, 858, 859
 granulocytic epithelial lesions (GELs) 513, 516, 520–521, 536, 546, 550
 histology 516, 518, 518
 groove (duodenal) pancreatitis 349, 406, 412, 1053
 CT and MRI 412–413, 413
 differential diagnosis 517
 growth, pancreatic 95–105
 adaptive, response to nutrients/hormones 98, 99, 99–100
 pancreatic cell culture 101
 regenerative 100–101
 regulation 98–101
 growth-associated protein-43 (GAP-43) 351
 growth factors, acinar cell culture, growth 101
 growth hormone (GH) 956
 growth hormone-releasing hormone (GHRH) 956, 1013, 1014
 GTP, and GDP, RAS protein action 867
 gut barrier 254
 failure, acute pancreatitis 168, 183–184
 gut flora, pancreatic cancer risk 669
 “gut motor” hypothesis 166
 gut permeability, acute pancreatitis 183–184, 184
 “gut rousing” concept 168
 “gut–lymph” hypothesis 166, 167, 167, 170
see also mesenteric lymph
 GVAX vaccine 858, 859, 860, 861
 combination therapy 861, 887
- h**
 Haaga criteria 550
 Halsted, William Stewart 783
- HbA_{1c} 1110
 islet transplantation and 1110, 1112, 1113
 pancreatic cancer 770
 total pancreatectomy, after 799
 type 3c diabetes 497, 497
see also blood glucose
- head of pancreas
 anatomy 3, 10, 11
 cancer 828, 1037
 inflammatory pancreatic head mass *vs* 366–367
 pancreatoduodenectomy 783
 resectability status 777
 CT image 12
 cysts
 surgery *vs* surveillance 619
see also cystic neoplasms/tumors
 inflammatory mass *see* inflammatory pancreatic head mass (IPHM)
 neural plexus, dissection 1086
 as “pacemaker” of pain 450
 resection
 chronic pancreatitis 450–451, 454, 459, 491
 for cystic neoplasms 622, 623
 duodenum-preserving *see* duodenum-preserving pancreatic head resection (DPPHR)
 of mass 450, 451
 pancreatitis in pancreas divisum 213
 in PanNETs 990–991, 991, 991, 992
 parenchyma-sparing (limited) 623
 partial, Frey procedure *see* Frey procedure
 procedures 450–451, 451, 491
 pylorus-preserving 491
 hedgehog pathway 5, 25
Helicobacter pylori 525, 540, 669, 954
 hematocrit, acute pancreatitis 207, 209, 259
 hemipancreatectomy
 chronic pancreatitis 459
see also pancreatectomy, distal
 hemolytic uremic syndrome (HUS) 873–874
 hemorrhage *see* bleeding
 hemorrhagic shock, models 166
 hemosuccus pancreaticus 451
 hepatic artery
 embolization 913
 pancreatic cancer staging 773
 PanNET invading 996, 996, 997
 resection, pancreatic cancer 784–785
see also common hepatic artery
 hepatic metastases *see* liver metastases
 hepatic steatosis 799
 hepaticocholecystojejunostomy 829
 hepaticogastrostomy, EUS-guided 837
 hepaticojejunostomy 473, 474, 644, 829, 831–832
 advanced pancreatic cancer 772
 hepatitis B virus (HBV) 558
 hepatitis E virus (HEV) 232
 hepatocyte growth factor (HGF) 111
- hepatocyte nuclear factor 1 α (HNF1 α) 7
 hepatoduodenal ligament, skeletonization 1086
 hepatoid variant, PDAC 696
 hepatomegaly, periampullary tumors 1038
 hereditary disorders
 metabolic, affecting pancreas 33–35, 34, 398
 pancreatic endocrine function 31–32
 congenital endocrine insufficiency 31–32
 hyperinsulinism 31
 pancreatic involvement (variable) 32–33
see also congenital anomalies
 hereditary factors *see* genetic susceptibility factors
 hereditary nonpolyposis colorectal cancer syndrome (HNPCC) 1074
 hereditary pancreatic cancer *see* pancreatic cancer, familial
 hereditary pancreatitis 35, 337, 374–383
 acute pancreatitis in 375–376
 age at onset of symptoms 375, 375
 chronic pancreatitis development 374, 375, 376
 clinical features 222, 375
 definition 374
 diabetes mellitus in 376, 377
 differential diagnosis 374
 epidemiology 374–375, 398
 exocrine insufficiency 376, 377
 gene mutations 377, 377–379, 379–380, 398
CFTR 374, 375, 378–379, 746
CTRC 378–379
PRSSI 159, 179, 180, 337, 374, 375, 377–378, 379, 746
PRSSI R122C 375
PRSSI R122H 141, 159, 180, 337, 375, 376
SPINK1 35, 179, 374, 378, 398, 746
 genetic counseling 379–380
 genetic testing 379–380, 402, 402
 in children 380
 genotype–phenotype correlations 378
 inheritance patterns/penetrance 337, 374, 379
 management 376–377, 451
 molecular genetics 377–379
 pancreatic cancer and 362, 376, 418–419, 669, 690
 screening, imaging 419
 surgical treatment 476
 hernia, incisional 327
 hindgut 4
 histamine H2 antagonists 974
 histology of pancreas (normal) 13–22
 endocrine pancreas 20–22, 21, 22
 exocrine pancreas 13–20, 17, 18, 19, 20
 histones 336, 940
 historical aspects 397
 acute biliary pancreatitis 146
 acute pancreatitis 178

- alcohol-induced acute pancreatitis 135–136
- chronic pancreatitis 397
- IPMN 707
- pancreatic ductal adenocarcinoma 679
- pancreatic middle segment resection 627
- pancreatoduodenectomy 783
- transplantation, pancreatic 1121–1122
- H⁺,K⁺-ATPase pump (ATP12A) 57, 58
- HLA antigens
- autoimmune pancreatitis, type 1 510
 - sensitization, islet transplant 1114
- homocystinuria 34
- Honolulu Consensus 521
- hormones
- pancreatic growth regulation 98, 99, 99–100
 - pancreatic secretion control *see* pancreatic secretion (process)
 - see also specific hormones*
- human equilibrative nucleoside transporter 1 (hENT1) 764, 852–853, 875
- human genome 679, 865
- human immunodeficiency virus (HIV) 80, 232
- hyaluronic acid 868
- hyaluronidase 868
- hydromorphone 260
- 3-hydroxy-3-methylglutaryl-CoA lyase deficiency 34
- 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors 234
- 3-hydroxykynurenine 168, 170
- 25-hydroxyvitamin D 429, 430
- hyperalgesia 352
- hypercalcemia
- acute pancreatitis and 230
 - chronic pancreatitis 398
 - intracellular, in acinar cells 158–159
 - PanNET causing, medical treatment 973
- hypercortisolemia 956
- hypergastrinemia, gastrinoma 718, 948, 954, 963
- hyperglycemia
- acute pancreatitis complication 324
 - corticosteroid side-effect 557
 - pancreaticobiliary secretion reduced 125
 - type 3 diabetes 498
- hyperinsulinism
- congenital 31
 - transient 31, 33
- hyperlipidemia 33, 231
- hyperparathyroidism, primary 230, 398
- hypertension, abdominal 205, 261, 262, 313
- hypertriglyceridemia 33, 35, 231
- acute pancreatitis and 230–231, 234, 259, 262
 - management 262
 - alcohol-induced acute pancreatitis 140
 - chronic pancreatitis 398
- hypertriglyceridemia-induced pancreatitis 230–231
- hypoblast 3, 4
- hypocalcemia, acute pancreatitis 186–187
- hypocomplementemia 513
- hypoglycemia
- Beckwith–Wiedemann syndrome 33
 - hyperinsulinemic, persistent, of infancy 31
 - impaired awareness (IAH) 1110, 1122
 - insulin-induced, pancreatic secretion stimulation 88
 - insulinoma 946–948, 947–948, 948, 954, 1002
 - diagnostic criteria 1002, 1003
 - treatment 1005
 - islet transplantation recipient selection 1110
 - pancreatic transplant indication 1122
 - risk in diabetes
 - in chronic pancreatitis 431, 497, 498, 500
 - in hereditary pancreatitis 376
 - severe episodes (SHE) 1110, 1122
- hypoglycemic drugs 400, 498–499
- hypokalemia, ECG in 185
- hypomagnesemia, acute pancreatitis 186–187
- hypoperfusion, acute pancreatitis 258, 260
- hypotension 261
- hypothyroidism, neonatal diabetes with 32
- hypovolemia 185, 258
- hypoxemia, acute pancreatitis 181
- hypoxia-induced factor (HIF) pathway 581, 940, 942
- i**
- idiopathic acute pancreatitis 150, 151, 213, 222
- idiopathic chronic pancreatitis *see* chronic pancreatitis, idiopathic
- idiopathic duct-centric pancreatitis (IDCP) 505, 520, 534, 550, 555
- see also* autoimmune pancreatitis (AIP), type 2
- IgG4 *see under* immunoglobulin G (IgG)
- IgG4-related sclerosing disease (IgG4-RD) 530, 539, 540, 550, 555, 556
- Ihh* gene 25
- ileus 168
- imaging *see specific diseases and imaging modalities*
- immune cells, in chronic pancreatitis 337, 337–338
- immune complex, autoimmune pancreatitis relapse 546, 546–547
- immune system 856–858, 857
- adaptive 856–858, 857
 - innate 67, 117, 856
 - nervous system crosstalk 351, 352
 - pancreatic cancer 856–858, 857
- immunoglobulin A (IgA), autoimmune pancreatitis 545
- immunoglobulin G (IgG)
- Fab-arm exchange 512
 - IgG1, type 1 autoimmune pancreatitis 510–511, 513
 - IgG4 512, 513, 544
 - elevated levels, diseases 540, 544
 - IL-4 and IL-10 role 511
 - IgG4, in type 1 AIP 505, 510–511, 512–513, 516–517, 520, 530
 - immunostaining 516–517
 - levels, disease activity 525
 - as marker for diagnosis, levels 524–525, 540, 541, 544, 545
 - as marker for differential diagnosis 545–546
 - as marker for relapse prediction 546, 546–547
 - pancreatic cancer *vs* 546
- immunoglobulin M (IgM), autoimmune pancreatitis 545
- immunomodulators
- autoimmune pancreatitis therapy 556, 557, 558
 - non-vaccine, pancreatic cancer 860
 - pancreatic cancer 844–845
 - side-effects 558
- immunotherapy, pancreatic cancer *see* pancreatic cancer
- Imrie, Clement 205
- inborn errors of metabolism 33–35, 34, 221
- incidentaloma 982
- incisional hernia 913
- incretins 497
- mimetics 234, 499
- Indian hedgehog (*Ihh*) 25
- indomethacin, rectal 251
- infants, persistent hyperinsulinemic hypoglycemia 31
- infected pancreatic necrosis *see* necrosis, in acute pancreatitis
- infectious diseases
- acute pancreatitis complication 265–266
 - acute pancreatitis due to 231–232, 232
 - pediatric acute pancreatitis 221
- inferior vena cava 12
- inflammation
- neurogenic *see* neurogenic inflammation
 - pancreatic *see* pancreatitis
 - pancreatic cancer 417, 857, 879
 - perineural, chronic pancreatitis 350, 351
 - systemic *see* systemic inflammation
- inflammatory bowel disease (IBD) 234, 535
- type 2 autoimmune pancreatitis 513, 521, 526, 535
- inflammatory cells, acinar cell injury 71–72, 252
- inflammatory mediators/molecules
- pancreatic cancer 857
 - release, sensory afferents in pancreas 175
 - release in acinar cell injury 71–72, 252
- inflammatory pancreatic head mass (IPHM) 365–370
- clinical workup 366–367
 - differential diagnosis 366–367
 - histopathology 368

- inflammatory pancreatic head mass (IPHM) (*cont'd*)
- imaging 366, 367, 412, 454
 - incidence 365
 - as “pacemaker” of pancreatitis 365
 - pathophysiology 365–366
 - symptoms and clinical problems 365–366, 367
 - treatment 367–368, 451, 453
- inflammatory (pseudo) tumor *see* inflammatory pancreatic head mass (IPHM)
- inflammatory response/pathways 334, 338
- acute pancreatitis 67–68, 71, 252
 - autoimmune pancreatitis 512–513
 - chronic pancreatitis 337, 337–338
 - coagulation, interactions 184
 - cytokine polymorphisms and 162
 - cytokine release 338
 - regulation 162
 - sentinel acute pancreatitis event model 334, 335
- inherited disorders *see* hereditary disorders
- injury–wound cycle 334–336, 335, 337–338
- innate immune system 67, 117, 856
- inositol 1,4,5-trisphosphate (IP₃) 46, 48, 49
- IRBIT (IP₃-binding protein released with IP₃) 58–59, 59
 - receptors 49
- insulin
- carbohydrate in diet, effect on amylase synthesis 96
 - elevated levels, insulinoma 954
 - functions 24
 - independence, after islet transplantation 1112, 1113
 - pancreatic protein synthesis stimulation 96, 97, 97–98
 - pancreatic secretion control 87, 124–125, 127
 - receptor, hepatic 497
 - regeneration of pancreas 100, 101
 - resistance, troglitazone reducing 128
 - secretagogues, type 3c diabetes 499
 - secretion 127
 - from β cells 21, 124
 - inherited disorders 32
 - pancreatic stellate cells inhibiting 110, 112
 - surreptitious exogenous use 954
 - therapy
 - pancreatic cystic lesions 569
 - total pancreatectomy, after 799
 - type 1 diabetes 1121
 - type 3c diabetes 498, 499
 - translation initiation PI3K–PKB–mTORC1 pathway 96, 97
- insulin growth factor-1 receptor (IGFR) 868
- insulin-like growth factor-1 (IGF-1) 101
- insulin-promoter factor-1 (*IPFI*) gene 24
- insulinoma 989, 1002–1008, 1019–1021
- adherence to pancreatic duct 983
 - clinical features 718, 719, 947–948, 948, 1002, 1003, 1019
 - diagnosis 949, 954, 1002–1003, 1020
 - gene mutations 938
 - hypoglycemia 946–948, 948, 954, 1002, 1003, 1005
 - incidence 1002
 - investigations 1002–1003, 1020
 - EUS 957, 1004, 1005, 1020
 - fasting test 949, 954, 1003, 1003, 1020
 - imaging 1003–1005, 1004, 1020
 - instrumental/invasive 957, 1005
 - mixed-meal tolerance test 1003
 - nuclear imaging 1005
 - serum-based laboratory 954, 955, 1002–1003
 - localization 1003–1005, 1004, 1020
 - long-term outcome 1032
 - malignant 1032
 - in MEN1 954, 962–963, 1002, 1005, 1020, 1021
 - secondary, in MEN1 1032
 - size and malignancy 1019
 - surgical treatment 963, 983–984, 1005–1006, 1020, 1021, 1032
 - glucose management 1020–1021
 - laparoscopic 1021
 - treatment 1005–1006
 - chemotherapy 1006
 - medical 964, 972–973, 973, 1005
 - “insulin–pancreatic acinar axis” 123
 - insulo–acinar portal system 124, 124
 - insulo–acinar relationship 123–131
 - islet/exocrine pancreas structural relationship 123–124
 - islet hormones regulating exocrine secretion 84–94, 124–127
 - see also* pancreatic secretion (process)
- intensive care unit (ICU) 511–512
- in acute pancreatitis *see* acute pancreatitis, treatment (ICU)
- interferon therapy, rare PanNETs 1016
- interferon γ (IFN γ) 118, 511
- interleukin-4 (IL-4)
- receptor signaling, blockade, fibrosis inhibition 119–120
 - in type 1 autoimmune pancreatitis 511, 511, 512
- interleukin-6 (IL-6)
- activated protein C decreasing 184
 - acute pancreatitis severity assessment 208, 209
 - pancreatic cancer cells producing 112
- interleukin-8 (IL-8) 162
- acute pancreatitis severity assessment 159, 208, 209
 - gene polymorphisms 162
 - release, substance P role 352
 - type 2 autoimmune pancreatitis 513, 513
 - ulcerative colitis 513
- interleukin-10 (IL-1), type 1 autoimmune pancreatitis 511, 511, 512
- interlobular ducts 16, 18
- necrosis 196, 196
- interlobular fibrosis 195
- International Association of Pancreatology (IAP) 619, 620, 655, 657
- interstitial edematous pancreatitis *see under* acute pancreatitis
- interstitial tissue 20, 20
- interventional radiology (IVR), obstructive jaundice 836–837
- intestinal-type adenocarcinoma 1050, 1050, 1059
- intestinal villi, ischemic injury 167
- intestine
- driving critical illness 166
 - dysfunction in acute pancreatitis 167–168, 168
 - injury, acute pancreatitis severity 167–168, 168
 - ischemic injury 167
 - MODS *see* multiple organ dysfunction syndrome (MODS)
 - permeability increase, acute pancreatitis 183–184
 - role in severe acute pancreatitis 167–168, 168
- intra-abdominal pressure 205, 261, 262, 313
- intra-ampullary biliary tract neoplasms (IPNB) 1047, 1049, 1052
- intra-ampullary papillary tubular neoplasms (IAPN) 1047–1048
- carcinomas associated 1049, 1049, 1051
 - dysplasia 1048
 - histology 1048, 1048
 - immunophenotype 1048
- intraductal neoplasms 709
- IPMN *see* intraductal papillary mucinous neoplasia (IPMN)
 - ITPN *see* intraductal tubulopapillary neoplasms (ITPN)
- intraductal oncocytic papillary neoplasm (IOPN) 698, 707
- “fish-eye/fish-mouth” papilla 596, 707
- intraductal papillary mucinous neoplasia (IPMN) 575–577, 581, 583, 641, 696, 707–709
- acute pancreatitis in 327
 - age at diagnosis 570, 612–613, 707
 - asymptomatic 604, 707
 - biomarkers 683
 - branch-duct (BD-IPMN) 570, 576, 591, 596, 598, 614, 642, 707
 - age and risk factors 570, 707
 - characteristics 611, 707
 - communicating ducts 634
 - enucleation 632, 633, 635
 - histology 662
 - malignant, enucleation
 - contraindication 633
 - malignant, growth rate 618
 - MRCP 632, 633
 - natural history 612, 612, 661
 - pathology 696–697
 - quality of life 619
 - resection, indications 633
 - surgery 642, 661
 - surveillance 661, 662
 - surveillance *vs* surgery 618, 619, 620
 - time-dependent progression 613
 - characteristics 590, 591, 611, 642

- classification 567, 575–576, 611, 641, 642
WHO 709
- clinical presentation 591, 707
- colloid carcinoma association 576, 695, 709
- cytology **604**, **605**, 605–607, **606**, **607**
- definition 575, 581, 707
- epidemiology 440, 567, **568**, 569–570, 573, 575, 581, **590**, 707
- familial cancer syndromes and 585, 707, 748
- “field defect” 613, 642, 644, 655
- gastric type 576, 613, **697**, 697–698, 707, 708–709
histology 697, **697**, 707–708, **708**
tubular growth 708, **709**
- gene mutations/molecular markers 577, 581, **582**, 583, 584–585, **683**, 696, 709, 941
- as biomarkers 683
- GNAS* gene mutations 577, 583, 584–585, 683, 697, 709, 748, 749
- KRAS* gene mutations 581, 583, 584–585, 683, 709
- pancreatic cancer screening 749
- PIK3CA* gene mutations 583, 585
- RNF43* gene mutations 583, 585, 709
- grading 576, 605–607, 613–614, 698, 707
- high-grade dysplasia 593, 612, 613–614, 642, 661, 698, 707
- genetic changes and microRNA 682
- histology 606, **606**, 613–614, 698
- progression to 596, 598, 642
- recurrence risk 657
- high-risk features 642, 662
- histology 576, **576**, 613, 662, 697
gastric type 697, **697**, 707–708, **708**
intestinal type 697, **697**, **708**, **709**
invasive IPMN 662
- historical aspects 707
- imaging 593, 596, **598**, 598–599, **599**, 600, 642, 748
- immunohistology 613, 709
- incipient 583, 707
- intermediate-grade dysplasia **606**, 613, 698, 707
- intestinal type 576, 613
histology 697, **697**, **708**, **709**
- invasive carcinoma in 576, 581, 596, 611, 613–614, 661
cytology 606–607, **607**, 662
heterogeneity 662
imaging 593, 598
lymph node status 663
outcome/prognosis 662, 663
risk, in recurrence 656, **656**
risk by morphologic type 567, 612–613, 642, 696, 698, 707
risk factors 570, 613
surgery 642
time to 612, 613, 661
- long-term outcome 619, 661–663
nonoperative management 661–662
after resection 662–663
- low-grade dysplasia 605–606, **606**, 613, 698, 707
- macroscopic appearance 576, **576**, 696
- main-duct (MD-IPMN) 570, 576, 591, 596, **598**, 642
age and risk factors 570, 707
characteristics 611, 707
enucleation contraindications 634
histology 662
natural history 612
pathology 696–697
surgery 642
- microsatellite instability and 681
- mixed/combined type 576, 591, 596, 642, 697, 709
characteristics 611
natural history 612, **612**
- molecular mechanisms 581, 583, 584–585, 709
clinical applications 584–585
microRNA dysregulation 583
- mucin production 591, 603, 605, **606**, 642
- natural history 611–614, 642, 655
- oncocytic variant 698, **708**, 709
- pancreatic cancer, IPMN as precursor for 576–577, 642, 661, 682, **683**
- pancreatic cancer concomitant 613
- pancreatic intraepithelial neoplasm and 705, 706, 707
- pancreatic remnant 655–656, 662, 663
- ductal adenocarcinoma 696
low-risk lesions in 657, 658
natural history 656
tumor in, total pancreatectomy 801
- pancreatobiliary-type 576, **697**, 698, 708, **708**
- pathology 696–697, **697**, 707–709
- prevalence in familial pancreatic cancer 688
- prognosis/survival 576, 577, 613, 656, 657, 661
invasive 662
noninvasive 661, 662
- prognostic factors 662, 663
- progression 611, 612, 613–614, 642, 709
colloid carcinoma 576, 695, 709
time to invasive IPMN 612, 613, 661
tubular carcinoma 576, 709
- recurrence 613, 614, 655, **656**
early diagnosis 657–658
invasive cancer 656, 657
long time periods 657
management 656
predictors 656–657
rate 655–656, **656**, 658, 662
terminology 655
- “remote” lesions 613
- residual, after surgery 655
- “Sendai-positive”, outcome 661, 662
- surgical management 613, 641–648, 655, 749
delayed, survival after 661
guidelines 619, 620, 655, 657
indications 642
laparoscopic 649
margin, recurrence risk and 657, 662
- pancreatoduodenectomy 642
- parenchymal-sparing pancreatectomy 655
- partial pancreatectomy 642
- recurrence after *see above*
- total pancreatectomy 642, 644, 800
- surveillance/follow-up 613, 655
importance 656, 658
indications 661
nonoperative management 661–662
postoperative strategy 657–658
after resection 662
- “worrisome features” 613, 642, 662
- intraductal papillary neoplasms of bile ducts (IPNB) 1052
- intraductal tubular carcinoma (ITC) 708
- intraductal tubulopapillary neoplasms (ITPN) 575, 708, 709–710
- biliary tract 1052
- clinical features 709
- immunohistochemistry 710
- molecular features 710
- nomenclature 708, **709**
- pathology 710
- prognosis/survival 709
- intraductal ultrasonography, ampullary adenoma 1069
- intrahepatic arteries 124, 252
- intrahepatic ducts 16, 18
histology **17**, 18, **19**
- intraoperative ultrasound (IOS)
cyst ablation 637
cyst enucleation 634
gastrinoma 1010
insulinoma 1020
pancreatic cancer 824
- intrathecal drug delivery systems (IDDS) 882–883
- ion channels *see specific ion channels*
- IPI-926 (SHH inhibitor) 868
- Ipilimumab 860, 861
- IPMN *see* intraductal papillary mucinous neoplasia (IPMN)
- IRBIT (IP₃-binding protein released with IP₃) 58–59, **59**, 60
- irinotecan 874, 876
- irreversible electroporation (IRE) 845, 876
- “islet-cell tumors” 921
- islet transplantation 1109–1120
adverse effects 1114–1115
allogeneic 1109–1115
Edmonton protocol 1112, 1113
effects on diabetes complications 1113–1114
infusion 1109, **1111**
after kidney transplant (IAK) 1110, 1112, 1113
long-term metabolic results 1113, **1114**
manufacturing, release testing 1109, **1111**, 1112, 1115
outcomes (one-/two-year) 1112–1113
recipient selection 1109–1112
simultaneous islet kidney (SIK) transplant 1109–1110, 1112–1113
survival and quality of life 1113–1114

- islet transplantation (*cont'd*)
 autotransplant *see* total pancreatectomy
 with islet cell autotransplantation
 (TPIAT)
 immunosuppression 1110, 1112, 1113
 adverse effects 1114–1115
 neoplasms after 1115
 research priorities 1115–1116
 unlimited islet cell supply,
 generation 1116
 xenotransplantation 1116
 “islet–acinar axis” 123
see also insulo–acinar relationship
 islet–acinar blood supply 22
 islets of Langerhans 3, 10, 123
 blood supply 22, 124, 124
 cells
 congenital hyperinsulism 31
 differentiation 123
 hyperplasia 31, 1019
 number per islet 123
 stem-cell derived, transplantation 1116
 turnover and division 98
 types 3, 123
see also endocrine cell(s); *specific cell*
types
 in chronic pancreatitis 496, 497
 congenital absence 32
 decay, after severe acute pancreatitis 324
 histology 17
 hormones
 regulation of exocrine
 secretion 124–127
 response to meal, diabetes 497, 498
see also specific hormones
 hyperplasia 31
 immunostaining 21, 21–22, 22
 innervation 123
 macrophages in 119
 number 21, 123
 reduced, chronic pancreatitis 496
 secretory granules 22, 22
 size and shape 20–21
 structural relationship with exocrine
 pancreas 123–124
 in tail *vs* head of pancreas 21
 ultrastructure 20–21, 22
see also endocrine pancreas
 isoamylase, newborn levels 222
 isolated congenital endocrine insufficiency
 31–32
 isolated pancreatic enzyme deficiencies
 28–29, 29
 isovaleric acidemia 34
 Izbicki pain score 422, 422
- j**
 Japanese Clinical Diagnostic Criteria for
 Chronic Pancreatitis 2009 371
 Japanese CT Severity Index, acute
 pancreatitis 245
 JASPAC-01 trial 848, 848–849, 851, 851
 jaundice
 autoimmune pancreatitis, type 1 522, 535
 chronic pancreatitis 400
- obstructive
 autoimmune pancreatitis 505, 535
 CA19-9 elevation 762
 ERCP in pancreatic cancer 835–836
 EUS in pancreatic cancer 836
 interventional radiology 836–837
 IPMN 642
 IVR in pancreatic cancer 836–837
 pancreatic cancer 770, 828, 835,
 836–837
 periampullary tumors 1037, 1042
 pancreatic cancer 718, 770
 serous cystic neoplasm 590
 work-up, algorithm 1043
 jejunal contractility, reduced, acute
 pancreatitis 183
 Jeune syndrome 33
 Johanson–Blizzard syndrome (JBS) 30,
 30–31
 JSAP-02 trial 896
 juxtapancreatic duplication cysts 28
- k**
 Kausch–Whipple resection 459, 491, 783
 cystic neoplasms 622–623
see also pancreatoduodenectomy
KCNJ11 gene mutations 31, 32
 Ki-67 labeling index, PanNETs 925, 930,
 982, 989, 1030, 1053
 grading 925, 926, 927, 930
 preoperative, enucleation 983
 somatostatin analog treatment 974–975
 WHO 2010 925, 926, 928, 930, 994
 kinase inhibitors 108
KRAS gene 679, 867
 acinar cell damage, nicotine effect
 674–675
 functions/mechanism 867
 inactivation 857
 inhibitors 867
 mutations 680
 actions 857, 867
 ampullary carcinoma 1050, 1059, 1074
 as biomarker of pancreatic cancer 683
 G12C 867
 IPMN 581, 584–585, 709
 mucinous cystic neoplasm 584
 pancreatic cancer 679, 680, 852, 859,
 865, 866, 867, 941
 pancreatic cancer screening 749
 pancreatic intraepithelial neoplasms
 706, 1051
 as therapeutic target 867
 as “undruggable” target 867
 vaccine 852
KRAS peptides, synthetic 859
 kynurenine, acute pancreatitis 168, 170
- l**
 laboratory tests
 acute pancreatitis 207–208, 209, 258, 260
 autoimmune pancreatitis *see* autoimmune
 pancreatitis (AIP)
 chronic pancreatitis diagnosis 400–402
 lachrymo–sialadenitis 526–527, 528
- lactic acidosis 262
 lactoferrin, autoantibodies against 540
 LAMP-2 344
 lanreotide 959, 964, 974, 1005, 1016
 laparoscopic cyst–enterostomy 308, 317
 laparoscopic cystogastrostomy 283, 308,
 483, 484
 laparoscopic surgery (pancreatic)
 in chronic pancreatitis 479–487
 clinical outcomes 480–481
 combination procedures 484–485
 cyst gastrostomy 483, 484
 distal pancreatectomy 479, 482–483
 drainage procedures 483–484
 Frey procedure 484–485, 485
 lateral pancreaticojejunostomy 483
 pancreatoduodenectomy 482
 patient selection 485
 for pseudocysts 483, 484, 489
 robotic-assisted 479, 482, 484, 485
 total pancreatectomy, islet
 autotransplant 479, 482
 video-assisted retroperitoneal
 debridement 483–484
 complications 650–651
 in cystic neoplasms 645, 649–654
 benefits 649, 651, 652
 central pancreatectomy 651
 complications 650
 contraindications 651
 distal pancreatectomy 649, 650,
 650, 652
 enucleation 650–651
 failure, risk factors 652
 future prospects 651–652
 indications 649
 morbidity 650
 pancreatoduodenectomy 651
 parenchymal preservation
 methods 650, 651
 splenic preservation 650
 debridement, necrosis in acute pancreatitis
 274, 274, 307
 distal pancreatectomy
 in chronic pancreatitis 479, 482–483
 cystic neoplasms 645, 649, 650, 652
 learning curve 811–812
 pancreatic cancer 792–793, 808, 810
 technique 808, 810
 enucleation of PanNETs 986
 future trends 651–652
 gastrojejunostomy 772
 learning curve 811–812
 operative landmarks 649
 in pancreatic cancer 778, 804–805
 distal/left pancreatectomy 792–793,
 808, 810
 indications 804, 808
 pancreatoduodenectomy 804–805
 pancreatoduodenectomy *see*
 pancreatoduodenectomy
 PanNETs resection 1021
 parenchymal transection method
 650, 650
 transperitoneal necrosectomy 283

- laparoscopic ultrasonography, pancreatic cancer 767
- laparoscopy
 historical aspects 479
 pancreatic cancer 766–767, 767, 772
 diagnostic, before pancreatectomy 791
 extended staging 766–767, 767
 staging 825
 periampullary tumors 1042
- laparotomy, staged, surgical necrosectomy and 290–292, 293, 317
- “large duct” theories 135–136
- lesser sac/cavity
 continuous closed lavage 290, 291, 291, 317
 staging laparoscopy in pancreatic cancer 766–767, 767
 surgical access 289–290, 290
- Lieber–DeCarli pair-feeding model 344, 345
- lipase, pancreatic 427
 congenital absence 28, 29
 elevated 539
 autoimmune pancreatitis 539
 pediatric acute pancreatitis 222, 224
 fat necrosis, pathophysiology 196–197
 pancreatic fistula diagnosis 317, 318
 reduced secretion, chronic pancreatitis 399, 399
 replacement, cystic fibrosis 393
- lipase/amylase ratio 152
- lipid(s)
 digestion 426
 isolated enzyme deficiencies 28–29, 29
 intolerance, alcohol-induced acute pancreatitis 140
 metabolism, inherited disorders 33–35, 34
see also fat (dietary)
- lipid-lowering therapy 34
- lipopolysaccharide (LPS) *see* endotoxin, bacterial
- lipoprotein lipase (LPL) 231, 262
 deficiency 33–34, 34, 398
- lithostathine 136
- liver
 abscess, pyogenic 913
 cancer, familial pancreatic cancer 688
 neuroendocrine tumors 1024
 transplantation 1011
- liver metastases
 gastrinoma 963, 1011, 1022, 1032
 pancreatic cancer primary *see* pancreatic cancer
 PanNETs *see* pancreatic neuroendocrine tumors (PanNET)
 periampullary tumors 1042
 resection 998
 simple, complex or diffuse 970
- loss of heterozygosity (LOH)
 ductal adenocarcinoma 680
 IPMN 583, 585
VHL gene, serous cystic neoplasm 581
- lumen-apposing self-expandable metal stents (LAMS) 442
- lung injury 166
- lymph
 mesenteric *see* mesenteric lymph
 thoracic duct 167
- lymph node(s)
 abdominal 15
 around pancreas 13, 15
 status in invasive IPMN 663
- lymph node metastases
 ampulla of Vater tumors 1049, 1061, 1075, 1075–1076, 1101–1102
 gastrinoma 1010
 in pancreatic cancer 693, 737–738, 779
 PanNETs *see* pancreatic neuroendocrine tumors (PanNET)
 para-aortic 779, 815
 periampullary tumors 1044
- lymph node ratio (LNR), distal
 cholangiocarcinoma 1084–1085
- lymphadenectomy type(s) [T]/Span [ActualText] [EFF2003] [BDC ()TjEMC3.54157 0 Td52194
 distal cholangiocarcinoma
 1084–1085, 1086 in(jss)(e)(anc)(9(ti))]Tj/Span [ActualText] [EFF2003] [BDC ()TjEMC 25.33 0 Td40119, , 19
- duodenal cancer 1081
 extended 815, 819
 pancreatic cancer 785, 815, 819
- lymphoepithelial cyst, imaging 595–596, 596
- lymphoid enhancer-binding factor 1 (LEF1) 584
- lymphoplasmacytic infiltrate 516
- lymphoplasmacytic sclerosing pancreatitis (LPSP) 350, 505, 516, 520, 525, 534, 550, 555
see also autoimmune pancreatitis (AIP), type 1
- Lynch syndrome 688, 690, 695, 707, 746, 1058
- lysine protein intolerance 34
- lysosomal-associated membrane protein-2 (LAMP-2) 344
- lysosomal enzymes
 inhibitors, effect on zymogen activation 180
see also cathepsin B
- lysosomes
 colocalization with zymogens 66, 66, 69
 stability, decreased by chronic alcohol use 137
- m**
- macronutrients 426
- macrophage(s) 117
 activation 118, 119, 119, 120
 arginase-1 expression 120
 characteristics 117–118
 in disease 117
 chronic pancreatitis 117, 119–120, 337, 338
 experimental chronic pancreatitis 119, 120
 interstitial acute pancreatitis 194–195
 necrotizing hemorrhagic pancreatitis 195
 pancreatic cancer/PDAC 117, 120, 857, 857
 type 1 autoimmune pancreatitis 517
- fibrogenesis, role 117, 119–120
 foamy 194
 functions/roles 117, 119, 338
 hemosiderin-laden 603, 605
 intestinal 118
 M2 subtypes 118, 119, 119, 120, 338
 ontogeny 118–119
 pancreatic
 origin and characteristics 118–119
 pancreatitis-associated fibrosis 119–120
 PSC interaction 118, 119, 120, 338
 re-education, as therapeutic target 120
 regulatory (M2b) 118, 119
- anc(e(s))Tj/Span [ActualText] [EFF2003] [BDC ()TjEMC 25.33 0 Td40119, , 19*

- magnetic resonance imaging (MRI) (*cont'd*)
 pancreatic cancer 412, 724, 738–741, 740, 741, 771
 diagnosis 755
 lesion identification 739–740, 740
 screening test 747
 staging 740–741
 pancreatic pseudocysts 593
 PanNETs 949, 950, 957, 968
 periampullary tumors 1039
 PET-MRI, pancreatic cancer 758, 758–759, 759
 secretin-stimulated, chronic pancreatitis 401
 serous cystic neoplasm 594, 594–595
 T1-weighted image 739–740, 740, 742
 T2-weighted image 739–740, 741
 technique 738
 main pancreatic duct (MPD) *see* pancreatic duct(s), main
 major histocompatibility complex (MHC) 856, 857, 860
 malabsorption 426
 chronic pancreatitis 399, 431
 tropical chronic pancreatitis 386
 maldigestion 426
 malnutrition
 chronic pancreatitis 429
 inflammatory pancreatic head mass 366, 367
 total pancreatectomy, after 799
 tropical chronic pancreatitis 385–386
 manometry, sphincter of Oddi motility 78, 78, 80
 MAPK pathway 101, 581
 maple syrup urine disease 34
 marginal ulcers 910, 910
 Marseille classification, chronic pancreatitis 371
 Marshall Score, acute pancreatitis 205, 206, 209
 matrix metalloproteinases (MMPs) 72, 338
 mature cystic teratoma 578
 maturity-onset diabetes of the young (MODY) 7, 32
 McCune-Albright syndrome 585, 707
 MCP 1 gene 158, 159, 162
 MCP 1 2518A/G 162
 Meckel syndrome 33
 median arcuate ligament (MAL) syndrome 644
 mediastinitis 318
 medullary carcinoma 681, 682, 695
 ampulla of Vater 1051
 MEK inhibition 867
 MEK pathway 867
 MELAS/MERFF 34
 membrane capacitance 52
 MEN1 gene 942, 961–962
 mutations 938, 939, 940, 961–962, 1019
see also multiple endocrine neoplasia type 1 (MEN1)
 6-mercaptopurine, acute pancreatitis and 234
 mesenchyme, stromal cells 3
 mesenteric abscess 274
 mesenteric lymph
 in acute pancreatitis
 composition change 168
 experimental pancreatitis 168, 169
 toxicity 169, 169
 translating into treatment 169–170
 drainage 167
 MODS *see* multiple organ dysfunction syndrome (MODS)
 organ failure due to 166
 mesenteric thrombosis 317
 mesentericoportal axis, PanNET invasion 996, 996
 mesoderm 3, 4, 5
 mesopancreas 778, 779, 823
 mesothelin
 anti-mesothelin vaccines 683
 overexpression 682, 683, 859, 910
 mesotrypsin 179
 metabolic diseases
 acute pancreatitis associated 230–231
 affecting pancreas 32–33
 inherited 33–35, 34
 metamizole 423
 metaplasia, ductal epithelium 19
 metastases *see* liver metastases; lymph node metastases
 metastatic disease, in pancreatic cancer *see* pancreatic cancer
 metformin 400, 498–499, 675
 methionine, in chronic pancreatitis pain 436
 methylmalonic acidemia 34
 methylthioadenosine phosphorylase (MTAP) 683
 Mezhir, James J. 911
 microadenoma 934, 942, 989
 microcirculation, pancreatic, acute pancreatitis 251–252
 microlithiasis, acute biliary pancreatitis 151, 151
 micronutrient deficiency
 chronic pancreatitis 429
 tropical pancreatitis 385, 386
 supplementation, chronic pancreatitis 430
 microRNA
 acute pancreatitis 168
 dysregulation, in IPMN 583
 high-grade dysplasia 682
 mucinous cystic neoplasm 584
 pancreatic cancer/PDAC 682, 764, 771
 pancreatic stellate cells 109
 PanNETs 957
 solid pseudopapillary neoplasms 584
 microsatellite instability
 acinar cell carcinoma 683
 ampullary carcinoma 1075
 ductal adenocarcinoma 681
 medullary carcinoma 695
 microvilli 15, 16
 midgut 4
 Mikulicz disease 527, 530
 Milwaukee classification, sphincter of Oddi disorders 79–80, 80
 minimal access retroperitoneal pancreatic necrosectomy (MARPN) 283–285, 284, 285
 minimally invasive surgery 804
 cystic neoplasms 645
 left pancreatectomy, in cancer 792–793, 793
 necrotizing pancreatitis *see* necrotizing pancreatitis, acute
see also laparoscopic surgery (pancreatic); robotic surgery
 minimally invasive therapy, pancreatic fluid collections 313–314
 miR-21 764
 Mitchell–Riley syndrome 25
 mitochondria
 acinar cells 15, 17, 46–47
 Ca²⁺ overload 53
 dysfunction, acute pancreatitis 70, 167
 mitochondrial disorder, Pearson syndrome 30
 mitochondrial DNA, mutations, pancreatic cancer 682
 mitochondrial permeability transition pore (MPTP) 53
 mitomycin C 1090, 1093
 mitotic count, PanNETs 925, 926, 927, 928, 930, 989
 mixed adenoneuroendocrine carcinoma (MANEC) 930
 mixed anti-inflammatory response syndrome (MARS) 178
 mixed-meal tolerance test 1003
 mixed neuroendocrine–nonneuroendocrine neoplasm (MiNEN) 930, 933
 models of pancreatitis *see* experimental pancreatitis
 monocyte(s) 117, 118
 monocyte chemotactic protein-1 (MCP-1) 158, 162
 Morgagni, Jean-Baptista 397
 MPACT trial 852
 mRNA 96, 100
 MTAP gene 680, 683
 mTOR pathway 585, 876, 938, 940–941, 943, 967
 complex 1 (mTORC1) 940–941, 942, 943
 pancreatic growth 99, 99, 100
 pancreatic protein synthesis 96, 98
 inhibitor *see* everolimus
 MUC1
 ampullary carcinoma 1050
 IPMN 576, 613, 698, 709
 mucinous cystic neoplasm 575
 pancreatic cancer prognosis 910
 pancreatic intraepithelial neoplasms 706
 MUC2
 ampullary neoplasms 1048, 1050, 1059
 cystic neoplasms 575, 709
 MUC4 674, 675
 MUC5AC
 ampullary carcinomas 1050
 intraductal tubulopapillary neoplasms 710, 1052
 IPMN 576, 613, 698, 709

- mucinous cystic neoplasms 575
 pancreatic intraepithelial neoplasms 706
 MUC6
 intraductal tubulopapillary neoplasms 710, 1052
 IPMN 576, 613, 698, 709
 pancreatic intraepithelial neoplasms 706
 mucin
 in bile, acute pancreatitis 151
 IPMN 591, 603, 605, 606, 642, 695
 mucinous cystic neoplasms 574, 603, 605, 606, 698, 710
 pancreatic intraepithelial neoplasms 705–706
 mucin-producing cysts *see* intraductal papillary mucinous neoplasia (IPMN); mucinous cystic neoplasm (MCN)
 mucinous carcinoma, ampulla of Vater 1051
 mucinous cystic neoplasm (MCN) 567, 574–575, 641, 642, 698–699, 710–711
 age at diagnosis 570, 574, 590, 614, 642, 710
 asymptomatic 604
 calcification 574, 596, 614
 characteristics 590, 590, 642
 clinical presentations 590–591, 710
 “cyst-in-cyst” appearance 574, 575, 596, 597, 710
 cytology 603, 604, 605, 606
 diagnosis 440, 596
 epidemiology 569, 570, 574, 590, 614, 642, 710
 gene mutations 582, 584, 585, 683, 711, 941
 high-grade/low-grade 574–575, 710, 710
 histology 574–575, 575, 614, 698, 698–699
 imaging 596, 597, 600
 immunohistology 575, 711
 invasive carcinoma in 570, 573, 575, 614, 642, 699, 710–711
 macroscopic appearance 574, 575, 614
 “minimally invasive” 575, 661
 misdiagnosis 591
 molecular mechanisms 584, 711
 natural history 614, 642
 ovarian-like stroma (OS) 574, 575, 575, 614, 698, 710
 pathology 573, 574–575, 596, 698–699, 710, 710–711
 as precursor for pancreatic cancer 682, 683, 710–711
 prognosis/survival 575, 614, 642, 661, 710
 staging 575
 surgery 614, 642, 661
 enucleation 632, 633
 indications 642–643
 laparoscopic 649
 long-term outcome 661, 710
 resection, indications 633, 642–643, 661
 surveillance after 614, 642–643, 661
 unilocular cyst 574, 596, 597
 mucinous metaplasia 706
 mucinous noncystic carcinoma *see* colloid (mucinous) carcinoma
 mucous cell hypertrophy 706
 Muir–Torre syndrome 1058
 multidisciplinary team
 infected pancreatic necrosis management 277
 pancreatic cancer resection 790
 multidrug resistance 266
 multiorgan failure, post-necrosectomy in
 necrotizing pancreatitis 286
 multiple endocrine neoplasia type 1 (MEN1) 933–934, 942, 1019
 chemotherapy 964
 epidemiology 961
 genetics 923, 942, 961–962
 pancreatic lesions, histology 934, 942
 PanNETs 923, 933–934, 937, 942, 961–966, 969, 989
 ATRX/DAXX and *MEN1* genes 941, 942
 clinical features 963
 cystic (CPanNET) 570, 591
 diagnosis 962, 962–963
 enucleation 984, 985
 follow-up 964, 965
 frequency 922, 961, 962
 functional types 954, 961, 963
 gastrinoma 961, 962, 963, 973–974, 1022
 insulinoma 954, 962–963, 1002, 1005, 1020, 1021
 medical treatment 964
 metastatic 963, 964
 nonfunctioning types 963, 994, 1022, 1031
 prognosis 964–965, 969
 surgical treatment 963–964, 969, 1021
 “three-P triad” 961
 tumors in 933–934, 961
 see also MEN1 gene
 multiple endocrine neoplasia type 4 (MEN4) 1019
 multiple organ dysfunction syndrome (MODS) 166, 178, 181, 205, 252
 altered gut–lymph composition 168
 early concepts/theories on 166–167
 gut–lymph toxicity 169
 translating into treatment 169–170
 intestine role 166–167, 167–168
 mesenteric lymph role 166–167, 168
 prognosis, acute pancreatitis severity 204
 multiple organ failure *see* multiple organ dysfunction syndrome (MODS)
 muscarinic receptors 86
 mutations *see specific genes*
 Myb transcription factor 118
 myeloid-derived suppressor cells (MDSC) 857
 myofibroblast-like cell *see* pancreatic stellate cell (PSC), activation
 myofibroblasts 18, 19
n
 Na⁺/H⁺ exchangers 56
 Na⁺/HCO₃⁻ cotransporter 160
 Na⁺/K⁺/2Cl⁻ cotransporter 52, 56
 Na⁺/K⁺ pump 52, 56, 57
 NAADP, Ca²⁺ releasing messenger 49–50
 nab-paclitaxel, pancreatic cancer 786, 852, 874
 nafamostat 170
 L-NAME 87
 NAPS2 study 342–343
 narcotic dependence 466, 468–469
 nasal potential difference (NPD) 393
 nasal wings, aplasia 30, 30
 nasocystic lavage, infected pancreatic necrosis 278
 nasogastric feeding, acute pancreatitis 254–255, 313
 nasojejunal feeding
 acute pancreatitis 254–255, 313
 chronic pancreatitis 431
 nasopancreatic stenting, preoperative 635
 National Comprehensive Cancer Network (NCCN) 728, 757, 768, 777, 814, 887, 898, 968
 navitoclax 867
 neck of pancreas 10, 11, 12
 serous cystadenoma 628
 necrosectomy 289, 306
 endoscopic 307
 direct, infected pancreatic necrosis 275, 278–279, 279, 280
 fistula formation after 317
 loss of tissue, dysfunction correlated 324
 minimal access
 complications 286, 287
 laparoscopic transperitoneal 283
 necrotizing pancreatitis 274, 278, 283–288
 outcome 287
 percutaneous retroperitoneal 283
 postoperative course 286–287
 retroperitoneal (MARPN) 283–285, 284, 285
 techniques 283–285, 284, 285, 285–286
 video-assisted retroperitoneal 285, 307
 open surgical *see under* necrotizing pancreatitis
 necrosis, in acute pancreatitis 178, 193, 277
 acute necrotic collection 195, 242–243, 243, 266, 277, 311
 acute peripancreatic fluid collection 195, 242, 243, 266, 277, 311
 acute renal failure and 183
 Atlanta classification 266, 272
 debridement *see under* necrotizing pancreatitis, acute
 definition 277, 311
 diagnosis 241
 by CT 238, 242, 243, 245, 277, 289
 early, need for 248
 overestimation by CT 289
 radiologic 242–244, 243, 244, 245, 246, 311
 diagnostic criteria, accuracy 239
 ductal 194, 196, 196
 early, diagnosis 245–247
 endoscopy *see* endoscopic therapy
 histopathological patterns 193, 194, 311

- necrosis, in acute pancreatitis (*cont'd*)
- infected 178, 265, 266, 272, 277, 311
 - air bubbles 307
 - antibiotic treatment 267–269, 272
 - definition 277
 - delayed surgical intervention 272
 - diagnosis 278, 311–312
 - dual-modality drainage 279
 - endoscopic therapy *see* endoscopic therapy
 - mechanical intervention 277–278
 - minimal access therapy *see under* necrotizing pancreatitis
 - mortality 178, 277, 280, 286
 - organ failure 178
 - prognosis 265
 - surgical interventions 271, 272, 277
 - timing of interventions 272, 278, 283
 - transmural drainage 278–280, 279
 - walled-off necrosis 244, 247, 265, 274, 277, 307
 - interventions/therapy *see under* necrotizing pancreatitis
 - pathophysiology/steps 196–197, 242, 316
 - sterile 311
 - interventions for 271, 272, 277–278, 283
 - type 1 193–195, 194, 195, 196, 197
 - type 2 194, 196, 196, 197
 - type 3 194, 196, 196, 197
 - types 193, 194, 241
 - walled-off *see* walled-off necrosis (WON), in acute pancreatitis
- see also* necrotizing pancreatitis
- necrosis–fibrosis sequence 135, 195, 323
- necrotizing pancreatitis, acute 193, 194, 242, 271, 277
- catheter drainage 307
 - defining/Atlanta system 242, 271
 - endoscopic therapy
 - debridement 274, 274
 - direct necrosectomy 275, 278–279
 - see also* endoscopic therapy
 - hemorrhagic, histopathology 194, 195
 - histopathology, initial phase 193–194, 194, 194, 195
 - inadequate fluid resuscitation 253
 - infections *see* necrosis, in acute pancreatitis
 - laparoscopic cystogastrostomy 283, 293
 - minimally invasive debridement/
 - lavage 269, 274, 283–288, 289
 - conversion to surgery 286
 - early complications 286
 - laparoscopic transperitoneal 283
 - late complications 286, 287
 - outcome and mortality 287
 - postoperative course 286–287
 - retroperitoneal approach 283–285, 284, 285
 - techniques 283–285, 284, 285
 - techniques, complex collections 285–286
 - video-assisted retroperitoneal 274, 285
 - mortality 271, 277, 287
 - outcome 195, 195
 - recovery, pancreatic stellate cell role 109
 - surgical debridement/necrosectomy 269, 271, 273–274, 289–295, 307
 - advantages 274
 - closed packing and 292–293, 293, 293, 317
 - continuous closed lavage 290, 291, 291, 317
 - fistula formation after 317
 - goals 289
 - minimally invasive technique
 - conversion 286
 - open packing/staged laparotomy 290–292, 292, 317
 - techniques, and access 289–290, 290
 - surgical treatment 271–276, 277, 307
 - historical perspective 271–272
 - indications and timing 272, 289
 - open cystogastrostomy 293
 - percutaneous catheter drainage 274–275, 307
 - procedures 273
 - step-up approach 307
 - treatment guidelines 283
 - see also* necrosis, in acute pancreatitis
- needle-based confocal endomicroscopy (nCLE) 600
- neoepitopes 860
- neonates, diabetes mellitus 31, 32
- NEOPA trial 907
- nephronophthisis 33
- nephrotoxicity, contrast media 247
- neprilysin (NEP) 351–352
- nerve growth factor (NGF) 110, 351, 879
- nerve plexus, pancreatic cancer invasion 718, 778, 778
- nerve supply
 - pancreas 13, 16, 88, 421
 - fiber increase, chronic pancreatitis 350–351
 - sensory afferents 173
 - sphincter of Oddi 76, 77
- nerve-targeted interventions 175
- nervous system, immune system crosstalk 351, 352
- nesidioblastosis 31, 957, 1019
- neuroD transcription factor 6
- neuroendocrine carcinoma (NEC)
 - ampullary 1053
 - pancreatic *see* pancreatic neuroendocrine carcinoma (PanNEC)
- neuroendocrine neoplasms 1053
- neuroendocrine tumors (NET) 947, 953, 1019
 - duodenum *see* duodenum
 - extrahepatic biliary tract 1024
 - foregut 1019
 - gallbladder 1025
 - gastroenteropancreatic 947
 - liver 1024
 - pancreatic *see* pancreatic neuroendocrine tumors (PanNET)
 - periampullary 1037, 1053
- neurofibromatosis type 1 1013, 1058
- duodenal NETs 1023
- PanNETs in 922, 923, 937, 942, 994
- neurogenic inflammation 173, 174, 350, 421
- neurogenic inflammation, in pancreatitis 173–177
 - experimental models 174, 174–175
 - management, silencing sensory neurons 174, 175
 - sensory afferents 173–174, 174
 - receptors expressed 174, 175
- neurogenic pain 421, 718, 879, 435421
- neurogenic remodeling 350–352
- neurokinin 1 receptor (NK-1R) 351
- neurologic injury, from celiac plexus neurolysis 882
- neurolysis, splanchnic nerves/celiac plexus 838, 880–882
- neuron-specific enolase (NSE) 935, 953, 1013, 1019
- neuropeptide Y (NPY) 22, 77, 959
- neurotensin 87
- neurotrophic factors
 - chronic pancreatitis 351
 - neurogenic inflammation 174, 174–175
- neutropenia 873, 875
- neutrophil(s)
 - acute lung injury in acute pancreatitis 182
 - functions 338
 - inflammation in chronic pancreatitis 338
 - priming, concept 166
 - second phase of trypsin activation 71–72
 - sequestration in pancreas, injury 71–72
 - type 2 autoimmune pancreatitis 513, 516, 518, 518
- neutrophil extracellular traps (NET) 72
- next-generation sequencing (NGS) 763
- NFI* gene 923, 942
- NFκB 67–68
 - activation, acute pancreatitis 67
 - activation, chronic pancreatitis 120, 344
 - chronic pancreatitis pathophysiology 344
 - induced by alcohol and acetaldehyde 138
 - inflammation regulation 67–68
- NGF/TrkA pathway, chronic pancreatitis 351
- NGN3 6
- NHE1 (Na⁺/H⁺ exchanger) 56, 57
- nicotine 674, 676
 - carcinogenesis (pancreatic) 674, 675, 676
 - pancreatic inflammation 674
- nitric oxide (NO) 76, 77, 87
- nivolumab 861
- NKCC1 56
- NKX2.2 transcription factor 6
- NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) 673, 674, 676
- NNN (N-nitrosornicotine) 674
- nociceptors, pancreatic 421, 879
 - silent 421
- nodose ganglia 173, 174
- non-oxidative metabolism, alcohol 137, 343
- non-steroidal anti-inflammatory drugs (NSAIDs) 251
 - acute pancreatitis associated/risk 233, 251
 - pancreatic cancer pain 879, 880
- nonalcoholic duct-destructive chronic pancreatitis (NADCCP) 520, 534

- nonalcoholic fatty liver disease (NAFLD) 912–913
- nonampullary duodenal carcinoma (NADC) **1038**, 1052–1053
- noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) 1003
- nonneoplastic cystic lesions *see* cystic lesions, pancreatic (PCL)
- NOTCH signaling 866, **866**, 869
- nuclear factor κ B *see* NF κ B
- nucleus, acinar cells 14
- nucleus tractus solitarius (NTS) 173
- nutrients 426
 - deficiency, chronic pancreatitis 429–430
 - pancreatic adaptive growth **99**, 99–100
 - nutritional assessment, structured 431, **432**
 - nutritional supplementation/support
 - acute pancreatitis 254–255, 313
 - chronic pancreatitis 429–434, 430–431
 - exocrine failure after acute pancreatitis 325
 - pancreatic fistula management 319
 - total pancreatectomy, after 799
- O**
- obesity
 - alcohol-induced acute pancreatitis 140
 - pancreatic cancer risk 667, 668, 720
- “obstructive pancreatitis” 216
- octreotide 974
 - chronic pancreatitis pain 350
 - long-acting release 974
 - pancreatic fistula and 635
 - PanNET investigations 958, 959
 - PanNET treatment 964, 973, 974, 1005, 1011
- Oddi, Rugero 75
- Oddi, sphincter *see* sphincter of Oddi
- “omental caking” 738, **739**
- oncocytic carcinoma 662
- oncogenes
 - cellular, regeneration of pancreas 101
 - KRAS* *see* *KRAS* gene
 - mutations, PanNETs 938
- open packing, necrotizing pancreatitis 290–292, **292**, 317
- Opie, Eugene 146, 147, 197
- opioids/opiates 260
 - bowel dysfunction due to 423
 - chronic pancreatitis pain 423, **423**
 - pancreatic cancer pain 880, 881
- organ failure 205
 - “early”, and persistent 205
 - see also under* acute pancreatitis; multiple organ dysfunction syndrome (MODS)
- organogenesis
 - early, in region of pancreas 3–4, **4**, 724
 - pancreas 3–4, **4**, 24, 98, 724, **725**
 - cell type differentiation 5–6
 - disorders associated 6–7
 - early development 4–5, **5**, 724
 - fusion process 4–5, **5**, 724, **725**
 - signalling 5
- L-ornithine 120
- ornithine transcarbamylase deficiency **34**
- osteomalacia 430
- osteopenia 430
- osteoporosis, chronic pancreatitis 430
- ovarian cancer, familial pancreatic cancer 688, 689
- overweight, pancreatic cancer risk 720
- oxaliplatin 874, 875, 876, 1092
- oxidative metabolism, alcohol 137, 140, 343
- oxidative stress
 - acute pancreatitis 70, 167
 - chronic pancreatitis 110, **335**, 435–436
 - tropical chronic pancreatitis 386
- oxygen
 - partial pressure (arterial PaO_2), reduced 181
 - supplemental, acute pancreatitis 260
- P**
- P-selectin 71
- p16/CDKN2A* gene mutation 583, **939**
 - familial pancreatic cancer 690, 746
 - screening 747, 750
 - pancreatic cancer 679, 680, 683
 - pancreatic intraepithelial neoplasia 706
- p53 protein, aberrant expression
 - ampullary carcinoma 1050, 1074–1075
 - ductal adenocarcinoma 680, **681**
 - see also* *TP53* gene
- paclitaxel, cyst ablation 637
- pain
 - abdominal *see* abdominal pain
 - acute pancreatitis 219, 222
 - long-term outcome 323, 326–327
 - sensory afferents, receptors 175
 - back 879
 - chronic pancreatitis *see* chronic pancreatitis
 - extrapancreatic 349–350
 - hereditary pancreatitis 377
 - inflammatory pancreatic head mass 365, 367
 - measurement, Izbic pain score 422, **422**
 - neurogenic/neuropathic 421, 718, 879, 435421
 - nociceptive 718
 - pancreatic 350, 879
 - pancreatic cancer *see* pancreatic cancer
 - periampullary tumors 1038
 - referred 352
 - sphincter of Oddi dysfunction 81
 - threshold 352
 - tropical chronic pancreatitis 387
- PALB2* mutations, familial pancreatic cancer 689, 746
- palliative therapy
 - ampullary tumors, malignant 1094
 - duodenal cancer 1092–1093
 - pancreatic cancer *see* pancreatic cancer
 - periampullary tumors 1042, 1089
- pancreas
 - absence 24–25
 - anatomy *see* anatomy
 - arterial blood supply 13, **14**, 124, **124**, 251–252
 - at birth 98
 - cell types *see* cell(s), of pancreas
 - development *see* organogenesis
 - dorsal 4–5, **5**
 - ectopic 26–27
 - enlargement
 - autoimmune pancreatitis type 1 522–523, 524, 551, **551**
 - “sausage-like appearance” 523, **525**, 551, **551**
 - failure, risk after acute pancreatitis 324
 - histology *see* histology of pancreas
 - hypertrophy 33
 - injury *see* pancreatic injury
 - location/position 10
 - malformations, primary *see* congenital anomalies
 - ultrastructure *see* ultrastructure of pancreas
 - ventral 4–5, **5**
 - weight 10
- pancreas annulare *see* annular pancreas
- pancreas divisum 26, **26**, 27
 - acute pancreatitis 213, **214**
 - chronic pancreatitis, gene mutations 26
- pancreastatin **86**, 89, 126
- pancreatectomy
 - blood vessels relationships 10
 - central
 - cystic neoplasms 642, 645, 651
 - IPMN 642
 - laparoscopic 651
 - parenchymal-sparing 645, 655
 - cystic neoplasms 643–645
 - postoperative management 645
 - preoperative evaluation 643
- distal (DP, left) 451, 790–796
 - body and tail cancer 790–796
 - chronic pancreatitis 466, 475–476, 479, 482–483
 - cystic neoplasms 627, 630, 642, 644, 650, 652
 - diagnostic laparoscopy before 791
 - en bloc celiac artery resection 792
 - gastrinoma 1022
 - indications, MIS approach 808
 - insulinoma 1021
 - IPMN 642
 - laparoscopic *see* laparoscopic surgery (pancreatic)
 - lymphadenectomy with 815
 - middle segment resection *vs* 627, 630
 - minimally invasive 792–793, 808
 - mucinous cystic neoplasm 614, 642, 644
 - pancreatic cancer 790–792, 808–811, **810**, 815
 - pancreatic cancer, outcome 792, 810, 911–912, **912**
 - pancreatic fistula after 793
 - PanNETs in MEN1 964
 - postoperative aspects 793
 - retrograde 791–792, **792**
 - robotically assisted 652, 792–793, **810**, 810–811, **811**
 - spleen-preserving 644, 650, 791
 - splenectomy with 791, 792
 - surgical technique 790–792, **791**

- pancreatectomy (*cont'd*)
- extended *see* pancreatic cancer, surgical resection
 - “isolated”, in pancreatic cancer 777
 - isolated left-sided 451
 - left *see* pancreatectomy, distal
 - PanNETs, nonfunctioning 968
 - parenchymal-sparing 645, 655
 - laparoscopic 651
 - partial 649
 - complications, salvage surgery after 797
 - conversion to total (TP) 801
 - IPMN 642
 - lesions identified by screening 749
 - proximal 469
 - contraindications 467
 - robotically assisted 652
 - distal 652, 792–793, **810**, 810–811, **811**
 - salvage completion 797
 - indications 801
 - perioperative outcomes 798
 - segmental, IPMN 642
 - spleen preservation with 644, 650, 791
 - total *see* total pancreatectomy (TP)
 - see also* pancreatic resections
- pancreatic abscesses 241, 302, 305, 316, 318, **441**
- pancreatic adenocarcinoma *see* pancreatic ductal adenocarcinoma (PDAC)
- pancreatic agenesis 24–25
- pancreatic amylase *see* amylase, pancreatic
- pancreatic anastomotic strictures 911
- pancreatic ascites 168, 318, 366, 451
- pancreatic atrophy 735, **736**
- pancreatic buds, development 4–5
- pancreatic cancer 665–917
- acinar cell lesions *see* acinar cell carcinoma (ACC)
 - acinar differentiation, mechanisms 683
 - acute pancreatitis complication 327, 718
 - adenocarcinoma *see* pancreatic ductal adenocarcinoma (PDAC)
 - adenosquamous carcinoma 694
 - adjuvant therapy 847–855, 906
 - chemoradiotherapy 848, **849**, 851–852, 886–887
 - future directions 852–853
 - immunotherapy 852
 - personalized medicine 852
 - radiotherapy 886–887
 - rationale 847–851
 - recurrence incidence/timing after 895–898, **896–897**
 - survival after 906–907
 - targeted 852
 - timing and duration 853
 - trials 847–851, **848**
 - vitamin D priming 868
 - adrenomedullin overexpression 127
 - advanced 770–775, 790, 835
 - biomarkers for stratifying patients 875
 - bypass surgery *see* pancreatic cancer, palliative surgical bypass
 - chemotherapy response rates 873
 - clinical burden 872
 - clinical presentation 770, 828–829
 - evaluation 770–772
 - first-line chemotherapy 873–874
 - management 872–877, **873**
 - second-line palliative chemotherapy 876–877
 - staging 772–773, **773**
 - strategies to improve therapy outcome 877
 - surgical treatment 772
 - survival 872
 - see also* pancreatic cancer, metastatic disease
 - age 667, 776
 - in autoimmune pancreatitis 517, 553, 557, 563
 - biomarkers *see* pancreatic cancer, tumor markers
 - biopsy 776
 - liquid, tumor profiling 869
 - body of pancreas 828
 - left pancreatectomy *see* pancreatectomy, distal
 - resectability status 777
 - staging and resection eligibility 790
 - borderline resectable 773, **777**, 783, **791**, 814
 - characteristics 773, **777**, 814, 843
 - downstaging by neoadjuvant therapy 783, 843–844, **844**
 - emerging recognition 843
 - evaluation, staging 736, 757, 773, **773**, **777**
 - pancreatoduodenectomy 783
 - proton beam therapy 888–891, **889**, **890**
 - radiotherapy 887–888
 - resectability criteria **784**, **791**
 - bypass surgery *see* pancreatic cancer, palliative surgical bypass
 - carcinogenesis 673–674
 - clinical studies 675, 676
 - experimental studies 673–675, **675**
 - signaling pathways 673, 674
 - cell proliferation/migration factors inducing 111–112
 - PSC role 111
 - chemoradiotherapy *see* chemoradiotherapy
 - chemoresistance, fibrotic stroma role 112
 - chemotherapy 683, 768, 773
 - adjuvant *see* pancreatic cancer, adjuvant therapy
 - neoadjuvant *see* pancreatic cancer, neoadjuvant therapy
 - palliative *see* pancreatic cancer, palliative chemotherapy
 - personalized, marker for 764
 - in chronic pancreatitis *see* chronic pancreatitis
 - classification 757
 - clinical history 717–719
 - diabetes mellitus 717–718
 - functional impairment 717–718, **719**
 - nerve plexus invasion 718, **719**
 - neuroendocrine *see* pancreatic neuroendocrine tumors (PanNET)
 - pain 717, 718, 838
 - symptoms 717, 718, **719**, 828–829, 872
 - symptoms at onset of pancreatitis 418
 - tumor cell ingrowth 718, **719**
- colloid carcinoma 695
- cone beam CT 891
- cystic *see* cystic neoplasms/tumors
- development from head to body/tail 778
- diabetes relationship 667, 668, 717–718
- diagnosis 127, 766, 770
 - CA19-9 and 762
 - NCCN guidelines 728, 757, 768, **777**, 814
 - radiologic *see* pancreatic cancer, imaging
 - resection indication 776
 - use of molecular markers 683
- differential diagnosis
 - autoimmune pancreatitis 419, 546, 550, 552
 - chronic pancreatitis 367, 411, 451, 756
- ductal *see* pancreatic ductal adenocarcinoma (PDAC)
- endoscopic management 772
- epidemiology 667–672, 835
- familial 688–692
 - age at diagnosis 688
 - cancer risk in relatives 688, 745
 - common genetic variants 690, 746
 - definition 688, 745
 - gene mutations 688, 689–690, 745, 746
 - low-penetrance genes 746
 - pathology 688–689
 - predisposition genes 689–690, 746
 - screening 745–746
 - surveillance 748
 - total pancreatectomy 800
 - treatment 689
- family history
 - IPMN recurrence risk 656, 657
 - pancreatic cyst lesions risk 569
 - as risk factor 670, 688, 721, 745–746
- genetic alterations 679, 745, 746, 852
 - as prognostic factors 910
 - see also under* pancreatic ductal adenocarcinoma (PDAC)
- head of pancreas *see* head of pancreas
- hereditary pancreatitis *see* hereditary pancreatitis
- IgG4 levels 545
- imaging 724–725, 728, 733–744, 771, 824
 - contrast-enhanced CT 734, 734–735, **735**, **815**, 824
 - CT *see* computed tomography (CT)
 - EUS *see* endoscopic ultrasound (EUS)
 - EUS-elastography 729
 - EUS-FNA *see under* endoscopic ultrasound (EUS)
 - FDG-PET *see* FDG-PET
 - intraoperative ultrasound (IOS) 824
 - MDCT 733–738, **739**, 740, 766, 771
 - MRCP 771
 - MRI 412, 738–741, **739**, 740, 755, 771
 - PET *see* positron emission tomography (PET)

- PET-CT 755, 756
 PET-MRI 758, 758–759, 759
 screening test 747
 secondary signs of malignancy 735, 735, 736
 surveillance by 748
 immunology 856–858, 857
 immunomodulator therapy 844–845
 immunotherapy 683, 852, 856–864
 antigen-specific vaccines 859–860
 checkpoint inhibitors 858, 858, 859, 860, 861
 combination 861
 neoantigen-based vaccines 860
 non-vaccine immunomodulators 860
 response, criteria 860
 tumor-associated macrophage 861
 vaccines with chemotherapy 858–859
 whole-cell vaccines 858–859, 861
 incidence 667
 inflammatory state 857, 879
 intraoperative radiotherapy 824
 in IPMN 576–577, 642, 661, 682, 683
 laparoscopy 766–767, 767, 772
 diagnostic 766
 pancreatoduodenectomy 804–805
 staging 766
 liver metastases 780
 CT 738, 739
 FDG-PET 757, 757
 MRI 740, 740–741
 surgery contraindication 814
 total pancreatectomy *vs*
 pancreatoduodenectomy 800
 local disease, survival trends 909, 909
 local invasion 778, 823
 local recurrence 898, 900, 901, 903
 chemoradiotherapy 901–903, 902
 patient selection for therapy 903
 re-resection 899, 901, 903
 survival 903
 treatment 901
 local *vs* metastatic, ratio 766
 locally advanced (LAPC) 773, 773, 783, 784, 832
 ablative therapy 872, 875–876
 chemoradiation 876
 chemotherapy 872, 873
 first-line chemotherapy 875–876
 FOLFIRNOX regimen 784, 785–786, 817, 824, 875, 876
 locoregional treatment strategies 872, 875–876
 neoadjuvant therapy 783, 784, 785–786, 844
 palliative surgery 825
 posterior artery-first approach 824
 proton beam therapy 888–891, 889, 890
 radiotherapy 887–888
 resections, long-term outcome 785–786
 resections, short-term outcome 783, 784
 lymph node metastases 693, 790, 815, 898, 910
 CT 737–738
 dissection 779
 lymphadenectomy 815
 MRI 740
 recurrence 900
 medical treatment 842–917
 metastatic disease 766, 772, 823, 898
 chemotherapy 872, 873, 874–875
 clinical features 770
 CT 737–738, 739
 detection 899
 distant, survival trend 909, 909
 distant metastases 738, 739, 780, 847
 limited, surgery 814
 liver *see above*
 lymph nodes *see above*
 management 872
 metastasectomy 901
 MRI 740–741
 nicotine stimulating 674
 pain 879
 peritoneal *see below*
 recurrence 895
 resection 818
 sites 737–738
 SMAD4 gene loss 876
 surgery 779–780, 818
 unresectable cancer 777
see also pancreatic cancer, advanced
 micrometastases 842, 847, 876, 895, 901
 microRNA 682, 764, 771
 migration of tumor cells, nicotine 674
 mixed tumors (endocrine/exocrine) 696, 930
 molecular mechanisms 679–687
 acinar differentiation neoplasms 683
 clinical applications 683–684
 personalized therapy and 683, 689, 868–869
 as prognostic factors 910
see also under pancreatic ductal
 adenocarcinoma (PDAC)
 morbidity (long-term/late) 910–913
 anastomotic strictures 911
 diabetes (type 3c) 668, 911, 912
 exocrine insufficiency 911–912, 912
 gastrectomy complications 910, 910–911
 incisional hernia 913
 nonalcoholic fatty liver disease 912–913
 pyogenic liver abscess 913
 mortality 733, 745, 770, 776, 872
 mortality trends 667
 MSI-high (microsatellite instability) 681, 683
 neoadjuvant therapy 773, 783, 784, 824, 825, 842–846, 907
 arterial resection/reconstruction after 784
 borderline resectable disease 843–844, 888
 challenges 844
 downstaging tumors 842, 843–844
 effect on recurrence 898
 future directions 844–845
 locally advanced cancer 783, 784, 785–786, 844, 888
 prognosis after 785
 proton beam therapy 889
 rationale 842
 regimens 786, 843, 844, 888
 resectable pancreatic cancer 842–843
 stereotactic radiotherapy 888
 survival after 907
 nerve plexus invasion 718, 778, 778, 879
 newly diagnosed, diabetes in 668
 pain 694, 717, 718, 838
 anatomy/physiology 879
 pain management 838–839, 879–885
 chemical ablation of nerves/plexus 880–882
 intrathecal drug delivery 882–883
 pharmacologic 879–880
 surgical 882–883
 palliative chemotherapy 839, 872–878
 first-line 873–874
 locally advanced carcinoma 875–876
 recent advances 874–875
 second-line 876–877
 in systemic recurrence 899, 901
 palliative surgical bypass 823, 825, 828–834, 835
 endoscopic therapy *vs* 829, 831
 gastric bypass 831
 gastric bypass *vs* no bypass 831
 multimodal therapy before 824
 procedure choice 831–832
 techniques 829
 palliative therapy 773, 823, 828
 aims 828
 anticancer therapy 839
 balloon enteroscopy-assisted ERCP 836
 double stenting (duodenal/biliary) 837–838
 duodenal metal stent placement 837
 endoscopic 772, 829, 830, 831, 835–841
 endoscopic biliary decompression 829, 835, 836
 endoscopic ultrasound 836
 ERCP 829, 835–836, 839
 EUS-celiac plexus neurolysis 838
 gastric decompression 831
 of gastric outlet obstruction 837–838
 interventional radiology (IVR) 836–837
 neoadjuvant therapy 825
 obstructive jaundice palliation 835–837
 pain management 838–839
 pancreatoduodenectomy 823–827
 percutaneous celiac plexus neurolysis 838–839
 PTBD 836
 pancreatitis relationship 669
 pathology 693–704
 acinar cell lesions 699–701, 700
 cystic neoplasms 696–699
 ductal adenocarcinoma *see* pancreatic
 ductal adenocarcinoma (PDAC)
 as prognostic factor 909–910

- pancreatic cancer (*cont'd*)
- peritoneal metastases 738, 739, 766, 768, 779–780
 - laparoscopy 766
 - peritoneal cytology and 767, 767–768, 779–780
 - personalized medicine 683, 852
 - genetic alterations 683, 689, 868–869
 - markers for 764, 852–853, 875
 - precancerous lesions 705–716, 748, 750
 - see also specific precursors*
 - prognosis 667, 693, 717, 776, 783, 847
 - CA19-9 levels 762
 - see also* pancreatic cancer, survival
 - prognostic factors 906, 909–910
 - after pancreatoduodenectomy 785
 - peritoneal cytology 768
 - progression
 - PSC role 112
 - time interval for 748
 - proteomic study 763–764
 - proton beam therapy (PBT) 888–891, 889, 890
 - PSC interactions (bidirectional) 111
 - radiotherapy *see* radiotherapy
 - recurrence
 - biomarkers 903
 - incidence, timing, pattern 895–898, 896–897, 901, 906–907
 - late 908
 - local *see* pancreatic cancer, local recurrence
 - PET and PET-CT 757–758
 - PSC role 111
 - risk factors 895
 - recurrence, management 895–905, 899
 - chemoradiation 899
 - chemoradiotherapy 901–903, 902
 - chemotherapy 899, 901
 - local ablative therapy 899
 - metastasectomy 901
 - neoadjuvant therapy 898, 901
 - surgery 899, 901, 903
 - total pancreatectomy for 801
 - regional disease, survival trends 909, 909
 - in remnant pancreas, total pancreatectomy 801
 - resectability 757, 773, 773, 783, 784, 814
 - CT determining 736
 - status, criteria 777, 791
 - vessels determining 736, 823
 - resection *see* pancreatic cancer, surgical resection
 - response to therapy
 - molecular genetics 683–684
 - PET and PET-CT 757–758
 - PET-MRI 759, 759
 - risk
 - allergies reducing 669–670
 - in chronic pancreatitis 361–362, 417–419, 419, 669
 - in hereditary pancreatitis 376, 418–419, 669
 - pancreatic cysts and 419
 - in tropical chronic pancreatitis 387
 - risk factors 719–721, 721
 - alcohol intake 668–669, 720–721
 - body mass index 667, 668, 720
 - carcinogen metabolizing enzymes 676
 - chronic pancreatitis 417–420, 669, 720–721, 746
 - diabetes 667, 668, 720
 - dietary 669
 - environmental 721, 721
 - family history 670, 688, 721, 745–746
 - gastrointestinal microbiome 669
 - gene mutations 670
 - hereditary pancreatitis 376, 418–419, 669
 - obesity 667, 668, 720
 - periodontal disease 669
 - smoking 667–668, 673–678, 675, 719–720
 - see also* smoking
 - screening 745
 - age to start/end 747
 - blood markers 749
 - BRCA2* or *BRCA1* gene carriers 746
 - guidelines 747, 747
 - imaging 747
 - improved tests, development 749
 - lesions identified by 747–748
 - long-term outcome after 750
 - pathology not detected by 748
 - results 748
 - surgery for lesions 749
 - tests 747, 771
 - stage I, 5-year survival 750
 - staging 693, 696, 725, 824
 - advanced PDAC 772–773, 773
 - CT 736, 736, 737, 777
 - downstaging by neoadjuvant therapy 842, 843
 - laparoscopy 766, 825
 - MRI 740–741
 - PET and PET-CT role 756–757, 757
 - PET-MRI 758, 758–759, 759, 760
 - preoperative 776, 777
 - resection indication 776, 777
 - TNM 772–773, 773
 - supportive care 872
 - surgical resection 777–778, 790, 814, 823, 842, 847
 - bypass surgery 772
 - clinical criteria 776, 790, 814
 - clinical volume, outcome 780
 - contraindications 814
 - curative intent 783, 847
 - cure rates 907, 908, 908
 - distal pancreatectomy *see* pancreatectomy
 - extrapancreatic nerve plexus invasion 778, 778
 - indications 776–782, 790, 814
 - “isolated” pancreatectomy 777
 - laparoscopic *see* laparoscopic surgery
 - late complications 910, 910–913, 912
 - left pancreatectomy *see* pancreatectomy, distal
 - for lesions identified by screening 749
 - for local invasion 778
 - for local recurrence 899, 901, 903
 - lymph node metastases 779, 815, 819
 - margin status, novel classification 824–825
 - median survival and mean survival 907
 - mesopancreas 778, 779
 - mortality 776
 - after neoadjuvant therapy 842–843, 907
 - outcomes 667, 828, 895, 910–913
 - palliative, bypass *see* pancreatic cancer, palliative surgical bypass
 - palliative resections 823, 825
 - pancreatoduodenectomy *see* pancreatoduodenectomy
 - perioperative multimodal therapy 824
 - peritoneal metastases 779–780
 - posterior artery–first approach 824
 - preoperative biliary drainage 835
 - preoperative therapy *see* pancreatic cancer, neoadjuvant therapy
 - R factor (residual disease status) 842
 - R0 825, 842, 843
 - R1 status 824–825, 842, 843
 - R2 conversion to R1 825
 - recurrence incidence/timing after 895–898, 896–897
 - robotic *see* robotic surgery
 - smoking after, decreased survival 676
 - surgical criteria 777, 814
 - surveillance after 898–899, 900, 901
 - survival after 785, 898, 906–909
 - survival rates (5-/10-year) 907, 908
 - total pancreatectomy 778, 797, 800
 - under-staged, management 825
 - for vascular invasion 778–779, 815–817, 823, 824
 - surgical resection, extended radical 814–822, 847
 - arterial resections 816–817, 817
 - combined vascular resections 818
 - definition 814
 - lymphadenectomy 815, 819
 - metastases resection 779, 818
 - multivisceral 818
 - postoperative outcome 818–819
 - procedures and outcomes 815–818
 - quality of life after 819
 - vascular resections 815–817, 823
 - venous resections 815–816, 816
 - surveillance 748, 898–899, 901
 - after surgical resection 898–899, 900, 901
 - survival 667, 693, 783, 847, 895, 906–917
 - after adjuvant chemotherapy 906–907
 - AJCC TNM staging 772–773, 773
 - long-term, rates 908
 - R1 resections 842, 843
 - after resection 785, 898, 906–909
 - after resection after neoadjuvant therapy 907
 - selection bias in trials 907
 - stage IV, extended surgery and 818
 - after total pancreatectomy 800

trends over time 908–909, *909*
see also pancreatic cancer, prognosis

tail of pancreas 828
CT imaging *791*
left pancreatectomy *see* pancreatectomy
resectability status *777*

- pancreatic ductal adenocarcinoma (PDAC) (*cont'd*)
 moderately differentiated 694
 molecular mechanisms 679–687, **866**
 chromosome instability 679, 681, 865
 clinical applications 683–684, 747
 DNA methylation changes 682
 DNA repair defect 681, 683, 746, 865
 locally rearranged subtype 866
 microRNA 682
 microsatellite instability 681
 precursor lesions 682, **683**
 signaling pathways **866**
 subtypes, therapeutic
 vulnerability 865–867
- MSI-high (microsatellite instability) 681, 683
- pancreatic intraepithelial neoplasia (PanIN-3) 706
- pathology 693–696
 gross pathology 693, **694**
 localization 693
- personalized therapy *see under* pancreatic cancer
- poorly-differentiated 694
- precursor/precancerous lesions 682, **683**, 705–716, 748, 750
see also intraductal papillary mucinous neoplasia (IPMN); mucinous cystic neoplasm (MCN); pancreatic intraepithelial neoplasms (PanIN)
- prognosis 662, 693, 770
- PSC role **111**, 111–112
- recurrence *see under* pancreatic cancer
- squamous subtype 866
- staging 693, 696
 surgical 772–773, **773**
- subtypes 865–866
- surgery 772
 extended *see under* pancreatic cancer
 margins in
 pancreatoduodenectomy 693
 prognostic factors after 785
 smoking after, decreased survival 676
- survival 693, 785, 818, 906
- targeted therapy 865–871
- TNM staging 772–773, **773**
- uncinate process *see* uncinate process
- undifferentiated 696
- undifferentiated with osteoclast-like giant cells 696
- variants 695–696
- well-differentiated 694
 type 1 autoimmune pancreatitis *vs* 517
- WNT signaling activated 6–7
see also pancreatic cancer
- pancreatic-enteric anastomotic leakage *see* pancreatic fistula
- pancreatic enzyme(s) *see* digestive enzymes; enzyme(s) (pancreatic)
- pancreatic enzyme replacement therapy (PERT) *see* enzyme replacement therapy
- pancreatic exocrine deficiency *see* exocrine insufficiency
- pancreatic exocrine system *see* exocrine pancreas
- pancreatic fistula 286, 316–322
 amylase level (drain) 645
 classification 317–318
 closure/healing 318, 320
 colonic 317, 320
 complications 316
 cyst enucleation 645
 management 635
 risk/risk factors 634, 635, **637**
 definition 316
 diagnosis 318
 external 316, 317, 320
 diagnosis/imaging 318
 failure to heal 318
 management 318–320
 nutrition 319
 surgery 318, 319–320
 timing of surgery 320
 incidence 317
 internal 316, 317, **319**
 diagnosis 318, **319**
 management 320
 middle segment resection
 complication 630
 morbidity 635
 pathogenesis 316–317
 postoperative (POPF) 317, 635, 645, 649–650
 diagnosis/symptoms 793
 laparoscopic surgery 649, 650, 651
 left pancreatectomy 793
 management 793
 pancreatoduodenectomy 785, **785**, 990
 surgery for PanNETs 990
 total pancreatectomy 801
 simple or complex 317
- pancreatic fluid collections (PFC) 277, 305–306
 acute 311
 conservative management 312–314
 imaging 312
 minimally invasive drainage 313–314
 acute necrotic *see* acute necrotic collection (ANC)
 acute peripancreatic *see* acute peripancreatic fluid collection (APFC)
 chronic pancreatitis 440
 conservative treatment 312–314
 encapsulated *see* walled-off necrosis (WON)
 management 311–315
 post-acute 301
 endoscopic drainage *vs*
 necrosectomy 301–302
 endoscopic therapy 301–304
 surgical therapy 305–310
- pseudocysts *see* pseudocysts, pancreatic
 recurrence, risk factors 302
 time frame 311
- pancreatic function tests 406
 chronic pancreatitis 400–401, **401**
 direct/indirect **401**
 noninvasive 401–402, **402**
- pancreatic head *see* head of pancreas
- pancreatic hyperplasia 98, 99
- pancreatic hypertrophy 98, 100
- pancreatic hypoplasia 24–25
- pancreatic incidentaloma 982
- pancreatic injury
 acinar-to-ductal metaplasia 338
 acute, fluid collections 277
 IgG4 and IgG1 causing 510
 immune cell activation **337**, 337–338
 repeated, chronic pancreatitis 334–336, **335**
 response to 333
 wound-healing responses 334
- pancreatic intraepithelial neoplasms (PanIN) 682, 705–706
 in autoimmune pancreatitis 517
 classification/progression 705–706, **706**, 748
 clinical features 705
 foam gland type 706
 genetic alterations **683**, 706
 intestinal type 706
 IPMN relationship 705, 706, 707
 not detected by imaging 748
 oncocytic type 706
 PanIN-3 706, **706**, 748
 screening tests 749
 pathology 705–706
 prevalence in familial pancreatic cancer 688
 PSC activation 111, 112
 surgical resections 749
- pancreatic islets *see* islets of Langerhans
- pancreatic juice
 carcinogens (smoking) 676
 composition 43
 leakage 316
 disconnected duct syndrome 302, 317–318
 pancreatic fistulas 317
 post-laparoscopic surgery 650
 postoperative, management 645
- markers, autoimmune pancreatitis 541
 in peritoneal cavity 318
 reflux, common channel syndrome 27
 secretin-stimulated 84, 125, 401, 409, 541, 562
 IPMN detection 585, 596, 683
 pancreatic cancer screening 749
 secretion by acinar cells *see* acinar cell(s); pancreatic secretion (process)
 stasis 197
 volume (daily) 84
- pancreatic lipase *see* lipase, pancreatic
- pancreatic lipase-related protein 2 **427**
- pancreatic middle segment resection (PMSR) 627–631
 complications 627, 630, **992**
 contraindications 627, 628, 629
 cystic neoplasms 627, **992**
 historical aspects 627
 indications 627
 minimally invasive 627, 630
 PanNETs **991**, 991–992, **992**

- results 630
- technique 629–630
- pancreatic neuritis 351
- pancreatic neuroendocrine carcinoma (PanNEC) 923, 926, 930, 931, **931**, 1019
- chemotherapy 975, 976, 1006
- classification and grading 926, 927, 930 **931**
- grade 3 941
- frequency 968
- high-grade 937, 941
- imaging 968
- immunohistochemistry 935
- lymph node metastases 1031
- molecular genetics 941, 967
- pathology (G3 NEC) 932
- prognosis 923, 937
- small-cell and large-cell 932–933, *935*, 937, 941
- treatment summary **970**
- unresectable on diagnosis 968
- pancreatic neuroendocrine neoplasms (PanNENs) 926, 930, 1019
- poorly-differentiated *see* pancreatic neuroendocrine carcinoma (PanNEC)
- well-differentiated *see* pancreatic neuroendocrine tumors (PanNET)
- pancreatic neuroendocrine tumors (PanNET) 872, 921–1034, 953, 1019–1022
- ACTH-secreting **955**, 956
- arterial invasion 996, *996*, *997*
- biomarkers 956–957, 1019
- classification and grading 922–929, 937, 994–995, 1030
- ENETS TNM 925, **925**, 926, 927, 1029, 1030
- functional vs nonfunctional 922, **923**, 937
- G1 **925**, 926, **928**, 930
- G2, G3 **925**, 926, 928, 930
- neuroendocrine carcinoma *see* pancreatic neuroendocrine carcinoma (PanNEC)
- RNA profiles 942–943
- sporadic vs syndromic 922–923, **923**, 937
- TNM 925, **925**, **926**, 927, 930, **931**
- tumor biology vs morphologic features 923–925, **924**
- WHO 2004 923, **924**, 925–926
- WHO 2010 **925**, 926–927, 928, 941, 994–995, 1030
- WHO 2017 930, **937**
- clinical features 718–719, 947–952
- functional PanNET 947–948, **948**, 1032
- nonfunctional PanNET 948, 967–968, 994, 1022
- cystic variants (CPanNET) 567, 569, 584, 931, 968
- clinical presentation 591
- cytology 607, *608*
- imaging 599, *600*
- cytology *933–934*, 934, *935*
- diagnosis 949–951, 994
- rare PanNETs 1015–1016
- time before/to 948
- differential diagnosis 934–936
- acinar cell carcinoma 936
- solid-pseudopapillary neoplasm 935–936
- enucleation 632, 633, 990, 1005, 1021, 1031
- advantages/disadvantages 983, 984
- indications 983, **983**, 990
- laparoscopic, outcome 986
- outcomes 984, 986
- preoperative assessment 982–983
- technique 983–984, *984*, *985*
- epidemiology 921–922, **922**, 947
- epigenetics 942–943
- functional 922, **923**, 937, 947, 953, 989, 1013
- clinical features 947–948, **948**, 1032
- diagnosis 949
- enucleation 983–984, *984*
- investigations 954–956, **955**, 982–983
- long-term outcome 1032
- medical treatment 964, 972–974, *975*
- in MEN1 954, 961, 963
- surgical treatment 963–964, 1005–1006
- types 954–956
- gastrin-secreting *see* gastrinoma
- gene mutations associated **923**, 937–938, **939**, 940, 941
- clinical implications 943
- regulatory regions of genes 938
- glucagon-secreting *see* glucagonoma
- histology 932
- imaging 949–951, 953, 957–959, 994
- CT, MRI and PET 949, *950*, 957, 968, *969*
- EUS 949, *951*, 957, 968, 971
- preoperative 982–983
- radionuclide studies 951, 957–959
- immunohistochemistry 934–936
- incidence 921–922, **922**, 937, 947
- inherited diseases with 922–923, **923**, 932, 937, 942, 967, 989, 994, 1013
- MEN1 *see* multiple endocrine neoplasia type 1 (MEN1)
- VHL 922, **923**, 932, 937, 942
- insulin-secreting *see* insulinoma
- interventional radiology
- treatment 979–981
- radiofrequency ablation 979, 980–981
- TAE/TACE 979–980
- investigations 953–960, 983, 994
- flow chart *958*, 959
- hormones 953
- instrumental/invasive 949, *951*, 957, 968, 971
- nonspecific biochemical markers 956–957, 1019
- RNA, DNA measurements 953, 957
- SASI/SACI test 951, 1009–1010
- serum-based laboratory 953–957, **955**, 1015
- liver metastases 963, 969–970, 979, *980*
- gastrinoma 963, 1011, 1022, 1032
- nonfunctioning PanNETs 969–970, 1022, 1031
- radiofrequency ablation 980–981
- surgery 998, 1031
- surgical debulking 980, *981*, 1031
- TAE/TACE treatment 979–980, *980*
- localization 949, 1015–1016
- gastrinoma 1009–1010, 1021
- insulinoma 1003–1005, *1004*, 1020
- locally advanced
- metastases 998
- surgery *995*, 995–998, *996*, 998
- long-term outcome 1015, 1029–1034
- lymph node metastases 986, 989, 995, 1016
- frequency 984, 989, 1031
- prognosis 1031
- surgery 633, 986, 995, 1031
- major, in PanNETs 994–1001
- medical treatment **970**, 972–978
- algorithm *975*, 977
- angiogenesis inhibitors 976
- chemotherapy 964, 975–976
- everolimus 941, 943
- molecular-targeted agents 976, **976**
- radionuclides 959, 977
- rare PanNETs 1016–1017
- of secretory syndromes 972–974
- selection, factors in **973**
- somatostatin analogs 964, 972, 974–975
- targeting tumor growth 974–976
- metastases 994–995
- ALT in lesion, biomarker 942, 943
- distant 998
- imaging *950*
- liver *see above*
- lymph node *see above*
- mixed tumors (endocrine/exocrine) 930
- molecular genetics 937–946, 967
- ATRX/DAXX* genes/pathway 938, 940, 941, 943
- chromosomal changes 938
- clinical implications 943
- comparison with other tumors 941–942
- MEN1 pathway/*MEN1* mutations 938, 940, 943
- methylation profiles 943
- mTOR pathway 938, 940–941, 943
- pathways changed 938, 940–941
- mortality 1030
- nonfunctional 949, 953, 967–971, 972,

lymph node metastases 984, 986,
995, 1031
malignant, surgery 990
medical treatment 971, **973**, 975
in MEN1 963–964, 994, 1022, 1031
metastatic, multidisciplinary treatment
969–971, 1031–1032
metastatic, surgery 963, 994, 998, 1031
multifocal, surgery 1031

- pancreatic secretion(s) *see* digestive enzymes;
pancreatic juice
- pancreatic secretory trypsin inhibitor
(PSTI) 160, 178, 398
see also *SPINK1* gene
- pancreatic stellate cell (PSC) 20, 20, 43,
106–109
- activated, characteristics 107, **108**, 338
- activation 107–109
- by alcohol 138
- animal studies 110
- chronic pancreatitis 109–110, 335,
337, 338
- factors causing 107, **108**, 110, 111, 138
- markers 107, **108**, 109
- in pancreatic cancer 111, 112
- in pancreatic injury 110, 335, 338
- in tropical chronic pancreatitis 385
- alcohol, direct effects on 136, 136, 138
- alcohol metabolism 137
- apoptosis 109
- chronic pancreatitis etiology 334
- discovery 106, 344
- fibrogenesis, in disease 106, 107–109,
110, 338
- acute pancreatitis 109
- animal studies of process 110
- chronic pancreatitis 109–110, 117, 338
- endocrine pancreas 110
- exocrine pancreas 110, 117
- pancreatic cancer 111, 111–112
- recovery in necrotizing pancreatitis 109
- fibrolysis role 109
- functions 43, 106, 110, 138, 338
- as progenitor cells 107
- regenerative 109, 338
- in health/normal 106–107
- macrophage interaction 118, 119,
120, 338
- morphology, and markers 106, 107, 107
- non-activated (quiescent) state 106, 108
- characteristics **108**
- numbers, increased 110
- proliferation, acute pancreatitis 109
- regulation, aberrant in chronic
pancreatitis 338
- signaling pathways **108**, 108–109, 112
- therapeutic targeting 112, 868
- pancreatic stone protein (PSP) 127
- pancreatic transplantation *see* transplantation,
pancreatic
- pancreatic triglyceride lipase, deficiency 29
- pancreatic tumors
- benign cystic *see* cystic neoplasms/tumors
- endocrine *see* pancreatic neuroendocrine
tumors (PanNET)
- exocrine *see* pancreatic cancer
- pancreaticobiliary maljunction *see* common
channel syndrome
- pancreaticobiliary reflex 27
- pancreaticoduodenal arteries 252
- pancreaticoduodenectomy *see*
pancreatoduodenectomy
- pancreaticogastrostomy 651
- pancreaticojejunostomy 472, 474
- chronic pancreatitis 470, 472, 474
- cystic neoplasms 644, 651
- duct-to-mucosa 644
- invagination method 644
- laparoscopic 483, 651
- laparoscopic
- pancreatoduodenectomy 805
- lateral 449
- chronic pancreatitis 470, 483, 490
- outcomes 490
- laterolateral 449, 450
- longitudinal 491
- in middle segment resection 629
- mucosa-to-mucosa, chronic pancreatitis
472, 474
- pancreatic cancer 785
- techniques 644
- telescopic 629
- pancreatitis 173
- acute *see* acute pancreatitis
- alcoholic *see* alcoholic pancreatitis
- autoimmune *see* autoimmune
pancreatitis (AIP)
- chronic *see* chronic pancreatitis
- ductal fluid secretion defects 60
- gallstone *see* acute biliary pancreatitis (ABP)
- hereditary *see* hereditary pancreatitis
- nicotine role 674
- pancreatic cancer relationship 669
- paraduodenal *see* groove (duodenal)
pancreatitis
- pancreatobiliary-type adenocarcinoma
1050, 1050
- pancreatoblastoma 700
- in Beckwith–Wiedemann syndrome 33
- genetic alterations 683
- histology/pathology 700, 701
- surgical resection 701
- pancreatoduodenectomy 469, 473, 643–644
- anatomic considerations 644
- in chronic pancreatitis 469–475
- laparoscopic 482
- laparoscopic vs open surgery 482
- long-term results 470, 473–475, 474,
476, 477, 491
- patient selection 469–470
- perioperative outcomes 470, 473, 475
- technique 470–473, 471, 472, 473
- classic (Whipple) 459, 491, 643–644, 804,
824, 1042
- ampullary carcinoma 1061, **1062**,
1076–1077, **1077**, **1078**
- chronic pancreatitis pain
management 424
- complications in pancreatic cancer 785,
785, **910**, 910–911
- laparoscopic technique vs 805, **807**
- long-term outcome in pancreatic cancer
785–787
- PanNETs 990
- short-term outcome in pancreatic cancer
783–785
- survival after, pancreatic cancer 785
- complications 622, **623**, 645–646, 785,
910–911
- anastomotic strictures 911
- diabetes mellitus (type 3c) 622,
623, 911
- exocrine insufficiency 622, **623**,
911–912, **912**
- nonalcoholic fatty liver disease
912–913
- in pancreatic cancer 785, **785**, **910**,
910–911
- type 3c diabetes 911, **912**
- cystic neoplasms 622–623, 643–644
- complications 645–646
- IPMN 642
- laparoscopic 651
- diabetes mellitus after 622, **623**
- distal cholangiocarcinoma 1083, 1087
- DPPHR vs **463**, 491–492, 622–623
- duodenal cancer 1081
- historical aspects 783
- “isolated”, in pancreatic cancer 777
- laparoscopic 651, 804, **806**
- learning curve 811
- open surgery vs 805, **807**
- outcomes 805
- pancreatic cancer 804–805, **807**
- patient selection and indications 804
- technique 804–805
- minimally invasive 787, 804
- modifications 469–470
- mortality 622, 783
- palliative 823–827
- pancreatic cancer (PDAC) 776, 777, 824
- factors affecting outcome 784–785,
786–787
- laparoscopic 804–805, **807**
- long-term outcome 785–787, **786**, 805,
806, 910–913
- lymphadenectomy in 815
- margin status, novel classification
824–825
- margins 693
- robotic surgery 804, 805–808, **809**
- short-term outcome 783–785, **785**
- total pancreatectomy vs 800
- PanNETs 990
- periampullary cancer 1061, **1062**, **1077**,
1078, 1097
- pyloric resection, distal
cholangiocarcinoma 1083
- pylorus-preserving 644
- distal cholangiocarcinoma 1083–1084
- pancreatic cancer 778
- pancreatic cancer, long-term outcome
785–787, 910
- pancreatic cancer, short-term outcome
783–785
- radical, inflammatory pancreatic head
mass 367, 368
- robotic (RPD) 804, **806**
- learning curve 811
- outcomes 806, 808
- pancreatic cancer 804, 805–808, **809**

- pancreatoduodenectomy (*cont'd*)
 patient selection and indications 804
 port configuration 805, **808**
 technique 805–806
 technique 643–644
- pancreatosplenectomy 791, 792
- PanNETs *see* pancreatic neuroendocrine tumors (PanNET)
- papilla of Vater 11, 75, 76, 1047, 1074
see also ampulla of Vater
- papillectomy, endoscopic 1068, 1069–1072, 1070, 1076
- para-aortic lymph node metastases 779, 815
- paraduodenal pancreatitis (PDP) *see* groove (duodenal) pancreatitis
- paraganglioma, duodenal gangliocytic 1053
- paralytic ileus, in acute pancreatitis 183–184, **184**, 262
- paramyxovirus, acute pancreatitis and 232
- paraneoplastic syndromes 718
- parasites, acute pancreatitis and 150, 232, **232**
- parasympathetic nervous system, pancreatic secretion 88
- parasympathetic postganglionic neurons 173, **174**
- parasympathetic preganglionic fibers 173, **174**
- parathyroid glands, disorders, hypercalcemia and acute pancreatitis in 230
- parathyroid hormone (PTH), increased, acute pancreatitis 186, 230
- parenchyma, interacinar 123
- atrophy, post-acute pancreatitis 326
- destruction, fibrosis in chronic pancreatitis 337
- macrophages in 119
- necrosis, in acute pancreatitis 193, 195, 242, 316
see also necrosis, in acute pancreatitis
- parenteral nutrition
 acute pancreatitis 254–255, 313
 chronic pancreatitis 431
 pancreatic fistula 319
- Partington–Rochelle procedure 449, 454, 459, 491
- pasireotide 645, 959, 973
- pathogen-associated molecular patterns (PAMP) 107
- patient education, acute pancreatitis recurrence risk 324
- PAX4 6
- PD-1 (programmed death-1) 858, **858**, 859, 860
 antibodies 860, 861
 ligands (PD-L1, PD-L2) 858, **858**, 860, 861
- PDX1* gene mutations 24
- PDX1* transcription factor 5, 6, 7, 345
- Pearson marrow pancreas syndrome 30
- pediatric acute pancreatitis 219–229
 challenges of 219
 diagnosis and criteria for 222, 224
 diagnostic difficulties 219
 etiology 219–220, **221–222**, **223**, **224**, 336
- imaging 224–225
 incidence 219, **220**
 inherited predisposition **221**, 222, **224**, 227
 investigations 220–221
 management 225–226
 mortality 226, **226**
 outcomes 226
 pathophysiology 220
 recurrent 226–227
 severity classification 224
- pembrolizumab 860
- Penrose drains 292, **293**
- peptide receptor radionuclide therapy (PRRT) 959, 977, 1022
- peptide YY (PYY) 89, 126
 pancreatic secretion inhibition 89, 126
 PYY1 and PYY2 receptors 126
- peptidergic neurons, chronic pancreatitis 351, 352
- percutaneous catheter drainage
 acute pancreatitis 274–275
 image-guided, pancreatic fluid collections 313–314
 pancreatic fistulas 318
- percutaneous transhepatic biliary drainage (PTBD) 835, 836, **836**
- percutaneous transhepatic cholangio-drainage (PTCD) 829
- periampullary tumors 1037–1046, 1058, 1074, 1089
 adenoma *see* ampullary adenoma
 adjuvant therapy 1089–1096
 ampulla *see* ampulla of Vater tumors
 benign 1037, 1040, **1040**
 biopsies 1043
 clinical presentation 1037–1038, 1089
 DBDC *see* distal common bile duct carcinoma (DBDC)
 diagnostic evaluation 1038–1043
 laboratory data 1038
 genetics 1050–1051
 head of pancreas *see* head of pancreas
 histology 1048, **1048**, 1050, **1050**
 imaging 1038–1043
 preoperative staging 1042–1043
 incidence 1089
 liver metastases 1042
 location/types 1037, **1038**
 long-term survival 1097–1106
 lymph node metastases 1044
 neuroendocrine 1053
 palliative therapy 1042, 1089
 preinvasive 1047–1048
 prognosis/survival rates 1089
 pseudotumors mimicking cancer 1053–1054
 secondary 1054
 staging, pathologic 1053
 surgery 1037, 1089, 1097
 extent of resection 1043–1044
 local resection 1043
 palliative 1042
 survival after 1097–1106
 treatment, nonoperative 1042
- periductal necrosis **194**
- perineural inflammation, chronic pancreatitis 350, 351
- perineural invasion, pancreatic cancer (PDAC) 694, **695**, 718
- periodic acid-Schiff stain (PAS)
 with diastase, acinar cell carcinoma 701
 serous cystadenoma 603, **605**
- periodontal disease, pancreatic cancer risk 669
- peripancreatic chronic inflammation, resection contraindication 468
- peripancreatic fluid *see* acute peripancreatic fluid collection (APFC)
- peripheral neuropathy, pancreatic diabetes 498
- peritoneal carcinomatosis *see* peritoneal metastases
- peritoneal cytology, pancreatic cancer **767**, 767–768, 779–780
- peritoneal metastases 738, 779
 CT **738**, **739**
see also pancreatic cancer, peritoneal metastases
- PERK (ER-resident kinase) 71, 98
- permanent neonatal diabetes mellitus (PNDM) 32
- persistent hyperinsulinemic hypoglycemia, of infancy 31
- personalized medicine, pancreatic cancer *see under* pancreatic cancer
- PERT *see* enzyme replacement therapy
- pethidine **423**
- Peutz-Jeghers syndrome (PJS)
 duodenal cancer 1081
 IPMN 707
 pancreatic cancer 690, 746, 747
 pancreatic cystic neoplasms 585
- phlebitis, obliterative 516, **517**, 525, **527**
- phosphatidylinositol 3-kinase (PI3K) 66
- phosphatidylinositol 4,5-bisphosphate (PIP₂) 46, 48, **48**
- phospholipase A2 (PLA-2) **427**
 acute lung injury in acute pancreatitis 182
 subtypes (I and II) 182
- phospholipase C 48
- physiology, pancreatic 41–131
see also acinar cell(s); experimental pancreatitis; pancreatic secretion (process)
- PI3K pathway
 inhibitors 867
 pancreatic cancer therapeutic target 867
 regeneration of pancreas 101
- PI3K–PKB–mTORC1 pathway
 pancreatic growth control 99, **99**
 translational initiation via 96, 97, **97**
- PIK3CA* gene, mutations 583, 585, 938
- intraductal tubulopapillary neoplasms 710
- pancreatic neuroendocrine tumors 938, **939**, 941, 943
- PKD1* and *PKD2* genes 32
- plasma cells
 infiltration, tropical chronic pancreatitis 385
 type 1 autoimmune pancreatitis 512–513

- plasma membrane, permeability to Ca^{2+} 50–51, 51
- plasma membrane Ca^{2+} -activated ATPase (PMCA) 50, 51
- plasma trypsin-like activity 539
- plasmablasts, type 1 autoimmune pancreatitis 512
- platelet-activating factor (PAF) 71
- platelet-derived growth factor 110
- platinum-based agents
cisplatin 976, 977, 1006, 1011, 1053
pancreatic cancer 683, 866, 869, 874
pancreatic neuroendocrine carcinoma 970, 976, 977
- pleural effusions 182
- plumbing theory 421–422
- PNLIP* gene mutations 29
- POINTER trial 301, 314
- polyamines 100
- Polyanalgesic Consensus Conference (PACC) 882
- polycystic kidney disease 32
- polyethylene glycol 168
- PONCHO trial 153
- porphyria, acute intermittent 34
- portal thrombosis 1114
- portal vein 13
occlusion 366
pancreatic cancer invasion 778–779, 779, 814
resection 784, 815–816
- portal venous hypertension, extrahepatic 468
- positive end-expiratory pressure (PEEP) 261
- positron emission tomography (PET) 755
FDG *see* FDG-PET
pancreatic cancer 755–761, 771
diagnosis 755–756, 759
response to therapy 757–758
staging 756–757, 757
- PanNETs 957
radiotracers 755, 957
- positron emission tomography (PET)-CT 755
DOTA compounds 958, 959, 962, 962
insulinoma 1005
pancreatic cancer 755–761
diagnosis 755, 756, 759
response to therapy 757–758
staging 756–757, 757
- PanNETs 958, 959, 962, 962
rare 1016
- positron emission tomography (PET)-MRI, pancreatic cancer 758, 758–759, 759, 760
- postoperative pancreatic fistula *see* pancreatic fistula
- potassium channel
 Ca^{2+} control of acinar fluid secretion 52, 56, 57
 β -cell ATP-dependent (K_{ATP}), defects 31
- PPoma, clinical features 719, 719
- prednisolone, autoimmune pancreatitis 560–561
- pregabalin, chronic pancreatitis pain 423
- primary biliary cirrhosis (PBC) 544, 545
- primitive streak 3, 4
- procalcitonin (PCT) 208, 209
- promoters, hypermethylation 682
- propionic acidemia 34
- prostaglandins, protective effect on pancreatic cells 233
- prostate cancer, familial pancreatic cancer 688
- protease(s), pancreatic 426, 427
activation, acute pancreatitis
pathogenesis 158, 178–179
cathepsin B role 180–181
clinical evidence for 179–180
see also trypsin
defect 29
degradation 179
functions 426
inactive 64
increased in mesenteric lymph in acute pancreatitis 168
inhibitors 65, 65, 180
pancreatic enzyme secretion
regulation 89–90
pathophysiologic significance 178–179
release, necrosis 316
synthesis 96, 178
in thoracic duct lymph 169–170
types 427
see also chymotrypsin; trypsin; trypsinogen
- protein (dietary)
CCK release 85
digestion 426
regeneration of pancreas 100
regulation of pancreatic growth 100
regulation of pancreatic protein synthesis 95–96
- protein(s)
expression, changes in IPMN 583
unfolded, in endoplasmic reticulum 70–71
- protein C, deficiency in acute pancreatitis 184
- protein C pathway 184
- protein kinase A (PKA), activation, ductal secretion 57, 58
- protein plug theory 136, 344
- protein plugs 136, 344
- protein synthesis, pancreatic
regulation 95–98
CCK and insulin role 96, 97, 97–98
fasting *vs* feeding 96
inhibition 98
long-term by diet 95–96
meal-to-meal regulation 96–98, 97
stimulation 96–98, 97
- proteinase-activated receptor-2 (PAR-2) 66
- proteomic study
pancreatic cancer 763–764
type 1 autoimmune pancreatitis 513, 541
- proton beam therapy (PBT)
complications 889, 891
dosimetry 888–889, 891
pancreatic cancer 888–891, 889, 890
- proton pump inhibitor (PPI) 799, 963, 964, 973–974
- PRSS1* gene 159, 377–378, 746
genetic testing 402
mutations 68, 141, 158, 159–160
acute recurrent pancreatitis in children 227
alcoholic chronic pancreatitis 346
chronic pancreatitis 346, 402
gain-of-function 377, 378
hereditary pancreatitis 68, 141, 159, 180, 337, 374, 375, 376, 377, 378
inheritance 379
N29I mutation 376, 378, 402
penetrance 374, 375, 377
R122C mutation 375
testing for 379
types and number 141, 158, 159–160, 180, 377–378
- product (cationic trypsinogen) 68, 141, 159–160, 377–378
- R122H mutation 68, 141, 159, 180, 337, 375, 376
actions 378
pathogenicity 377, 378
- PRSS1–PRSS2 ratio, autoimmune pancreatitis 539
- PRSS2* gene, variants 68, 141
anionic trypsinogen 68, 141
- PRSS7* gene mutations 29
- pruritus, pancreatic cancer 718
- psammomatous calcification 932
- pseudocysts, pancreatic 27, 305, 316, 611
in chronic pancreatitis 440
clinical features 226, 589
definition 305–306, 311, 440, 593
endoscopic treatment 301–304, 314
drainage 440–441
drainage *vs* necrosectomy 301–302
indications 301
imaging 414, 593
CT 307, 414, 593
MRI and EUS 593, 594
with necrosis 195
see also walled-off necrosis (WON)
- needle aspiration 440
- pain due to 350, 440
- pediatric acute pancreatitis
complication 226
- radiologic diagnosis 244, 248, 307
- surgical treatment 305, 307–308, 440–442, 488
indications 306, 440
internal/external drainage 488–489
outcomes 488–489
treatment 440–442, 488
laparoscopic cyst gastrostomy 483, 484, 489
outcomes 488
transgastric/transduodenal drainage 442, 488
transmural drainage 441, 441–442, 488
- “pseudoinfarction” 185
- pseudoprogession 860
- PTEN* gene mutations 938, 939, 941, 943

- PTF1A* gene mutations 24
 PTF1A transcription factor 5, 6, 24
 Puestow procedure *see*
 pancreaticojejunostomy, lateral
 pulmonary dysfunction, acute
 pancreatitis 261
 pulmonary failure, pathogenesis 181–183
 pulmonary infiltrates, acute pancreatitis
 181, 182
 “pyloric gland adenoma” 708
 pyogenic liver abscess 913
 pyruvate kinase deficiency 34
- q**
 quality of life
 acute pancreatitis outcome 326–327,
 357–358
 allogeneic islet transplantation
 1113–1114
 asymptomatic cystic neoplasms 619
 chronic pancreatitis 362, 436, 437
 extended pancreatectomy after 819
 total pancreatectomy, after 798, 799–800
- r**
 R122H gene 68, 141, 159
 RADIANT trials 1011
 radiation therapy *see* radiotherapy
 radical antegrade modular
 pancreatosplenectomy (RAMPS) 792
 radioembolization 979–980
 radiofrequency ablation
 EUS-guided 772, 839
 PanNETs 979, 980–981
 radiology *see specific modalities*
 radionuclide studies, PanNETs 957,
 958–959
 multitracer 959
 radionuclide therapy, PanNETs 959, 977
 radiotherapy
 chemotherapy with *see* chemoradiotherapy
 conformal, pancreatic cancer 886–887
 intensity modulated (IMRT), pancreatic
 cancer 887, 888
 pancreatic cancer 886–888, 891
 adjuvant 849, 849, 851–852, 886–887
 borderline resectable disease 887–888
 chemoradiotherapy *see*
 chemoradiotherapy
 intraoperative 824
 locally advanced disease 887–888
 toxicity reduction 887
 stereotactic body, pancreatic cancer 786,
 876, 887, 891
 borderline resectable disease 887–888
 locally advanced disease 887–888
 neoadjuvant 888
 RAF/MAPK pathway 581
 Ranson, John 205
 rapid on-site evaluation (ROSE) 731
 Raptor 100
 RAS protein, pancreatic cancer therapy 867
RBI gene mutations 939, 941
 RBP-Jk transcription factor 6
 RBP-Jl transcription factor 6
 reactive oxygen species (ROS) 70, 137
 recrudescence, definition 555–556
 recurrent pancreatitis *see* acute pancreatitis,
 recurrent (RAP)
 redundancy, built-in, signaling 109
 referral bias 342
 regenerating protein (Reg) 127
 regeneration of pancreas 100–101
 PSC role 109
 remission, definition 555
 renal failure 183, 207, 262
 renal involvement, autoimmune pancreatitis
 type 1 529, 530
 renal–hepatic–pancreatic dysplasia 33
 resection of pancreas *see* pancreatic
 resections
 residual bodies 16
 retroduodenal arteries, in
 pancreatoduodenectomy 470, 472
 retroperitoneal fibrosis 527, 529, 529
 reverse transcriptase inhibitors,
 nucleoside 234
RFX6 gene mutations 25
 rhodanase 386
 Ringer’s solution, lactated, acute pancreatitis
 252, 253, 254, 313
 rituximab (RTX)
 autoimmune pancreatitis
 management 556, 557, 559, 560
 relapse 557, 559, 561
 side-effects 558
 RNA processing
 measurements, PanNETs 953, 957
 in pancreatic cancer 866, 866
RNF43 gene, mutations
 IPMN 583, 585, 709
 mucinous cystic neoplasm 584, 585,
 607, 711
 robotic surgery 479
 cystic neoplasms 651, 652
 distal pancreatectomy 652, 792–793, 793,
 810, 810–811
 outcomes 810–811
 technique 810, 811
 learning curve 811–812
 pancreatic cancer 778, 792–793, 804,
 805–808, 809
 pancreatoduodenectomy *see*
 pancreatoduodenectomy
 Rome III criteria, sphincter of Oddi
 dysfunction (SOD) 79, 80
 rough endoplasmic reticulum (RER) 15, 17,
 19, 22
 Roux-en-Y gastric bypass 836
 Roux-en-Y jejunal loop, pancreatic
 fistula 320
 RTOG 9704 study 887, 896, 906, 910
 ryanodine receptor (RyR) 49, 50
- s**
 S6 kinase (S6K) 97
 salt-and-pepper chromatin distribution 931,
 933, 935
 Santorini, duct of *see* accessory pancreatic
 duct
 Sarles, Henri 136
SBDS gene mutations 30
 scintigraphy
 autoimmune pancreatitis 551–552
 insulinoma 1005
 somatostatin receptor *see* somatostatin
 receptor (SSTR) scintigraphy
 sclerosing cholangitis 150
 primary, IgG4 levels 545
 in type 1 autoimmune pancreatitis
 526, 528
 screening, pancreatic cancer *see* pancreatic
 cancer
 secretagogues
 arterial injection 949, 951, 1009–1010,
 1010, 1015, 1021
 pancreatitis models 63
 secretin
 actions/functions 84–85
see also pancreatic juice
 endoscopic, test for chronic
 pancreatitis 401, 401, 406
 injection, MRCP
 in chronic pancreatitis 409, 410, 412
 IPMN 596
 injection test
 PanNETs 951, 1009–1010, 1010, 1021
 rare PanNETs 1015
 pancreas sensitivity to 84–85
 pancreatic function test involving
 401, 401
 regulation of pancreatic protein
 synthesis 96
 release, acid/nonacid factors affecting 84
 secretin stimulation test, gastrinoma 954,
 1009–1010
 secretin–cholecystokinin test, chronic
 pancreatitis 401, 401
 secretion, by pancreas *see* pancreatic
 secretion (process)
 secretory granules, islets of Langerhans
 22, 22
 secretory insufficiency *see* exocrine
 insufficiency
 secretory vesicles *see* zymogen granules (ZG)
 SEER cancer database 908, 909
 selective arterial calcium injection (SACI)
 test 949, 951, 1005, 1009–1010, 1010
 selective arterial secretagogue injection
 (SASI) test 949, 951, 1009–1010,
 1010, 1015, 1021
 selenium 436
 self-expandable metal stents (SEMS) 279
 common bile duct obstruction 444
 common bile duct strictures 439, 444
 drainage of pancreatic pseudocysts 442
 infected pancreatic necrosis drainage 278,
 279, 279
 adverse event management 281
 placement 280
 pancreatic cancer 772, 829, 836
 pancreatic duct strictures 443

- selumetinib 867
- sensory nervous system 173–174, 174
pancreatitis role, neurogenic inflammation 173, 174
- sensory neurons, in pancreas
“efferent” function, molecule release 173
in neurogenic inflammation 173, 174, 174–175, 350
afferents 173–174, 174
“final common pathway” 174, 174–175
receptors expressed 174, 175
silencing, in pancreatitis management 174, 175
- sentinel acute pancreatitis event (SAPE)
model 323, 334–336, 335, 338–339
- sepsis, acute lung injury 183
- serine protease 1, gene *see PRSSI* gene
- serine protease inhibitors 179
Kazal type 1, gene *see SPINK1* gene
- serotonin (5-HT)
pancreatic secretion control 86, 87
PanNETs secreting 956
release 85, 87
synthesis in GI tract 87
- serous cystadenocarcinoma 574
- serous cystadenoma
clinical features 589–590
cytology 603, 604, 605
imaging 593–595, 594, 595, 628
pancreatic middle segment resection 628
see also serous cystic neoplasm (SCN)
- serous cystic neoplasm (SCN) 567, 573–574, 580–581, 590, 641
asymptomatic 589, 604, 614, 643
characteristics 643
classification (WHO) 574
clinical features 589–590
cytology 603, 604, 605
differential diagnosis 574
epidemiology 569, 570, 573, 614, 643
gene mutations (*VHL*) 580–581, 582, 585, 595, 603, 614, 941
growth rate 643
histology 573–574, 574, 614, 698
imaging 590, 593–595, 594, 595, 600
immunohistology 573
long-term outcome 660
macrocytic 573, 590, 594, 603, 614, 699
malignant transformation (rare) 614, 660
microcytic 573, 590, 594, 603, 614, 699
misclassification 580, 581
molecular mechanisms 580–581
natural history 614–615, 643
oligocystic 580, 584
pathology 573, 574, 699
prognosis 614–615, 660
surgery
enucleation 632
indications 643
resection 633, 660
surveillance 660
VEGF elevation 581
von Hippel–Lindau syndrome and 573, 574, 580–581, 585, 590, 593, 614
- serum amyloid A (SAA) 208
- serum elastase-1 539
- Shh* gene 26
see also sonic hedgehog (SHH)
- Shwachman–Diamond syndrome (SDS) 29, 29–30
- sialadenitis, autoimmune pancreatitis 526–529, 528
- Sialyl-Lewis A antigen 762, 770, 910
- signaling pathways
autoimmune pancreatitis type 1 513
carcinogenesis in pancreatic cancer 673, 674
early pancreatic development 5
in pancreatic disorders 6–7
pancreatic stellate cells 108, 108–109, 112
regeneration of pancreas 101
signet ring variant, PDAC 696
- SIGRIL 66
- simultaneous islet kidney (SIK) transplant 1109–1110, 1112
outcomes (one-/two-year) 1112–1113
- simultaneous pancreas kidney (SPK)
transplant 1121, 1122
- single nucleotide polymorphism (SNP), *PRSSI* 141
- single-photon emission computed tomography (SPECT) 957, 1020
- insulinoma 1005
- sitagliptin 234
- Sjögren syndrome 527, 544, 545
- slc26a6 exchanger 57, 58, 59, 60
- Smad4 expression 681, 683, 891
- SMAD4* gene, mutations 583, 607, 939
IPMN 709
pancreatic cancer 679, 680–681, 681, 876
pancreatic intraepithelial neoplasia 706
- small bowel adenocarcinoma 1093
see also duodenum, cancer
- “small duct disease” 455
- smoking
acute pancreatitis progression to chronic 359
alcohol-induced acute pancreatitis 139–140, 324
alcoholic chronic pancreatitis 345, 398, 435
carcinogenesis mechanisms 673–674, 673–675, 675, 676
cessation
hereditary pancreatitis 376–377
pancreatic cancer risk reduction 668
after pancreatic resection 469
chemicals in cigarette smoke 673–674
diabetes risk in chronic pancreatitis 496
inflammatory pancreatic head mass and 367
oxidative stress due to 435
pancreatic cancer risk 667–668, 673–678, 719–720
carcinogens role 673–675, 675, 676
clinical data 675, 676, 719–720
epidemiologic data 667–668, 673, 720
experimental data 673–675, 675
recurrent acute pancreatitis 357
- α-smooth muscle actin (αSMA) 107, 109, 111
- snaring and transection, ampullary adenoma 1069, 1070, 1071
- sodium–bicarbonate cotransporter 160
- sodium–glucose cotransporter-2 (SGLT-2)
inhibitors 499
- SOFA Score, acute pancreatitis 205, 206–207, 209
- solid organ transplant recipients, cystic lesions 569
- solid-pseudopapillary neoplasm (SPN) 567, 573, 577, 641, 643
clear-cell variant 936
clinical presentation 591
cytology 607, 608, 935–936
epidemiology 569, 570, 577, 615, 643
gene mutations 582, 584, 615
histology 577, 577, 699, 700
imaging 599
immunohistochemistry 577, 699
macroscopic appearance 577, 577, 615
molecular markers 577
molecular mechanisms 584
natural history 615, 643
neuroendocrine tumors *vs* 935–936
pathology 699, 700, 935–936
prognosis 577, 615, 643, 663
surgery 633, 643, 644
- solid serous adenoma 699
- somatostatin (SST) 125
analogs 964, 972, 973, 974–975
in insulinoma 1005
long-acting 964, 973, 974, 1016
radiolabeled, therapy 959, 977
for rare PanNETs 1016
pancreatic fistula management 319, 645
pancreatic secretion inhibition 89, 125–126
see also δ cells
- somatostatin receptor (SSTR)
scintigraphy 951
PanNETs 957–958, 962–963, 1010, 1020
rare 1013, 1015, 1016
- somatostatin receptors (SSTR) 125, 962–963, 973
subtypes 959, 973, 974
- somatostatinoma
ampullary 1053
clinical features 719, 719, 948, 948, 1013, 1014
duodenal 1023–1024
investigations 955, 956
long-term outcome 1032
medical treatment 973
- sonic hedgehog (SHH) 5, 26
inhibition, pancreatic cancer 868
- SOX9 transcription factor 5
- SPAK/OSR1 kinase 58, 59
- SPan-1 763, 776
- sphincter of Oddi 75–83, 1047
anatomy and morphology 75–76, 76
bile flow 76, 77, 79
dysfunction (SOD) 79–81, 260

- sphincter of Oddi (*cont'd*)
- acute pancreatitis due to 150
 - classification 79–80, **80**
 - diagnostic criteria 79–80, **80**
 - dyskinetic pattern subtype 80–81
 - endoscopic therapy indication 296
 - pain, causes 81
 - stenotic pattern subtype 80
 - ethanol effect 343–344
 - functions 76, 77
 - innervation 76, 77
 - motility 77
 - abnormalities 79–81
 - animal studies 77
 - bioactive agents effect 77, 77
 - CCK action 78, **78**
 - humans 78–79
 - mucosa 75–76
 - phasic contractions 77
 - fasting 78–79, **79**
 - humans 78, **78**
 - inhibition, bile flow 77
 - meal ingestion 79
 - physiology 75–83, **76**
 - pressures 78, **78, 79**
 - spasm 296
 - stenosis 80
 - tone, regulation 77
 - sphincteroplasty 213
 - sphincterotomy 80
 - acute biliary pancreatitis treatment 152–153, **328**
 - acute pancreatitis association 150
 - ductal stones in chronic pancreatitis 442
 - endoscopic *see* endoscopic sphincterotomy (ES)
 - spinal cord inflammation 175
 - spindle cells
 - autoimmune pancreatitis type 1 516
 - mucinous cystic neoplasm 575, 698, **698**
 - SPINK1* gene 160, **378**
 - as disease-modifier gene 161
 - mutations 141
 - acute pancreatitis and 158, 160, 179
 - acute recurrent pancreatitis in children 227
 - alcohol-induced pancreatitis 141
 - chronic pancreatitis risk 337, 378, 398
 - hereditary pancreatitis 35, **377, 378, 398, 746**
 - loss-of-function 378
 - N34S 141, 160, 161, 378
 - pancreas divisum, idiopathic pancreatitis 26
 - tropical chronic pancreatitis **387**
 - overexpression, pancreatitis model 179
 - pancreatic secretory trypsin inhibitor (PSTI) 160, 178, 398
 - SPINK1 protein 160, 178, 398
 - autoantibodies against 540, 541
 - splanchnic nerves 173, **174**
 - ablation, pancreatic cancer pain 880–882
 - activation, pancreatic secretion and 88
 - splanchnic vasoconstriction 167, **167**
 - splanchnicectomy, thorascopic 882
 - spleen, preservation, pancreatectomy 644, 650, 791
 - splenectomy 469, 644, 650
 - splenic artery 252, 644
 - splenic vein 13
 - occlusion 366
 - thrombosis 449, 469
 - squamoid nests 700, 701
 - ST-segment elevation, acute pancreatitis 185
 - statins, acute pancreatitis associated 234
 - steatorrhea 428
 - autoimmune pancreatitis 557
 - CFTR-associated pancreatic disease 392
 - chronic pancreatitis 361, 384, 399
 - exocrine insufficiency 28, 324, 361
 - isolated enzyme deficiencies 28
 - pancreatic cancer 717
 - Shwachman–Diamond syndrome 29
 - total pancreatectomy, after 799
 - stellate cell system 106
 - stellate cells *see* pancreatic stellate cell (PSC)
 - stemness, in cancer cells, PSC role 111
 - stent(s)
 - double-pigtail 442
 - plastic, bile ducts 444, 836
 - plastic, pancreatic duct 443–444
 - SEMS *see* self-expandable metal stents (SEMS)
 - stenting
 - common bile duct 367, 439, 443
 - disconnected duct syndrome 319
 - endoscopic *see* endoscopic stenting
 - nasopancreatic, preoperative 635
 - pancreatic duct *see* pancreatic duct(s), stenting
 - stereotactic body radiotherapy (SBRT) *see* radiotherapy
 - steroids *see* corticosteroids
 - storiform fibrosis, autoimmune pancreatitis 516, **517, 525, 527**
 - streptozotocin, PanNETs 975, 977, 1006, 1011
 - stress response, chronic pancreatitis pathogenesis 334
 - stromal cells 3
 - reprogramming 868
 - targeted therapy, pancreatic cancer 868
 - substance P (SP)
 - chronic pancreatitis 350, 351–352
 - cytokines interacting 352
 - functions 351
 - receptors 71, 351
 - sensory afferents releasing 173
 - synthesis, regulation 351
 - sulfonylureas 499
 - sunitinib 964, 976, **976, 1011**
 - “super trypsin” 386
 - superior mesenteric artery (SMA) 12, 13, 252
 - pancreatic cancer involvement 725, 814, 824, **900**
 - resection 784–785, 816–817, **817**
 - pancreatoduodenectomy procedure 470, 472
 - PanNET invading 996, **997**
 - resection of nerve plexus around 778, **778, 779**
 - uncinate process pancreatic cancer 725
 - superior mesenteric vein (SMV) 12, 13
 - pancreatic cancer invasion 778–779, 814, 824
 - resection 784, 815–816
 - pancreatic cancer staging 736, **737**
 - pancreatoduodenectomy 470, **471**
 - PanNET invading 996, **996, 997, 998**
 - uncinate process pancreatic cancer 725
 - superior mesenteric vein–portal vein (SMV/PV) 649, 651
 - invasion, uncinate process cancer 725
 - pancreatic cancer 823
 - imaging 736, **737**
 - resectability 814
 - staging 773
 - robotic pancreatoduodenectomy 806
 - surgery *see specific procedures, and diseases*
 - surgical debridement *see* necrotizing pancreatitis, acute
 - susceptibility factors *see* genetic susceptibility factors
 - sweat test, cystic fibrosis 393
 - sympathetic nervous system, pancreatic secretion 88
 - synthetic lethality 867
 - systemic inflammation
 - acute pancreatitis 178, 184
 - “gut–lymph” hypothesis 166, 167, **167, 170**
 - systemic inflammatory response syndrome (SIRS)
 - acute pancreatitis 181, 182, 183, 184, 258, 261, 268
 - fluid resuscitation 254, 258, 313
 - necrotizing pancreatitis 271
 - pancreatic ischemia and 252
- t**
- T cells (T lymphocytes) 856, **857, 857–858**
 - activation/deactivation 857–858
 - autoimmune pancreatitis, type 1 511–512, **512, 513**
 - B cell interaction 512, 513
 - checkpoint inhibitor action 857–858, **858**
 - in chronic pancreatitis 338
 - cytokines 511
 - cytotoxic (CD8) 856, 857, **857**
 - helper (CD4⁺) 118, 856, **857**
 - autoimmune pancreatitis type 1 511, 517
 - Th2, autoimmune pancreatitis 511, **511**
 - response to mesothelin 859
 - Treg cells 335, 856, **857**
 - autoimmune pancreatitis, type 1 511, 512
 - T lymphocytes *see* T cells (T lymphocytes)
 - T7-KO gene/mice 67, 68–69, **69**
 - tail of pancreas
 - anatomy 3, 10–11, 790–791
 - cancer *see under* pancreatic cancer

- targeted therapy
 pancreatic cancer *see* pancreatic cancer
 PanNETs 976, **976**
- telomerase 852
- telomerase peptide vaccine (GV1001) 852
- telomerase reverse transcriptase (TERT)
 functions 940
TERT promoter, mutations 938
- telomere(s) 852, 940
 alternative lengthening (ALT) 938, 940,
 942, 943
- TELOVAC trial 852
- temozolomide, PanNETs 975, 977, 1006
- TERT* promoter mutations 938
- tetraspanin (Tm4sf3) 25
- thalidomide 975
- thoracic duct
 canine models involving 168, 170
 ligation 169
 lymph 166, 167, 168
 surgical drainage 169
- thoroscopic splanchnic denervation
 (TSD) 175
- thoroscopic splanchnicectomy 882
- thyroid hormone, pancreatic growth 100
- TIGAR-O 333, 334
- tight junctions 15, 18, 52
- tissue inhibitors of matrix metalloproteinases
 (TIMPs) 106, 338
- TLR4 **119**, 140
- tobacco smoking *see* smoking
- total lymph node count (TLNC), distal
 cholangiocarcinoma 1084–1085
- total pancreatectomy (TP) 451, 469, 644
 classification/types 797
 complications 797, 798, 801
 anastomotic ulcer 799
 diabetes 798–799
 exocrine insufficiency 797, 799
- elective, pancreatic cancer 797,
 798, **798**
- indications 800–801
 chronic pancreatitis 476–477
 conversion from partial
 pancreatectomy 801
 cystic neoplasms 642, 644, 800
 hereditary pancreatitis 377, 476
 inherited diseases 800
 IPMN 642, 800
 for lesions identified by screening 749
 pancreatic cancer 778, 797, 800
 after tumor recurrence 801
- limitations 801
- long-term outcomes 798–800, **799**
- lymphadenectomy in 815
- mortality rate 797, 798
- perioperative outcomes 798, **798**
- rationale for 797
see also pancreatectomy, salvage
 completion
- total pancreatectomy with islet cell
 autotransplantation (TPIAT)
 797–803, 1115
 chronic pancreatitis 451, 476–477, 1115
 diabetes (type 3c) in 500
- laparoscopic 479, 482
 robotic-assisted laparoscopic 480,
 482, **482**
- complications 1115
- hereditary pancreatitis 377
- outcomes 1115
- prophylactic 476
- research priorities 1116
- toxins, pediatric acute pancreatitis **222**
- TP53* gene 679
 mutation
 cystic neoplasms 583, 607
 ductal adenocarcinoma 679, 680, **681**
 IPMN 709
 pancreatic intraepithelial neoplasia 706
 PanNEC 941
 PanNETs 938, **939**
- tramadol **423**
- trametinib 108
- transabdominal ultrasound (TUS)
 acute fluid collections 312
 ampullary tumors 1059
 gallstones investigation 151
 pediatric acute pancreatitis 224–225
 periampullary tumors 1038–1039
- transarterial chemoembolization (TACE)
 979–980, 1011
- transarterial embolization (TAE) 979–980
- transcription factors, pancreatic
 development 5, 6
- transforming growth factor β (TGF β) **512**,
680, 681, **866**
 inhibition, pancreatic fibrosis reversal 110
 PSC activation 110, 338
- transient neonatal diabetes mellitus
 (TNDM) 31
- transient receptor potential (TRP) channel
 family 84
 on sensory afferents 175
 TRPA1;TRPV1 **174**, 174–175
- translation (protein synthesis) 96
 regulation, pancreatic 96–98, **97**
- transmural drainage
 infected pancreatic necrosis 278–280,
 279, 280–281
 pancreatic pseudocysts **441**, 441–442
- transpapillary drainage
 acute pancreatic fluid collection 313–314
 infected pancreatic necrosis 278
- transplantation, pancreatic 1121–1128
 back-table graft preparation 1125, **1125**
 bladder drainage 1122, 1125–1126, **1126**
 cardiac risk assessment 1123
 current status/results (USA) 1127
 deceased cardiac death donors
 (DCD) 1124
 donor operation 1123–1124, **1124**
 donor selection and risk index
 (pDRI) 1123
 enteric drainage 1122, 1126, **1126**
 epidemiology and sequelae 1121, 1122
 exocrine secretion management
 1125–1127
 historical aspects 1121–1122
 immunosuppression 1122, 1125
- indications 1122–1123
 after kidney transplant 1121, 1122, 1127
 living donors 1123
 postoperative care 1127
 preoperative workup 1123
 preservation of pancreas graft 1124
 recipient operation 1122, 1124–1127
 rejection, biopsy 1127
 simultaneous with kidney transplant
 1121, 1127
 vascular anastomosis 1125, **1125**
see also islet transplantation
- transplantation, solid organ transplant 569
- trauma, pediatric acute pancreatitis **222**
- trefoil factor 1 (TFF1) 111
- Treitz, ligament, in pancreatoduodenectomy
 470, **472**
- “trickle” feeding 255
- triglyceride(s) 262
 elevated *see* hypertriglyceridemia
 lipolysis 262
 normal and elevated levels 231
- triglyceride lipase, pancreatic
 deficiency 29
 increased synthesis, high-fat diet 96
- TrkA 351
- troglitazone 128
- tropical chronic pancreatitis (TCP) 342,
 362, 384–390
 calculi in 385
 clinical features 384
 diabetes in 385, 387
 differential diagnosis 385
 epidemiology 384–385
 etiology 385–387
 genetics 386, **387**
 histology 385
 malnutrition 385–386
 natural history 384, 387
 pancreatic cancer risk 387
 pathogenesis 386
 pathology 385
 pathophysiology 385
 survival 387
- TRPA1 **174**, 174–175
- TRPV1 **174**, 174–175
- trypsin 64, **427**
 actions/functions 178
 activation 159, 178
 acute pancreatitis pathogenesis 158,
 178–179
 clinical evidence 179–180
 hereditary pancreatitis 378
 premature 158, 178–179, 378
- activation, acute pancreatitis models
 64–65, **65**, 66, 67, 179
 acinar cell apoptosis by cathepsin B **69**,
 69–70, 180
 acinar cell injury **68**, 68–69
 chronic alcohol use and 137
 second phase, neutrophils and 71–72
- autodegradation 179, 378
- CCK release inhibition 90
- colocalized organelles, leaky **69**, 69–70
- inactive zymogen *see* trypsinogen

- trypsin (*cont'd*)
 inhibition (protective role) 68,
 178–179, 378
 release from injured acinar cells 68,
 68–69, 175
 stabilization 179
 structure 159
 trypsin 7 (isoform) 179
 trypsinogen 64, 178, 377–378, 427
 activation 197, 242, 378
 acute pancreatitis models 64, 66, 72, 179
 cathepsin B role 180–181
 inhibition 160
 premature 158, 160, 179, 378
 anionic 68, 141
 gene (*PRSS2*) 68, 141
 autodigestion (at R122) 378
 autodigestion, chymotrypsinogen C
 162, 179
 cationic 68, 141, 159–160, 377–378
 gene *see PRSSI*
 deficiency 29, 29
 expression, cigarette smoke effect 674
 gene(s) 68
 triplication 179
 gene mutations 141, 337
 alcohol-induced acute pancreatitis 141
 hereditary pancreatitis 141, 179
PRSSI variants *see PRSSI* gene
PRSS2 variants 68, 141
 serum levels, autoimmune
 pancreatitis 539
 synthesis by acinar cells 159
 trypsinogen activation peptide (TAP) 159, 180
 tryptophan metabolites 168, 170
TSC2 gene mutation 938, 939, 941, 942
 tuberous sclerosis complex (TSC), PanNETs
 922, 923, 938, 939, 942, 994
 tubular adenocarcinoma 662, 710
 tubular carcinoma, pancreatobiliary-type
 IPMN 709
 tubular complexes 14, 194
 tumor-associated macrophages (TAM) 117,
 118, 119, 857, 857
 fibrogenesis in pancreatic cancer 120
 targeting 861
 tumor-infiltrating lymphocytes (TIL) 857
 tumor markers
 acinar cell carcinoma 763
 pancreatic cancer *see* pancreatic cancer
 PanNETs 956–957, 1019
 tumor microenvironment (TME) 856,
 857, 859
 tumor necrosis factor alpha (TNF α)
 acute pancreatitis 159, 162, 182, 183
 fibrogenesis 119
 inhibition, pancreatic fibrosis reversal 110
 polymorphisms 162
 tumor seeding, by EUS-FNA 730
 tumor suppressor genes 679
 deletions, pancreatic neuroendocrine
 tumors 938, 942
 inactivation in IPMN 583
see also p16/CDKN2A gene; *SMAD4* gene;
TP53 gene; *VHL* gene
- tumoral intraepithelial neoplasms,
 ampulla 1047
 “two-hit model”, tropical chronic
 pancreatitis 386
 two-pore channel (TPC) 50
 tyrosine kinase inhibitor (TKI) 852,
 868, 874
- U**
 ubiquitin protein ligase E3 540
 n-recogin 2 (UBR2) 525, 540
UBR1 gene mutations 30
 UDP-glucuronyltransferase 1A1
 (UGT1A1) 764
 ulcerative colitis, interleukin-8 (IL-8) 513
 ultrasonography
 abdominal *see* abdominal ultrasound
 endoluminal, gallstones investigation 151
 endoscopic *see* endoscopic ultrasound
 (EUS)
 intraoperative *see* intraoperative
 ultrasound (IOS)
 periampullary tumors 1038–1039
 transabdominal *see* transabdominal
 ultrasound (TUS)
 ultrastructure of pancreas 13–23
 endocrine pancreas 20–22, 21, 22
 exocrine pancreas 13–20, 17, 18, 19, 20
 uncinate process 724
 pancreatic ductal adenocarcinoma
 (UPDAC) 724–727, 777
 clinical characteristics 725–727, 726
 imaging (CT) 737
 outcome/prognosis 725, 727, 727
 resection 725, 727
 PanNET in, surgery 991, 996
 PP cells and α cells 22
 uncinctomy 624
 undernutrition *see* malnutrition
 unfolded protein response (UPR)
 70–71, 336
 alcohol effects 138
 pancreatic protein synthesis inhibition
 98, 98
 urine, discoloration 718
- V**
 vaccines, therapeutic 858–860, 861
 antigen-specific 859–860
 neoantigen-based 860
 whole-cell 858–859, 861
 vagal afferent fibers/pathway
 activation, pancreatic growth and 100
 CCK action on pancreatic secretion 86
 secretin release and 84–85
 serotonin release and 87
 vagus nerve 173
 efferent fibers 86
 pancreatic secretion control 88
 parasympathetic preganglionic fibers
 173, 174
 sensory fibers 173
 sphincter of Oddi physiology 77
 validation, acute pancreatitis
 classification 200, 201
- valproic acid (VPA) 234, 336
 van der Kamer technique 402
 vanilloid receptor type 1 (VR1) 352
 vascular endothelial growth factor (VEGF)
 581, 910
 inhibitor (sunitinib) 964, 976, 976, 1011
 VEGF-A
 antibody against (bevacizumab) 976
 elevated, serous cystic neoplasm 581
 vascular endothelial growth factor receptor
 (VEGFR) 976
 vascular injury, pancreatic parenchymal
 necrosis 242
 vascular invasion, ductal adenocarcinoma
 694, 695, 778–779, 814
 surgical resection 778–779, 815–817,
 823, 824
 vascular leak syndrome (VLS) 258, 259
 vasoactive intestinal polypeptide
 (VIP) 100
 elevated (serum) 956
see also VIPoma
 vasopressors, acute pancreatitis 261
 Vater, ampulla *see* ampulla of Vater
 vemurafenib 867
 venotomy 845
 venous bleeding, post-necrosectomy 286
 ventilation, acute pancreatitis 261
 ventral pancreas 4, 724
 ventral pancreatic bud 4, 5, 24, 724
 Verner–Morrison syndrome (WDHA
 syndrome) 948, 948, 956, 963,
 1013, 1032
 very low-density lipoproteins (VLDL) 231
VHL gene
 function 581, 942
 mutations 580–581, 595, 603, 614, 941
 germline 581, 585
VHL protein 581
 video-assisted retroperitoneal debridement
 (VARD) 274, 285, 307
 laparoscopic, chronic pancreatitis
 483–484
 video-assisted retroperitoneal debridement,
 necrosectomy 285, 307
 VIPoma 990, 1013
 clinical features 719, 719, 948, 948,
 1013, 1014
 investigations 955, 956
 long-term outcome 1032
 medical treatment 973, 974, 1016
 surgical treatment 963, 990
 Virchow, Rudolf 417, 418
 Virchow’s node 770
 viruses, acute pancreatitis and 232, 232
 visual defects 429
 vitamin A 430
 deficiency 429, 430
 storage, pancreatic stellate cells 106
 vitamin C, supplement, in chronic
 pancreatitis 436
 vitamin D 429–430
 deficiency 429, 430, 499
 receptor 868
 supplementation 430

- vitamin E
 deficiency 429, 430
 supplement, in chronic pancreatitis 436, 437
- vitamin K, deficiency 429, 1042
- vitamin supplementation 430, 436, 437
- von Hippel–Lindau syndrome (VHL) 33, 569, 942
 PanNETs 922, **923**, 932, 937, 942, 994
 serous cystic neoplasms 573, 574, 580–581, 585, 590, 593, 614, 699
see also VHL gene
- von Recklinghausen disease *see* neurofibromatosis type 1
- W**
- walled-off necrosis (WON), in acute pancreatitis 239, 244, **247**, 265, **266**
 acute necrotic collection developing 242, 244
 asymptomatic 273, **273**
 Atlanta classification 239, **266**, 273
 definition 195, 244, **266**, 272, 277, 301, 305–306, 311
 development 242, 243, **244**
 histopathology 195, 244
 imaging **243**, 244, **247**, **273**, **274**, **307**
 infected **244**, **247**, 265, **274**, **277**, **307**
see also necrosis, in acute pancreatitis
- in inflammatory pancreatic head mass 366, **366**
- symptom complex 273, **274**
- therapy/interventions 278, 305–310
 direct endoscopic necrosectomy 275, 278
 endoscopic debridement **274**
 endoscopic drainage *vs* necrosectomy 301–302
 endoscopic therapy (post-acute) 301–304
 laparoscopic cyst gastrostomy 483, **484**
- open cystogastrostomy 293
- percutaneous catheter drainage 274–275
- surgical, indications 306
- surgical debridement 272–273
- timing and optimal strategy 306–307
- walled-off necrosis (WON), in chronic pancreatitis 440
 endoscopic debridement 442
- Wallerian degeneration 881
- Warburg effect 581, 680
- Warshaw technique 650
- WDHA syndrome (watery diarrhea, hypokalemia and achlorhydria) 948, **948**, 956, 963, 1013, 1032
- weight loss
 chronic pancreatitis 399
 pancreatic cancer 718
- Whipple procedure *see* pancreatoduodenectomy
- Whipple's triad 949, 963, 1002
- whole-cell vaccines 858–859, 926–927
- whole-exome sequencing (WES) 937, 938
- “wind-up”, pain mechanism, chronic pancreatitis 349
- WNK kinases 58, **59**
- Wnt signaling 6, **866**
 acinar cell carcinomas 7, 683
 cystic neoplasms 7, 583, 584, 585
 pancreatic ductal adenocarcinoma 6–7
- Wnt/ β -catenin signaling 583
- Wolcott–Rallison syndrome 32
- WON, WOPN *see* walled-off necrosis (WON)
- World Health Organization (WHO)
 pancreatic cancer pain management 879–880, **880**
- PanNETs 923, **924**
 2004 **924**, 925–926
 2010 **925**, 926–927, 928, 941, 994–995
 2017 930, **931**
- wound-healing responses, in pancreas 334
- X**
- X-box binding protein 1 (XBP1) 336
- XBP-1 71
- Y**
- Yin Yang 1 (YY1) transcription factor 938, **939**
- Z**
- zinc deficiency, tropical chronic pancreatitis 386
- Zollinger–Ellison syndrome 948, 961, 963, 965, 1021, 1032
 investigations 1009–1010, **1010**
 medical treatment 974
see also gastrinoma
- zonula occludens 18
- zymogen(s) 178
 activation
 acinar cell protection against 64
 acute pancreatitis 65, 66, 178–179
 acute pancreatitis models 64–65
 biphasic pattern 179
 cathepsin B role 180–181
 colocalization with lysosomes 66, **66**, 69
 secretion inhibition, pancreatitis models **65**, 65–66
see also digestive enzymes; protease(s), pancreatic
- zymogen granules (ZG) 5
 in acinar cells 13, 16, **17**, **20**, 178
 mitochondria location 46–47
 Ca²⁺ release 47, 47–48
 enzymes secretion mechanism 43
 fragility, alcohol increasing 344
 fusion, secretion 16
 immature 16
 stability decrease by chronic alcohol use 137

